PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 25725171-0 2015 Long-term oral administration of the NMDA receptor antagonist memantine extends life span in spinocerebellar ataxia type 1 knock-in mice. Memantine 62-71 ataxin 1 Mus musculus 93-122 25725171-3 2015 Here we examined the potential involvement of extrasynaptic N-methyl-d-aspartate receptor (NMDAR) activation in the pathogenesis of SCA1 by administering memantine, a low-affinity noncompetitive NMDAR antagonist, in SCA1 knock-in (KI) mice. Memantine 154-163 ataxin 1 Mus musculus 132-136 25725171-5 2015 Memantine was administered orally to the SCA1 KI mice from 4 weeks of age until death. Memantine 0-9 ataxin 1 Mus musculus 41-45 25725171-8 2015 These findings support the contribution of aberrant activation of extrasynaptic NMDARs to neuronal cell death in SCA1 KI mice and suggest that memantine may also have therapeutic benefits in human SCA1 patients. Memantine 143-152 ataxin 1 Mus musculus 113-117 25725171-8 2015 These findings support the contribution of aberrant activation of extrasynaptic NMDARs to neuronal cell death in SCA1 KI mice and suggest that memantine may also have therapeutic benefits in human SCA1 patients. Memantine 143-152 ataxin 1 Homo sapiens 197-201 25656790-6 2015 Our data suggest that memantine causes a selective block of extrasynaptic NMDA receptors that are likely to contain GluN2C/2D subunits. Memantine 22-31 glutamate ionotropic receptor NMDA type subunit 2C Rattus norvegicus 116-122 25376930-7 2015 CONCLUSION: The BCHE-K genotype may be related to a poor cognitive response to rivastigmine patch or memantine add-on therapy, especially in the presence of apolipoprotein E epsilon 4. Memantine 101-110 butyrylcholinesterase Homo sapiens 16-20 25239809-5 2015 We report that extrasynaptic NMDAR blocker memantine, reduced in a dose-dependent manner cortically induced NMDA excitatory currents in striatal neurons (recorded in zero-Mg(++) plus DNQX 10 muM). Memantine 43-52 latexin Homo sapiens 191-194 25239809-6 2015 Moreover, memantine (2-4 muM) significantly reduced the NMDAR-dependent membrane potential oscillations called up and down states. Memantine 10-19 latexin Homo sapiens 25-28 25239809-10 2015 After severing connections between compartments, active striatal neurons in the presence of memantine (1 muM) and CNQX (10 muM) were predominantly fast spiking interneurons (FSI). Memantine 92-101 latexin Homo sapiens 105-108 25475686-0 2015 Memantine exerts functional recovery by improving BDNF and GDNF expression in 3-nitropropionic acid intoxicated mice. Memantine 0-9 brain derived neurotrophic factor Mus musculus 50-54 25475686-0 2015 Memantine exerts functional recovery by improving BDNF and GDNF expression in 3-nitropropionic acid intoxicated mice. Memantine 0-9 glial cell line derived neurotrophic factor Mus musculus 59-63 25793384-5 2015 Recently, the N-methyl-D-aspartate (NMDA) receptor antagonist, memantine, was shown to rescue performance of the Ts65Dn in several L/M tasks. Memantine 63-72 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 113-119 25793384-9 2015 We show that, compared with wild type littermate controls, (i) of the dynamic responses seen in control mice in normal learning, >40% also occur in Ts65Dn in failed learning or are compensated by baseline abnormalities, and thus are considered necessary but not sufficient for successful learning, and (ii) treatment with memantine does not in general normalize the initial protein levels but instead induces direct and indirect responses in approximately half the proteins measured and results in normalization of the endpoint protein levels. Memantine 325-334 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 151-157 25376930-7 2015 CONCLUSION: The BCHE-K genotype may be related to a poor cognitive response to rivastigmine patch or memantine add-on therapy, especially in the presence of apolipoprotein E epsilon 4. Memantine 101-110 apolipoprotein E Homo sapiens 157-183 26444756-9 2015 The use of memantine and cholinesterase inhibitor-memantine combination treatment increased with disease severity. Memantine 50-59 butyrylcholinesterase Homo sapiens 25-39 25624417-0 2015 Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. Memantine 105-114 butyrylcholinesterase Homo sapiens 23-37 24876182-4 2015 RESULTS: Cholinesterase inhibitors (ChEIs) and atypical antipsychotics improved NPI total scores (ChEIs: standardised mean difference (SMD) -0.12; 95% CI -0.23 to -0.02; atypical antipsychotics: SMD -0.21; 95% CI -0.29 to -0.12), but antidepressants (95% CI -0.35 to 0.37) and memantine (95% CI -0.27 to 0.03) did not. Memantine 277-286 butyrylcholinesterase Homo sapiens 9-23 26504355-5 2015 The TNFR-1 agonist R32W (10 pg/mL) caused an increase in the VGSC current (I(Na(V))) by 27.2 +- 5.1%, while the TNFR-2 agonist D145 (10 pg/mL) increased the current by 44.9 +- 2.6%. Memantine 127-131 TNF receptor superfamily member 1B Rattus norvegicus 112-118 26504355-7 2015 Treating isolated NaV1.8 with R32W (100 pg/mL) resulted in an increase in I(NaV(1.8)) by 18.9 +- 1.6%, while treatment with D145 (100 pg/mL) increased the current by 14.5 +- 3.7%. Memantine 124-128 neuron navigator 1 Rattus norvegicus 18-22 24870966-9 2015 Memantine attenuated the sevoflurane-induced reductions in the levels of hippocalcin and PSD-95, as well as the sevoflurane-induced cognitive impairment in mice. Memantine 0-9 hippocalcin Mus musculus 73-84 24870966-9 2015 Memantine attenuated the sevoflurane-induced reductions in the levels of hippocalcin and PSD-95, as well as the sevoflurane-induced cognitive impairment in mice. Memantine 0-9 discs large MAGUK scaffold protein 4 Mus musculus 89-95 25338822-6 2015 Exposure to 1.5% sevoflurane resulted in increased MeCP2 phosphorylation in the hippocampus, which was reversed by memantine injection. Memantine 115-124 methyl CpG binding protein 2 Mus musculus 51-56 24493627-3 2014 This strategy could potentially maintain the positive outcomes of memantine-acetylcholinesterase inhibitor combinations, but with the benefits of a single molecule therapy. Memantine 66-75 acetylcholinesterase (Cartwright blood group) Homo sapiens 76-96 25513882-0 2014 Altered Actions of Memantine and NMDA-Induced Currents in a New Grid2-Deleted Mouse Line. Memantine 19-28 glutamate receptor, ionotropic, delta 2 Mus musculus 64-69 25609125-9 2014 CONCLUSION: The neurobehavioral impairments induced by CIH are mediated, at least in part, by intracellular calcium concentration overload, neuron apoptosis, dephosphorylation of ERK1/2, which can be attenuated by memantine. Memantine 214-223 mitogen-activated protein kinase 3 Mus musculus 179-185 25394486-7 2014 Consistent with this model of Abeta-induced synaptic loss, Abeta synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). Memantine 146-155 amyloid beta precursor protein Homo sapiens 30-35 25394486-7 2014 Consistent with this model of Abeta-induced synaptic loss, Abeta synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). Memantine 146-155 amyloid beta precursor protein Homo sapiens 59-64 25285073-9 2014 Interestingly, memory deficit induced by sAbeta was reversed by a NMDA-receptor antagonist, memantine (5 mg/kg i.p), administered immediately after the familiarization trial (T1). Memantine 92-101 SH3-domain binding protein 5 Rattus norvegicus 41-47 24717258-8 2014 Tumor necrosis factor alpha levels were significantly lower in the VPA + memantine group than in the VPA + placebo group (P = 0.013). Memantine 73-82 tumor necrosis factor Homo sapiens 0-27 24898267-13 2014 In conclusion, this muPET experiment clearly indicates that subanesthetic doses of memantine induce significant increases of [(18)F]FDG SUVs in discrete brain areas and that the novel mGluR2 PAM has the capacity to dose-dependently and specifically reverse memantine-induced brain activation. Memantine 83-92 glutamate receptor, ionotropic, AMPA2 (alpha 2) Mus musculus 184-190 24898267-13 2014 In conclusion, this muPET experiment clearly indicates that subanesthetic doses of memantine induce significant increases of [(18)F]FDG SUVs in discrete brain areas and that the novel mGluR2 PAM has the capacity to dose-dependently and specifically reverse memantine-induced brain activation. Memantine 257-266 glutamate receptor, ionotropic, AMPA2 (alpha 2) Mus musculus 184-190 24937439-12 2014 A single intraperitoneal dose of the NMDAr antagonists, memantine or MK-801, shortly before the intruder test decreased aggressive behavior. Memantine 56-65 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 37-42 24938836-9 2014 CONCLUSIONS: Our results suggest that memantine improves stroke outcomes in an apparently non-neuroprotective manner involving increased brain-derived neurotrophic factor signaling, reduced reactive astrogliosis, and improved vascularization, associated with improved recovery of sensory and motor cortical function. Memantine 38-47 brain derived neurotrophic factor Mus musculus 137-170 23414063-0 2014 Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by memantine. Memantine 93-102 brain-derived neurotrophic factor Rattus norvegicus 0-33 23414063-2 2014 Memantine, a non-competitive antagonist of N-methyl-D-aspartate receptors, induces expression of BDNF in several brain regions including the striatum. Memantine 0-9 brain-derived neurotrophic factor Rattus norvegicus 97-101 23414063-6 2014 The possible role for BDNF in the memantine effect was tested by blockade of the TrkB receptor using the pharmacological agent K252a and by the BDNF scavenger TrkB-Fc. Memantine 34-43 brain-derived neurotrophic factor Rattus norvegicus 22-26 23414063-6 2014 The possible role for BDNF in the memantine effect was tested by blockade of the TrkB receptor using the pharmacological agent K252a and by the BDNF scavenger TrkB-Fc. Memantine 34-43 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 81-85 23414063-9 2014 In addition, we found that inhibition or blockade of the BDNF signalling pathway prevented the early, but not the delayed decrease in EtOH consumption induced by memantine. Memantine 162-171 brain-derived neurotrophic factor Rattus norvegicus 57-61 24846616-0 2014 Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice. Memantine 0-9 nerve growth factor Mus musculus 73-76 24846616-0 2014 Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice. Memantine 0-9 presenilin 1 Mus musculus 94-97 24486947-13 2014 Finally, loss of the anti-dyskinetic effect of memantine was associated to increased synaptic GluN2A/GluN2B ratio at striatal synaptic membranes. Memantine 47-56 glutamate ionotropic receptor NMDA type subunit 2A Rattus norvegicus 94-100 24717258-11 2014 Treating bipolar II depression with VPA + memantine may improve the plasma TNF-alpha level. Memantine 42-51 tumor necrosis factor Homo sapiens 75-84 24593912-6 2014 Low concentrations (100 muM) of MK-801 and memantine reduced adrenaline-induced CD62P expression by 47 +- 5 and 42 +- 3%, respectively, and inhibited adrenaline-induced platelet aggregation by 17 +- 6 and 25 +- 5%, respectively (P<0.05). Memantine 43-52 selectin P Homo sapiens 80-85 24486947-13 2014 Finally, loss of the anti-dyskinetic effect of memantine was associated to increased synaptic GluN2A/GluN2B ratio at striatal synaptic membranes. Memantine 47-56 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 101-107 24240127-5 2014 The NMDAR blockers MK-801 and memantine decreased mouse melanoma K1735-M2 cell proliferation. Memantine 30-39 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-9 24839611-0 2014 GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Memantine 84-93 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 0-6 24839611-5 2014 In vitro analysis with NMDA receptor blockers indicated that GLuN2A-L812M-containing NMDARs retained their sensitivity to the use-dependent channel blocker memantine; while screening of a previously reported GRIN2A mutation (N615K) with these compounds produced contrasting results. Memantine 156-165 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 61-67 24839611-5 2014 In vitro analysis with NMDA receptor blockers indicated that GLuN2A-L812M-containing NMDARs retained their sensitivity to the use-dependent channel blocker memantine; while screening of a previously reported GRIN2A mutation (N615K) with these compounds produced contrasting results. Memantine 156-165 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 208-214 24344200-2 2014 NMDAR antagonists are neuroprotective in animal models of neuronal diseases, and the NMDAR open-channel blocker memantine is used to treat Alzheimer"s disease. Memantine 112-121 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 85-90 24011542-2 2014 Recently, its has been proposed that the combination of memantine with vitamin D, a neurosteroid hormone, may prevent amyloid-beta and glutamate neurotoxicity. Memantine 56-65 amyloid beta precursor protein Homo sapiens 118-130 24269729-5 2014 Chronic (2-month) treatment of YAC128 and WT mice with memantine (1 and 10mg/kg/day), which at a low dose selectively blocks Ex-NMDARs, reduced striatal Ex-NMDAR expression and current in 4-month old YAC128 mice without altering synaptic NMDAR levels. Memantine 55-64 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 128-133 24269729-7 2014 In YAC128 mice, memantine at 1mg/kg/day rescued CREB shut-off, while both doses suppressed p38 MAPK activation to WT levels. Memantine 16-25 cAMP responsive element binding protein 1 Mus musculus 48-52 24491052-5 2014 RESULTS: MTT assay showed gp120 produced dose-dependent neuronal injury when added to the culture media and the gp120-induced neuronal injury was blocked by memantine, a specific NR2B receptor antagonist. Memantine 157-166 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 26-31 24491052-5 2014 RESULTS: MTT assay showed gp120 produced dose-dependent neuronal injury when added to the culture media and the gp120-induced neuronal injury was blocked by memantine, a specific NR2B receptor antagonist. Memantine 157-166 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 112-117 24491052-5 2014 RESULTS: MTT assay showed gp120 produced dose-dependent neuronal injury when added to the culture media and the gp120-induced neuronal injury was blocked by memantine, a specific NR2B receptor antagonist. Memantine 157-166 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 179-183 24267175-8 2014 In the presence of the glial glutamate transporter-1 (GLT-1) blocker, dihydrokainate, memantine also reduced the MNC firing rate in euhydrated rats. Memantine 86-95 solute carrier family 1 member 2 Rattus norvegicus 23-59 24356417-0 2014 The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole. Memantine 31-40 colony stimulating factor 2 Homo sapiens 92-95 24473380-9 2014 RESULTS: Memantine pretreatment improved the LPS-induced ALI lung tissue morphological changes, reduced their lung wet/dry ratio, the levels of TNF-alpha and LDH activity in BALF, and also reduced the MPO and MDA content in the lung tissue. Memantine 9-18 tumor necrosis factor Mus musculus 144-153 24473380-9 2014 RESULTS: Memantine pretreatment improved the LPS-induced ALI lung tissue morphological changes, reduced their lung wet/dry ratio, the levels of TNF-alpha and LDH activity in BALF, and also reduced the MPO and MDA content in the lung tissue. Memantine 9-18 myeloperoxidase Mus musculus 201-204 23810967-3 2013 Here memantine is administered in animals before or after spinal nerve ligation (SNL) in order to evaluate the induced antinociceptive/cognitive effects and associated molecular events, including the phosphorylation of several tyrosine (pTyr(1336), pTyr(1472)) and serine (pSer(1303)) residues in the NR2B subunit of the NMDA receptor. Memantine 5-14 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 301-305 25287877-7 2013 RESULTS: Although memantine had beneficial effects on PBA, it also had a crucial impact on behavioural symptoms, especially aggression and agitation (to an average of 3.5 times higher end-point scores on OAS-M and increase of NPI total scores for an average of 114% of initial value). Memantine 18-27 SPARC related modular calcium binding 1 Homo sapiens 204-207 24103632-7 2014 To adjust within-subject dependence over repeated assessments, multiple linear regression with generalized estimating equation methods was used to analyze the effects of the BDNF Val66Met polymorphism on the clinical performance of memantine. Memantine 232-241 brain derived neurotrophic factor Homo sapiens 174-178 24103632-10 2014 We conclude that the BDNF Val66Met polymorphism influenced responses to add-on memantine by decreasing depressive symptoms in patients with BP-II. Memantine 79-88 brain derived neurotrophic factor Homo sapiens 21-25 24011542-0 2014 Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Memantine 15-24 amyloid beta precursor protein Homo sapiens 77-89 24107805-0 2014 Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer"s disease. Memantine 91-100 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 24011542-3 2014 Here, our purpose was to examine the potential protective effects of memantine and vitamin D against amyloid-beta peptide and glutamate toxicity in cortical neuronal cultures. Memantine 69-78 amyloid beta precursor protein Homo sapiens 101-113 24136243-7 2013 In addition, selective enhancement of synaptic activity by low doses of NMDA, or reduction of extrasynaptic activity by memantine, a non-competitive NMDAR antagonist, halts Abeta-induced neurotoxicity. Memantine 120-129 amyloid beta precursor protein Homo sapiens 173-178 24260528-13 2013 Interestingly, we also showed that GK11 elicited less inflammation and neuronal damage, even when compared to Memantine, which like GK11, preferentially inhibits extrasynaptic NMDAR. Memantine 110-119 kallikrein 1-related peptidase C6 Rattus norvegicus 132-136 23332671-0 2013 Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer"s disease. Memantine 61-70 butyrylcholinesterase Homo sapiens 31-45 23332671-1 2013 OBJECTIVES: To examine in an observational study (1) relationships between cholinesterase inhibitors (ChEI) and memantine use, and functional and cognitive end points and mortality in patients with Alzheimer"s disease (AD); (2) relationships between other patient characteristics and these clinical end points; and (3) whether effects of the predictors change across time. Memantine 112-121 butyrylcholinesterase Homo sapiens 75-89 23396088-9 2013 Animals receiving memantine exhibited elevated ERK-1/2 and decreased p21 and p38/MAPK activations, while it had no significant effect on phosphorylated Akt and SAPK/JNK1/2 in the ischemic brain. Memantine 18-27 mitogen-activated protein kinase 3 Mus musculus 47-54 23727219-4 2013 Memantine (10 muM) caused robust inhibition of whole-cell (synaptic and extrasynaptic) NMDARs activated by NMDA at a high concentration or a long duration, low concentration. Memantine 0-9 latexin Homo sapiens 14-17 24166606-12 2013 Taken together, the results obtained in this study seem to confirm the neuroprotective effect of memantine on increasing levels of cells with active caspase-3 and active caspase-9. Memantine 97-106 caspase 3 Rattus norvegicus 149-158 24166606-12 2013 Taken together, the results obtained in this study seem to confirm the neuroprotective effect of memantine on increasing levels of cells with active caspase-3 and active caspase-9. Memantine 97-106 caspase 9 Rattus norvegicus 170-179 23800465-8 2013 Differently, memantine (5mg/kg) did not increase Homer1a signal compared to vehicle, whereas it induced c-fos in the somatosensory and in the medial agranular cortices. Memantine 13-22 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 104-109 23800465-10 2013 When compared to ketamine and MK-801, memantine significantly increased the expression of c-fos, Homer1b and PSD-95. Memantine 38-47 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 90-95 23800465-10 2013 When compared to ketamine and MK-801, memantine significantly increased the expression of c-fos, Homer1b and PSD-95. Memantine 38-47 homer scaffold protein 1 Homo sapiens 97-104 23800465-10 2013 When compared to ketamine and MK-801, memantine significantly increased the expression of c-fos, Homer1b and PSD-95. Memantine 38-47 discs large MAGUK scaffold protein 4 Homo sapiens 109-115 24081314-4 2013 Whether adding memantine to an acetylcholinesterase inhibitor is more effective than an acetylcholinesterase inhibitor alone remains to be established; clinical trial results have been mixed. Memantine 15-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 24014511-0 2013 Treatment of the Ppt1(-/-) mouse model of infantile neuronal ceroid lipofuscinosis with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine. Memantine 140-149 palmitoyl-protein thioesterase 1 Mus musculus 17-21 24014511-6 2013 At 20 mg/kg, memantine treatment induced a delayed but notable improvement in Ppt1(-/-) mice. Memantine 13-22 palmitoyl-protein thioesterase 1 Mus musculus 78-82 23593992-9 2013 The association of memantine with the acetylcholinesterase inhibitor drugs used to treat dementia symptoms appears to be beneficial, in both experimental and clinical studies. Memantine 19-28 acetylcholinesterase (Cartwright blood group) Homo sapiens 38-58 23132651-4 2013 KAT-II expression in control and TAA-treated rats was increased by NMDAr antagonist memantine, and the effects of TAA and memantine appeared additive. Memantine 84-93 aminoadipate aminotransferase Rattus norvegicus 0-6 23641686-6 2013 A recent study demonstrated that NR2C- and/or NR2D-containing NMDARs are the primary targets of memantine, a drug that is widely prescribed to treat Alzheimer"s disease. Memantine 96-105 glutamate receptor, ionotropic, NMDA2C (epsilon 3) Mus musculus 33-38 23641686-6 2013 A recent study demonstrated that NR2C- and/or NR2D-containing NMDARs are the primary targets of memantine, a drug that is widely prescribed to treat Alzheimer"s disease. Memantine 96-105 glutamate receptor, ionotropic, NMDA2D (epsilon 4) Mus musculus 46-50 23641686-7 2013 Our laboratory demonstrated that memantine prevents the loss of retinal ganglion cells (RGCs) in GLAST glutamate transporter knockout mice, a model of normal tension glaucoma (NTG), suggesting that NR2D-containing receptors may be involved in RGC loss in NTG. Memantine 33-42 solute carrier family 1 (glial high affinity glutamate transporter), member 3 Mus musculus 97-102 23641686-7 2013 Our laboratory demonstrated that memantine prevents the loss of retinal ganglion cells (RGCs) in GLAST glutamate transporter knockout mice, a model of normal tension glaucoma (NTG), suggesting that NR2D-containing receptors may be involved in RGC loss in NTG. Memantine 33-42 glutamate receptor, ionotropic, NMDA2D (epsilon 4) Mus musculus 198-202 22436083-3 2013 METHODS: Memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, was titrated to a maximum dose of 10 mg BID in 34 adult subjects aged 18-55 who met DSM-IV criteria for ADHD or ADHD NOS on structured interview. Memantine 9-18 BH3 interacting domain death agonist Homo sapiens 112-115 23894498-2 2013 A recent report suggested that the non-competitive antagonist of NMDA receptors, memantine, could decrease MSO and improve fixation in patients with spinocerebellar ataxia with saccadic intrusions (SCASI). Memantine 81-90 spinocerebellar ataxia 24 (with saccadic intrusions) Homo sapiens 198-203 24555069-10 2013 Blocking NMDA receptors by memantine significantly increased cognitive performance, GFAP and Arc in the type 1 insulin-memantine group compared to the type 1-insulin group and significantly increased Arc in the type 2-memantine group compared to the untreated type 2 diabetic group. Memantine 27-36 glial fibrillary acidic protein Rattus norvegicus 84-88 24555069-10 2013 Blocking NMDA receptors by memantine significantly increased cognitive performance, GFAP and Arc in the type 1 insulin-memantine group compared to the type 1-insulin group and significantly increased Arc in the type 2-memantine group compared to the untreated type 2 diabetic group. Memantine 27-36 activity-regulated cytoskeleton-associated protein Rattus norvegicus 93-96 24555069-10 2013 Blocking NMDA receptors by memantine significantly increased cognitive performance, GFAP and Arc in the type 1 insulin-memantine group compared to the type 1-insulin group and significantly increased Arc in the type 2-memantine group compared to the untreated type 2 diabetic group. Memantine 27-36 activity-regulated cytoskeleton-associated protein Rattus norvegicus 200-203 23098644-1 2013 Acetylcholinesterase inhibitors (AChEIs) are the most widely used symptomatic treatment for mild to severe Alzheimer"s disease (AD) patients, while N-methyl-d-aspartic acid (NMDA) receptor antagonist memantine is licensed for use in moderate to severe AD patients. Memantine 200-209 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 24427199-5 2013 In addition, the analysis of coupling direction based on phase dynamics showed that the unidirectional influence from thalamus to mPFC was diminished in depression state only in theta rhythm, while it was partly recovered after the memantine treatment in a depression model of rats. Memantine 232-241 complement factor properdin Mus musculus 130-134 23396088-9 2013 Animals receiving memantine exhibited elevated ERK-1/2 and decreased p21 and p38/MAPK activations, while it had no significant effect on phosphorylated Akt and SAPK/JNK1/2 in the ischemic brain. Memantine 18-27 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 69-72 23396088-9 2013 Animals receiving memantine exhibited elevated ERK-1/2 and decreased p21 and p38/MAPK activations, while it had no significant effect on phosphorylated Akt and SAPK/JNK1/2 in the ischemic brain. Memantine 18-27 mitogen-activated protein kinase 14 Mus musculus 77-80 23396088-11 2013 Synergistic effects of memantine and melatonin were observed in the inactivation of p21, p38/MAPK and SAPK/JNK1/2 pathways. Memantine 23-32 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 84-87 23396088-11 2013 Synergistic effects of memantine and melatonin were observed in the inactivation of p21, p38/MAPK and SAPK/JNK1/2 pathways. Memantine 23-32 mitogen-activated protein kinase 14 Mus musculus 89-92 23396088-11 2013 Synergistic effects of memantine and melatonin were observed in the inactivation of p21, p38/MAPK and SAPK/JNK1/2 pathways. Memantine 23-32 mitogen-activated protein kinase 8 Mus musculus 107-111 23396088-12 2013 Moreover, memantine reversed the effects of melatonin on the activation of ERK-1/2 pathway. Memantine 10-19 mitogen-activated protein kinase 3 Mus musculus 75-82 23396088-13 2013 Here, we provide evidence that free radical scavenger melatonin potentiates the effects of memantine on ischemic brain injury via inactivations of p21 and stress kinases p38/MAPK and SAPK/JNK1/2 pathways. Memantine 91-100 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 147-150 23396088-13 2013 Here, we provide evidence that free radical scavenger melatonin potentiates the effects of memantine on ischemic brain injury via inactivations of p21 and stress kinases p38/MAPK and SAPK/JNK1/2 pathways. Memantine 91-100 mitogen-activated protein kinase 14 Mus musculus 170-173 23396088-13 2013 Here, we provide evidence that free radical scavenger melatonin potentiates the effects of memantine on ischemic brain injury via inactivations of p21 and stress kinases p38/MAPK and SAPK/JNK1/2 pathways. Memantine 91-100 mitogen-activated protein kinase 8 Mus musculus 188-194 23631274-2 2013 It is established that the memantine action is due to its influence on the cholinesterase activity in the brain, blood plasma, and erythrocytes in addition to its NMDA-blocking action. Memantine 27-36 butyrylcholinesterase Mus musculus 75-89 23493925-5 2013 To better elucidate the effect of memantine on hippocampal circuitry, we studied its pharmacology on NMDAR currents in both pyramidal cells (PCs) and interneurons (Ints) in the CA1 region of the hippocampus. Memantine 34-43 carbonic anhydrase 1 Rattus norvegicus 177-180 23276665-5 2013 Acute single-dose administrations of memantine, a low-to-moderate-affinity N-methyl-d-aspartate (NMDA) antagonist, showed improvements in working memory deficits at 4 months of age, whereas donepezil, an acetylcholinesterase (AChE) inhibitor, did not. Memantine 37-46 acetylcholinesterase Mus musculus 226-230 23276665-9 2013 Since donepezil and memantine have been widely used for treating patients of Alzheimer"s disease, these results also suggest that cognitive deficits in PS1/APP mice assessed in the Y-maze and Morris water maze tasks are a useful animal model for evaluating novel Alzheimer"s disease therapeutics. Memantine 20-29 presenilin 1 Homo sapiens 152-159 23532860-8 2013 A similar potentiation was also observed when memantine was replaced with ifenprodil, suggesting a possible involvement of the NR2B subunit of the NMDA receptor. Memantine 46-55 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 127-131 23371894-8 2013 NR1I2 rs1523130 was identified as the unique significant genetic covariate for memantine clearance (p = 0.006), with carriers of the NR1I2 rs1523130 CT/TT genotypes presenting a 16 % slower memantine elimination than carriers of the CC genotype. Memantine 79-88 nuclear receptor subfamily 1 group I member 2 Homo sapiens 0-5 23371894-8 2013 NR1I2 rs1523130 was identified as the unique significant genetic covariate for memantine clearance (p = 0.006), with carriers of the NR1I2 rs1523130 CT/TT genotypes presenting a 16 % slower memantine elimination than carriers of the CC genotype. Memantine 79-88 nuclear receptor subfamily 1 group I member 2 Homo sapiens 133-138 23371894-8 2013 NR1I2 rs1523130 was identified as the unique significant genetic covariate for memantine clearance (p = 0.006), with carriers of the NR1I2 rs1523130 CT/TT genotypes presenting a 16 % slower memantine elimination than carriers of the CC genotype. Memantine 190-199 nuclear receptor subfamily 1 group I member 2 Homo sapiens 0-5 23371894-8 2013 NR1I2 rs1523130 was identified as the unique significant genetic covariate for memantine clearance (p = 0.006), with carriers of the NR1I2 rs1523130 CT/TT genotypes presenting a 16 % slower memantine elimination than carriers of the CC genotype. Memantine 190-199 nuclear receptor subfamily 1 group I member 2 Homo sapiens 133-138 23421676-3 2013 To determine key binding interactions of memantine, we made side-by-side comparisons of IC(50) for memantine and amantadine, a structurally related drug, in the GluN1/GluN2B NMDA receptor. Memantine 41-50 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 161-166 23421676-3 2013 To determine key binding interactions of memantine, we made side-by-side comparisons of IC(50) for memantine and amantadine, a structurally related drug, in the GluN1/GluN2B NMDA receptor. Memantine 41-50 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 167-173 23421676-4 2013 We identified hydrophobic binding pockets for the two methyl groups on memantine formed by the residues A645 and A644 on the third transmembrane helices of GluN1 and GluN2B, respectively. Memantine 71-80 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 156-161 23421676-4 2013 We identified hydrophobic binding pockets for the two methyl groups on memantine formed by the residues A645 and A644 on the third transmembrane helices of GluN1 and GluN2B, respectively. Memantine 71-80 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 166-172 23538441-8 2013 Next, we found that memantine, which was previously identified as an ex-NMDAR blocker, inhibited intracellular signaling mediated by syn- or ex-NMDAR. Memantine 20-29 synemin Homo sapiens 133-136 23538441-9 2013 Simultaneous blockade of syn- and ex-NMDAR by memantine dose-dependently attenuated NMDAR-mediated death. Memantine 46-55 synemin Homo sapiens 25-28 23376060-7 2013 Intraventricular microinjection of recombinant rat IL-1beta aggravated cerebral ischemic injury, which was significantly reduced by memantine. Memantine 132-141 interleukin 1 beta Rattus norvegicus 51-59 23021418-3 2013 STZ also significantly altered NMDA subunits, NR2A and NR2B protein and mRNA expression which were restored by Memantine only. Memantine 111-120 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 55-59 22683643-0 2012 Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Memantine 36-45 renin binding protein Mus musculus 0-3 23022311-1 2012 The therapeutic effects of UDP-glucose (UDPG), an endogenous agonist of GPR17 that may promote the self-repair of white matter, glial cell line-derived neurotrophic factor (GDNF), a neurotrophic factor correlated with the growth and survival of nerve cells, and memantine, an antagonist of NMDA receptors, were evaluated for functional improvement of neonatal rats with experimental periventricular leukomalacia (PVL). Memantine 262-271 glial cell derived neurotrophic factor Rattus norvegicus 173-177 23181523-7 2012 We then demonstrated the differential effect of memantine, an N-Methyl-D-aspartic acid (NMDA) subunit selective weak inhibitor, in early and late AD pathology, and show that inhibition of the NMDA receptor NR2C/NR2D subunits located on inhibitory interneurons compensates for the greater excitatory decline observed with pathology. Memantine 48-57 glutamate ionotropic receptor NMDA type subunit 2C Homo sapiens 206-210 23180021-6 2012 RESULTS: Assuming mono treatment (either a cholinesterase inhibitor or memantine), treatment costs would increase from CHF 22.7 million in 2012 to CHF 26.1 million in 2016, the additional yearly treatment costs for the combination treatment (cholinesterase inhibitor and memantine) would be between CHF 1.7 million and CHF 1.9 million. Memantine 271-280 butyrylcholinesterase Homo sapiens 242-256 23513957-2 2013 Memantine was precolumn derivatized with 9-fluorenylmethyl chloroformate, and the fluorescent derivative was separated on an RP C18 column using a mobile phase composed of acetonitrile-10 mM orthophosphoric acid containing 1 mL/L triethylamine with gradient elution. Memantine 0-9 RNA polymerase II, I and III subunit H Homo sapiens 125-131 23554783-8 2012 Consistent with the behavior results, pathological studies showed that both memantine and EE significantly reduced hippocampal CA1 neurofibrilliary tangles (NFTs) as well as amyloid beta precursor protein (APP) levels. Memantine 76-85 carbonic anhydrase 1 Mus musculus 127-130 23554783-8 2012 Consistent with the behavior results, pathological studies showed that both memantine and EE significantly reduced hippocampal CA1 neurofibrilliary tangles (NFTs) as well as amyloid beta precursor protein (APP) levels. Memantine 76-85 amyloid beta (A4) precursor protein Mus musculus 174-204 22824463-0 2012 Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40. Memantine 0-9 BCL2, apoptosis regulator Rattus norvegicus 52-57 22824463-0 2012 Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40. Memantine 0-9 caspase 8 Rattus norvegicus 62-71 22824463-3 2012 In this study, we tested the hypothesis that memantine prevents Abeta(1-40)-mediated cognitive impairment, neurodegeneration, and apoptosis of hippocampal neurons in rats. Memantine 45-54 amyloid beta precursor protein Rattus norvegicus 64-69 22824463-4 2012 In addition, we hypothesized that Abeta(1-40) injection would induce changes in the levels of one or more apoptosis-related proteins, and that these changes would be attenuated by memantine treatment. Memantine 180-189 amyloid beta precursor protein Rattus norvegicus 34-39 22824463-7 2012 Injection of Abeta resulted in neurodegeneration, DNA fragmentation, increased Bcl-2 immunostaining, and significantly impaired performance in an active avoidance task, all which were significantly attenuated in rats treated with memantine. Memantine 230-239 amyloid beta precursor protein Rattus norvegicus 13-18 22824463-7 2012 Injection of Abeta resulted in neurodegeneration, DNA fragmentation, increased Bcl-2 immunostaining, and significantly impaired performance in an active avoidance task, all which were significantly attenuated in rats treated with memantine. Memantine 230-239 BCL2, apoptosis regulator Rattus norvegicus 79-84 22824463-9 2012 Additional experiments demonstrated that an increase in caspase 8 immunostaining, observed 3 days after Abeta(1-40) injection, was significantly attenuated in memantine-treated rats. Memantine 159-168 caspase 8 Rattus norvegicus 56-65 22824463-9 2012 Additional experiments demonstrated that an increase in caspase 8 immunostaining, observed 3 days after Abeta(1-40) injection, was significantly attenuated in memantine-treated rats. Memantine 159-168 amyloid beta precursor protein Rattus norvegicus 104-109 23256654-4 2012 Apart from the above mentioned cholinesterase inhibitors, memantine is used for AD treatment as well acting as Nmethyl-D-aspartate (NMDA) non-competitive antagonist. Memantine 58-67 butyrylcholinesterase Homo sapiens 31-45 22668780-9 2012 Moreover, both NMDAR-mediated apoptosis and CREB-off signaling are blocked by co-application of either memantine or the GluN2B subunit-selective antagonist ifenprodil in YAC128 MSNs. Memantine 103-112 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 15-20 22668780-9 2012 Moreover, both NMDAR-mediated apoptosis and CREB-off signaling are blocked by co-application of either memantine or the GluN2B subunit-selective antagonist ifenprodil in YAC128 MSNs. Memantine 103-112 cAMP responsive element binding protein 1 Mus musculus 44-48 22683643-7 2012 At a later stage of the disease, in 6-7-month-old Cln3(Deltaex1-6) mice, memantine induced a delayed but extended (8 days) improvement of motor skills similarly to that observed previously with EGIS-8332 treatment. Memantine 73-82 ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) Mus musculus 50-54 22683643-8 2012 An age-dependent therapeutic effect of memantine implies that the pathomechanism in juvenile Batten disease changes during disease progression. Memantine 39-48 renin binding protein Mus musculus 3-6 22631440-8 2012 Interestingly, these effects were prevented by MK-801 and memantine, suggesting a role for extrasynaptic NMDARs in Abeta toxicity, and by ifenprodil, further indicating the involvement of GluN2B-containing NMDARs. Memantine 58-67 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 188-194 22297273-1 2012 The present studies were aimed to verify the hypothesis that treatment with memantine, a low affinity NMDA glutamate receptor antagonist, can reduce possible stress-induced alterations in cell proliferation in the hippocampus and in the heart and has consequences on stress hormone release. Memantine 76-85 glutamate ionotropic receptor NMDA type subunit 2C Rattus norvegicus 102-125 22806212-2 2012 The N-methyl-D-aspartate (NMDA) receptor uncompetitive antagonist, memantine hydrochloride (memantine), has been shown to improve learning/memory and rescue one form of hippocampus synaptic plasticity dysfunction in the best-studied mouse model of DS available, the Ts65Dn mouse. Memantine 67-90 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 266-272 22806212-2 2012 The N-methyl-D-aspartate (NMDA) receptor uncompetitive antagonist, memantine hydrochloride (memantine), has been shown to improve learning/memory and rescue one form of hippocampus synaptic plasticity dysfunction in the best-studied mouse model of DS available, the Ts65Dn mouse. Memantine 67-76 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 266-272 22564863-4 2012 IC(50) values for Mg(2+) and memantine increased when receptors contained GluN3A subunits and were further increased when they contained GluN3B, e.g. IC(50)s at -75mV for block of GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B receptors respectively were 4.2, 22.4 and 40.1muM for Mg(2+), and 2.5, 7.5 and 17.5muM for memantine. Memantine 29-38 glutamate ionotropic receptor NMDA type subunit 3A Rattus norvegicus 74-80 22564863-4 2012 IC(50) values for Mg(2+) and memantine increased when receptors contained GluN3A subunits and were further increased when they contained GluN3B, e.g. IC(50)s at -75mV for block of GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B receptors respectively were 4.2, 22.4 and 40.1muM for Mg(2+), and 2.5, 7.5 and 17.5muM for memantine. Memantine 29-38 glutamate ionotropic receptor NMDA type subunit 3B Rattus norvegicus 137-143 22564863-4 2012 IC(50) values for Mg(2+) and memantine increased when receptors contained GluN3A subunits and were further increased when they contained GluN3B, e.g. IC(50)s at -75mV for block of GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B receptors respectively were 4.2, 22.4 and 40.1muM for Mg(2+), and 2.5, 7.5 and 17.5muM for memantine. Memantine 29-38 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 180-185 22564863-4 2012 IC(50) values for Mg(2+) and memantine increased when receptors contained GluN3A subunits and were further increased when they contained GluN3B, e.g. IC(50)s at -75mV for block of GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B receptors respectively were 4.2, 22.4 and 40.1muM for Mg(2+), and 2.5, 7.5 and 17.5muM for memantine. Memantine 29-38 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 193-198 22564863-4 2012 IC(50) values for Mg(2+) and memantine increased when receptors contained GluN3A subunits and were further increased when they contained GluN3B, e.g. IC(50)s at -75mV for block of GluN1-1a/2A, GluN1-1a/2A/3A and GluN1-1a/2A/3B receptors respectively were 4.2, 22.4 and 40.1muM for Mg(2+), and 2.5, 7.5 and 17.5muM for memantine. Memantine 29-38 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 193-198 24551770-8 2012 Also an increase in Bax/Bcl-2 ratio in rat hippocampus cells .Memantine pretreatment could not change the levels of Bax, Bcl-2, Caspase-3 significantly in rat"s hippocampus cells. Memantine 62-71 BCL2 associated X, apoptosis regulator Rattus norvegicus 20-23 24551770-8 2012 Also an increase in Bax/Bcl-2 ratio in rat hippocampus cells .Memantine pretreatment could not change the levels of Bax, Bcl-2, Caspase-3 significantly in rat"s hippocampus cells. Memantine 62-71 BCL2, apoptosis regulator Rattus norvegicus 24-29 22311382-0 2012 Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. Memantine 0-9 reticulon 4 Homo sapiens 69-74 22311382-6 2012 Memantine had attenuated effects in FHP vs. FHN subjects: For No-Go false alarms, memantine was associated with limited reduction in subcortical, cingulate, and temporal regions in FHP subjects and reduced activity in fronto-striatal-parietal networks in FHN subjects. Memantine 0-9 reticulon 4 Homo sapiens 62-67 22311382-6 2012 Memantine had attenuated effects in FHP vs. FHN subjects: For No-Go false alarms, memantine was associated with limited reduction in subcortical, cingulate, and temporal regions in FHP subjects and reduced activity in fronto-striatal-parietal networks in FHN subjects. Memantine 82-91 reticulon 4 Homo sapiens 62-67 22311382-7 2012 For No-Go correct rejects, memantine (relative to placebo) reduced activity in left cingulate and caudate in FHP but not FHN subjects. Memantine 27-36 reticulon 4 Homo sapiens 4-9 22142193-8 2012 Memantine (10 microM) and ifenprodil (10 microM), which preferentially inhibit GluN2B-containing NMDA receptors, protected from Tat-induced cell death with no effect on synapse loss. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 79-85 21834130-11 2012 Memantine was the dominant strategy with cost savings of $3739 (30 041 NOK) per patient. Memantine 0-9 serine/threonine/tyrosine kinase 1 Homo sapiens 71-74 22205542-11 2012 Low-dose memantine also significantly potentiated serum and brain BDNF levels. Memantine 9-18 brain-derived neurotrophic factor Rattus norvegicus 66-70 22327556-0 2012 Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Memantine 0-9 brain-derived neurotrophic factor Rattus norvegicus 87-91 22327556-6 2012 Memantine treatment reversed anhedonia and the increase of adrenal gland weight, normalized corticosterone levels and increased BDNF protein levels in the prefrontal cortex in stressed rats. Memantine 0-9 brain-derived neurotrophic factor Rattus norvegicus 128-132 22249110-8 2012 In the experiments with NCX reversal by gramicidin, MK801 and memantine robustly inhibited NCXrev while AP-5 was much less efficacious. Memantine 62-71 solute carrier family 8 member A1 Rattus norvegicus 24-27 22119002-3 2012 BsHSPMG inhibited the activity of NR1/NR2A and NR1/NR2B receptors more strongly and did it for those of NR1/NR2C and NR1/NR2D receptors more weakly than a therapeutic drug of Alzheimer"s disease, memantine. Memantine 196-205 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-37 22290557-9 2012 In the TCC, the increase in formalin-induced Fos immunoreactivity was significantly attenuated in the memantine group (p < 0.01). Memantine 102-111 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 45-48 22442066-10 2012 Blocking NMDARs with memantine (30 mum) or GluN2B-containing receptors with ifenprodil (3 mum) prevents CREB shutoff effectively in CTX and MSNs, and also rescues both neuronal types from NMDA-mediated toxicity. Memantine 21-30 cAMP responsive element binding protein 1 Rattus norvegicus 104-108 23051684-0 2012 Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients. Memantine 46-55 apolipoprotein E Homo sapiens 95-111 23051684-7 2012 CONCLUSION: Moderately severe AD patients with the APOE epsilon4 allele may respond more favorably to memantine plus rivastigmine patch than epsilon4 noncarriers. Memantine 102-111 apolipoprotein E Homo sapiens 51-55 22792283-4 2012 Furthermore, memantine significantly inhibited nicotine-elicited inward currents in Xenopous oocytes expressing alpha3beta2-, alpha7- or alpha4beta2-nAChR, and nicotine-induced calcium influx in cultured rat SCG neurons. Memantine 13-22 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 149-154 21384431-5 2012 The approach was applied in a post-hoc analysis of ADAS-cog results from two randomized, placebo-controlled and double-blind clinical trials with memantine in mild to moderate Alzheimer"s disease (AD). Memantine 146-155 alkylglycerone phosphate synthase Homo sapiens 51-55 21955815-2 2012 In this 12-week, international, randomized, double-blind, placebo-controlled trial of memantine (10 mg bid), the functional communication abilities of patients with AD (MMSE range: 10-19) were assessed using the Functional Linguistic Communication Inventory (FLCI; primary measure). Memantine 86-95 BH3 interacting domain death agonist Homo sapiens 103-106 22134197-9 2012 Memantine treatment up-regulated the expression of Foxp3 in spleen CD4+ T cells followed by an increase in CD4+CD25+ regulatory T cells. Memantine 0-9 forkhead box P3 Mus musculus 51-56 22792283-5 2012 These results suggest that memantine is a non-specific antagonist for nAChR. Memantine 27-36 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 70-75 22615862-8 2012 Memantine treatment of Fmr1-KO CGCs promoted cell adhesion properties. Memantine 0-9 fragile X messenger ribonucleoprotein 1 Mus musculus 23-27 22615862-9 2012 Memantine also stimulated the development of mushroom-shaped mature dendritic spines and restored dendritic spine to normal levels in Fmr1-KO CGCs. Memantine 0-9 fragile X messenger ribonucleoprotein 1 Mus musculus 134-138 22615862-10 2012 Furthermore, we demonstrated that memantine treatment promoted synapse formation and restored the excitatory synapses to a normal range in Fmr1-KO CGCs. Memantine 34-43 fragile X messenger ribonucleoprotein 1 Mus musculus 139-143 21277908-6 2011 Interestingly, pretreatment with memantine at the lowest effective dose (0.02 mg/kg/injection) reversed cocaine conditioning-enhanced IL-6 and -decreased TNF-alpha levels in these brain regions. Memantine 33-42 interleukin 6 Mus musculus 134-138 21624454-3 2011 Memantine is another use-dependent NMDAR antagonist with shorter binding kinetics and has been demonstrated to be protective in a rat model of PVL, without effects on normal myelination or cortical growth. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 35-40 21715609-6 2011 The NMDAR inhibitors APV, MK-801, and memantine also restore the normal levels of phospho-mTOR in dendrites of Ts1Cje hippocampal neurons. Memantine 38-47 mechanistic target of rapamycin kinase Homo sapiens 90-94 21715609-6 2011 The NMDAR inhibitors APV, MK-801, and memantine also restore the normal levels of phospho-mTOR in dendrites of Ts1Cje hippocampal neurons. Memantine 38-47 reciprocal translocation, Chr 12 and 16, Epstein 1 Mus musculus 111-117 21277908-0 2011 Memantine abolishes the formation of cocaine-induced conditioned place preference possibly via its IL-6-modulating effect in medial prefrontal cortex. Memantine 0-9 interleukin 6 Mus musculus 99-103 22448134-13 2012 Using the NMDA receptor (NMDAR-1) inhibitor, memantine, we observed partial protection from gp120-induced BBB injury. Memantine 45-54 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 25-32 22448134-13 2012 Using the NMDA receptor (NMDAR-1) inhibitor, memantine, we observed partial protection from gp120-induced BBB injury. Memantine 45-54 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 92-97 22036080-0 2011 Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3beta decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Memantine 21-30 glycogen synthase kinase 3 beta Rattus norvegicus 91-99 22212311-6 2011 Aside from NMDA receptor antagonism, numerous studies have reported that memantine can also affect dopamine receptors, block excessive calcium influx and production of reactive oxygen species (ROS) induced by Abeta oligomers, and inhibit the internal ribosome entry site (IRES), thus preventing the expression of the amyloid precursor and tau proteins which are considered as early indicators of Alzheimer"s. Memantine 73-82 amyloid beta precursor protein Homo sapiens 209-214 22212311-6 2011 Aside from NMDA receptor antagonism, numerous studies have reported that memantine can also affect dopamine receptors, block excessive calcium influx and production of reactive oxygen species (ROS) induced by Abeta oligomers, and inhibit the internal ribosome entry site (IRES), thus preventing the expression of the amyloid precursor and tau proteins which are considered as early indicators of Alzheimer"s. Memantine 73-82 microtubule associated protein tau Homo sapiens 339-342 21705496-6 2011 Using a murine model of HHcy (cbs(+/-)), treatment for 2 weeks with an NMDAr antagonist (memantine) rescued cerebrovascular expression of claudin-5 and blood-brain barrier permeability to both exogenous sodium fluorescein and endogenous IgG. Memantine 89-98 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 71-76 21705496-6 2011 Using a murine model of HHcy (cbs(+/-)), treatment for 2 weeks with an NMDAr antagonist (memantine) rescued cerebrovascular expression of claudin-5 and blood-brain barrier permeability to both exogenous sodium fluorescein and endogenous IgG. Memantine 89-98 claudin 5 Mus musculus 138-147 20363261-5 2011 Ts65Dn mice were treated with memantine for a period of 6 months, beginning at 4 months of age. Memantine 30-39 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 0-6 20363261-7 2011 Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls. Memantine 0-9 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 79-85 20363261-9 2011 However, memantine treatment of Ts65Dn mice gave rise to elevated brain-derived neurotrophic factor expression in the hippocampus and frontal cortex, suggesting a mechanism of behavioral modification. Memantine 9-18 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 32-38 20363261-9 2011 However, memantine treatment of Ts65Dn mice gave rise to elevated brain-derived neurotrophic factor expression in the hippocampus and frontal cortex, suggesting a mechanism of behavioral modification. Memantine 9-18 brain derived neurotrophic factor Mus musculus 66-99 21088041-4 2011 Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for mild to moderate Alzheimer"s disease (A) and memantine for moderate to severe Alzheimer"s disease (A). Memantine 132-141 butyrylcholinesterase Homo sapiens 0-14 21277908-6 2011 Interestingly, pretreatment with memantine at the lowest effective dose (0.02 mg/kg/injection) reversed cocaine conditioning-enhanced IL-6 and -decreased TNF-alpha levels in these brain regions. Memantine 33-42 tumor necrosis factor Mus musculus 154-163 21277908-10 2011 Finally, intra-mPFC infusion of recombinant IL-6, but not thalidomide, reversed memantine (0.02 mg/kg/injection x 6)-decreased cocaine-induced CPP. Memantine 80-89 interleukin 6 Mus musculus 44-48 21277908-12 2011 Moreover, an extremely low dose of memantine may decrease the acquisition of cocaine-induced CPP by reversing cocaine conditioning-increased IL-6 levels in mPFC. Memantine 35-44 interleukin 6 Mus musculus 141-145 21272612-3 2011 Previous pre-clinical studies have shown that memantine (an N-methyl-d-aspartate receptor antagonist) and erythropoietin can be neuroprotective in other models of brain injury. Memantine 46-55 erythropoietin Homo sapiens 60-120 21385152-8 2011 EXPERT OPINION: For the treatment of moderate to severe AD, memantine should be offered as a therapeutic option, either on its own, or in combination with a cholinesterase inhibitor. Memantine 60-69 butyrylcholinesterase Homo sapiens 157-171 19446369-0 2011 Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Memantine 88-97 amyloid beta precursor protein Rattus norvegicus 19-24 19446369-2 2011 Here, the ability of the NMDA receptor (NMDAR) antagonist memantine to prevent synthetic Abeta-mediated rapid functional deficits in learned behavior and synaptic plasticity was assessed in the rat. Memantine 58-67 amyloid beta precursor protein Rattus norvegicus 89-94 19446369-3 2011 In vitro, pretreatment with a clinically relevant, NMDAR blocking concentration of memantine partially inhibited the induction of long-term potentiation (LTP) in the dentate gyrus and prevented further inhibition caused by exposure to Abeta(1-42). Memantine 83-92 amyloid beta precursor protein Rattus norvegicus 235-240 19446369-4 2011 Whereas systemic injection with memantine alone inhibited LTP in the CA1 area in vivo, a subthreshold dose partially abrogated the inhibition of LTP by intracerebroventricular soluble Abeta(1-42). Memantine 32-41 carbonic anhydrase 1 Rattus norvegicus 69-72 19446369-4 2011 Whereas systemic injection with memantine alone inhibited LTP in the CA1 area in vivo, a subthreshold dose partially abrogated the inhibition of LTP by intracerebroventricular soluble Abeta(1-42). Memantine 32-41 amyloid beta precursor protein Rattus norvegicus 184-189 19446369-5 2011 Similarly, systemic treatment with memantine alone impaired performance of an operant learning task and a subthreshold dose prevented the Abeta(1-42)-mediated increase in perseveration errors. Memantine 35-44 amyloid beta precursor protein Rattus norvegicus 138-143 19446369-6 2011 The acute protection afforded by memantine, albeit in a narrow dose range, against the rapid disruptive effects of soluble Abeta(1-42) on synaptic plasticity and learned behavior strongly implicate NMDAR-dependent reversible dysfunction of synaptic mechanisms in Abeta-mediated cognitive impairment. Memantine 33-42 amyloid beta precursor protein Rattus norvegicus 123-128 21671540-8 2011 Memantine can also be used in combination with acetylcholinesterase inhibitors. Memantine 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-67 21440043-12 2011 In conclusion, memantine in dose of 20 mg/kg improves the sucrose consumption, reversal learning and prefrontal cortical synaptic plasticity, but impairs spatial memory, which is probably due to different extent of up-regulating NR2B receptor expression in prefrontal cortex and hippocampus in stressed rats. Memantine 15-24 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 229-233 21281652-0 2011 Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer"s disease. Memantine 11-20 presenilin 1 Mus musculus 107-110 21845571-8 2011 However, memantine treated rats showed significantly higher number of spared neuron counts and reduced nitric oxide synthase immunoreactivity in CA1 and CA2 regions compared with the non-treated rats. Memantine 9-18 carbonic anhydrase 1 Rattus norvegicus 145-148 21246320-9 2011 Subgroup analysis indicated that the effects of IP-10 and IL-8 were influenced by effective antiretroviral therapy and that memantine treatment may mitigate the neuronal effects of IP-10. Memantine 124-133 C-X-C motif chemokine ligand 10 Homo sapiens 181-186 21246320-11 2011 In particular, the findings identify relationships between the immune response-particularly an interferon-inducible chemokine, IP-10-and cerebral metabolites and suggest that antiretroviral therapy and memantine modify the impact of the immune response on neurons. Memantine 202-211 C-X-C motif chemokine ligand 10 Homo sapiens 127-132 20955720-0 2011 Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. Memantine 67-76 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 122-127 20955720-0 2011 Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. Memantine 67-76 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 128-134 20955720-3 2011 This study quantifies the extent to which Mg(2+) alters the potency of the block produced by both amantadine and memantine at human recombinant GluN1/GluN2A NMDARs. Memantine 113-122 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 144-149 20955720-3 2011 This study quantifies the extent to which Mg(2+) alters the potency of the block produced by both amantadine and memantine at human recombinant GluN1/GluN2A NMDARs. Memantine 113-122 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 150-156 20955720-5 2011 Amantadine and memantine blocked human GluN1/GluN2A NMDARs in a voltage-dependent manner with IC(50) values (at -80 mV) of 49 +- 6 muM (n = 7) and 1.0 +- 0.3 muM (n = 7), respectively. Memantine 15-24 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 39-44 20955720-5 2011 Amantadine and memantine blocked human GluN1/GluN2A NMDARs in a voltage-dependent manner with IC(50) values (at -80 mV) of 49 +- 6 muM (n = 7) and 1.0 +- 0.3 muM (n = 7), respectively. Memantine 15-24 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 45-51 20955720-7 2011 Similarly in the presence of amantadine or memantine the potency of Mg(2+) in blocking GluN1/GluN2A NMDARs was reduced. Memantine 43-52 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 87-92 20955720-7 2011 Similarly in the presence of amantadine or memantine the potency of Mg(2+) in blocking GluN1/GluN2A NMDARs was reduced. Memantine 43-52 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 93-99 21419002-5 2011 RESULTS: At week 24 the patients in the memantine group had better MMSE (22.8 +- 1.8), ADAS-cog (18.6 +- 2.3), and UPDRS-III (34.6 +- 4.2) scales scores than those taking placebo MMSE (18.5 +- 1.7), ADAS-cog (21.9 +- 2.4), and UPDRS-III (41.2 +- 4.0). Memantine 40-49 alkylglycerone phosphate synthase Homo sapiens 87-91 21419002-5 2011 RESULTS: At week 24 the patients in the memantine group had better MMSE (22.8 +- 1.8), ADAS-cog (18.6 +- 2.3), and UPDRS-III (34.6 +- 4.2) scales scores than those taking placebo MMSE (18.5 +- 1.7), ADAS-cog (21.9 +- 2.4), and UPDRS-III (41.2 +- 4.0). Memantine 40-49 alkylglycerone phosphate synthase Homo sapiens 199-203 21419002-6 2011 Patients treated with memantine had better improvement on the MMSE (P < 0.05), ADAS-cog (P < 0.05), and UPDRS-III (P < 0.05) scales compared with the control group by the end of study week 24. Memantine 22-31 alkylglycerone phosphate synthase Homo sapiens 79-83 21220675-8 2011 Alzheimer-disease patients who received ChEIs and memantine took them longer, were more functionally impaired, and showed greater decline on the MMSE and CDR (but not on the ADAS-cog or FAQ) than those who received ChEIs only. Memantine 50-59 alkylglycerone phosphate synthase Homo sapiens 174-178 20577261-4 2011 Sustained calcium (Ca(2+)) signals and caspase-3 activation in thymocytes were induced by interaction with antigen-pulsed dendritic cells (DCs) and were inhibited by NMDAR antagonists MK801 and memantine. Memantine 194-203 caspase 3 Mus musculus 39-48 20577261-4 2011 Sustained calcium (Ca(2+)) signals and caspase-3 activation in thymocytes were induced by interaction with antigen-pulsed dendritic cells (DCs) and were inhibited by NMDAR antagonists MK801 and memantine. Memantine 194-203 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 166-171 21893967-4 2011 This article provides a snapshot of potential pharmacotherapies for DS, with emphasis on our recent results showing that the N-methyl-D-aspartate receptor antagonist memantine can reverse learning and memory deficits in Ts65Dn mice. Memantine 166-175 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 220-226 22167136-0 2011 Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats. Memantine 54-63 cytochrome P450, family 2, subfamily d, polypeptide 2 Rattus norvegicus 97-103 22167136-8 2011 The intensity of inhibitory effects on the CYP2D2 activity were: memantine < memantine + fluoxetine < fluoxetine. Memantine 65-74 cytochrome P450, family 2, subfamily d, polypeptide 2 Rattus norvegicus 43-49 22167136-8 2011 The intensity of inhibitory effects on the CYP2D2 activity were: memantine < memantine + fluoxetine < fluoxetine. Memantine 80-89 cytochrome P450, family 2, subfamily d, polypeptide 2 Rattus norvegicus 43-49 22167136-9 2011 CONCLUSION: The results presented suggest that the clinical pharmacotherapeutical approach to combine memantine with fluoxetine is from the point of view of pharmacokinetic drug-drug interaction on the level of CYP2D2 isoenzyme safe and even of benefit as memantine could elicit a suppression of the inhibitory influence of fluoxetine. Memantine 102-111 cytochrome P450, family 2, subfamily d, polypeptide 2 Rattus norvegicus 211-217 21130810-8 2011 These results suggest that involvement of dopaminergic and/or serotonergic neurotransmission may play a crucial role in memantine-induced PPI disruption, and additionally, indicate that blockade of either the D(2) or 5-HT(2A) receptor may prevent disruption of PPI induced by memantine in mice. Memantine 120-129 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 217-234 21130810-8 2011 These results suggest that involvement of dopaminergic and/or serotonergic neurotransmission may play a crucial role in memantine-induced PPI disruption, and additionally, indicate that blockade of either the D(2) or 5-HT(2A) receptor may prevent disruption of PPI induced by memantine in mice. Memantine 276-285 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 217-234 21364371-3 2011 Evidence that the use of memantine in a patient already on cholinesterase inhibitor therapy can provide a clinically significant benefit is limited. Memantine 25-34 butyrylcholinesterase Homo sapiens 59-73 21364371-4 2011 OBJECTIVE: To review the evidence supporting the addition of memantine therapy in patients with moderate-to-severe AD who are already receiving treatment with a cholinesterase inhibitor. Memantine 61-70 butyrylcholinesterase Homo sapiens 161-175 21845571-8 2011 However, memantine treated rats showed significantly higher number of spared neuron counts and reduced nitric oxide synthase immunoreactivity in CA1 and CA2 regions compared with the non-treated rats. Memantine 9-18 carbonic anhydrase 2 Rattus norvegicus 153-156 21845571-10 2011 Early anti-excitotoxic treatment with memantine seems to have a neuroprotective effect especially in the CA1 and CA2 subunits of the hippocampus. Memantine 38-47 carbonic anhydrase 1 Rattus norvegicus 105-108 21845571-10 2011 Early anti-excitotoxic treatment with memantine seems to have a neuroprotective effect especially in the CA1 and CA2 subunits of the hippocampus. Memantine 38-47 carbonic anhydrase 2 Rattus norvegicus 113-116 20839903-8 2010 After therapy with memantine, patients had a 27% decline in CSF tau levels (p = 0.04) and four patients whose CSF tau dropped to healthy control levels lost only -0.42 ALSFRS points per month. Memantine 19-28 microtubule associated protein tau Homo sapiens 64-67 20839903-8 2010 After therapy with memantine, patients had a 27% decline in CSF tau levels (p = 0.04) and four patients whose CSF tau dropped to healthy control levels lost only -0.42 ALSFRS points per month. Memantine 19-28 microtubule associated protein tau Homo sapiens 114-117 20493916-8 2010 Furthermore, the memantine-mediated inhibition on 4-AP-evoked glutamate release could be diminished by the protein kinase C (PKC) inhibitors, and memantine significantly reduced the depolarization-induced phosphorylation of PKC, and PKCalpha. Memantine 17-26 protein kinase C, alpha Rattus norvegicus 125-128 21106831-10 2010 Finally, memantine dose-dependently inhibited extrasynaptic NMDAR-induced KPI-APPs expression as well as neuronal Abeta release. Memantine 9-18 cathepsin B Homo sapiens 74-82 20979032-5 2010 Memantine effectiveness was assessed through the following scales: MMSE, CGI-S, FAST, ACDS-ADL, NPI-Q Severity, NPI-Q Stress, at 6 and at 12 months. Memantine 0-9 Fas activated serine/threonine kinase Homo sapiens 80-84 20821339-4 2010 In the present study, we set out to investigate the effect of intravenously applied memantine on iontophoresed NMDA-evoked firing of hippocampal CA1 neurons using in vivo conditions. Memantine 84-93 carbonic anhydrase 1 Rattus norvegicus 145-148 20537812-5 2010 Participants were then randomized to receive either memantine 20mg bid (N=39) or placebo (N=42) for 12-weeks in combination with individual relapse-prevention therapy. Memantine 52-61 BH3 interacting domain death agonist Homo sapiens 67-70 20493916-8 2010 Furthermore, the memantine-mediated inhibition on 4-AP-evoked glutamate release could be diminished by the protein kinase C (PKC) inhibitors, and memantine significantly reduced the depolarization-induced phosphorylation of PKC, and PKCalpha. Memantine 17-26 protein kinase C, alpha Rattus norvegicus 224-227 20493916-8 2010 Furthermore, the memantine-mediated inhibition on 4-AP-evoked glutamate release could be diminished by the protein kinase C (PKC) inhibitors, and memantine significantly reduced the depolarization-induced phosphorylation of PKC, and PKCalpha. Memantine 17-26 protein kinase C, alpha Rattus norvegicus 233-241 20493916-8 2010 Furthermore, the memantine-mediated inhibition on 4-AP-evoked glutamate release could be diminished by the protein kinase C (PKC) inhibitors, and memantine significantly reduced the depolarization-induced phosphorylation of PKC, and PKCalpha. Memantine 146-155 protein kinase C, alpha Rattus norvegicus 224-227 20493916-8 2010 Furthermore, the memantine-mediated inhibition on 4-AP-evoked glutamate release could be diminished by the protein kinase C (PKC) inhibitors, and memantine significantly reduced the depolarization-induced phosphorylation of PKC, and PKCalpha. Memantine 146-155 protein kinase C, alpha Rattus norvegicus 233-241 20493916-9 2010 Thus, the effect of memantine on evoked glutamate release is linked to a decrease in [Ca2+]i contributed by Ca2+ entry through presynaptic voltage-dependent Ca2+ channels and to the subsequent suppression of the PKC signaling cascade. Memantine 20-29 protein kinase C, alpha Rattus norvegicus 212-215 20613638-9 2010 N-methyl-D-aspartate receptor activation upregulated pro-MMP-9 and increased MMP-9 gelatinase activity, and memantine, an N-methyl-D-aspartate receptor blocker, mitigated gp120-induced BBB abnormalities. Memantine 108-117 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 171-176 19959636-6 2010 RESULTS: At 30-microM concentrations, the genistein, resveratrol, and memantine inhibitors were able to reverse significantly the loss of cell viability, the activation of caspase-3/7 and caspase-9, and the production of ROS/RNS in ARPE-19 cell cultures. Memantine 70-79 caspase 3 Homo sapiens 172-181 20127811-6 2010 Furthermore, the N-methyl-D-aspartate (NMDA) receptor antagonist memantine prevented memory impairment and dynamin 1 degradation, suggesting that these changes might be mediated by NMDA receptors. Memantine 65-74 dynamin 1 Rattus norvegicus 107-116 20446294-1 2010 A nonionic surfactant MEKC method with LIF detection was developed for the simultaneous determination of memantine, an anti-Alzheimer"s disease agent, and amantadine, an anti-Parkinson"s disease drug, in human plasma. Memantine 105-114 LIF interleukin 6 family cytokine Homo sapiens 39-42 20109533-0 2010 Pigment epithelium-derived factor up-regulation induced by memantine, an N-methyl-D-aspartate receptor antagonist, is involved in increased proliferation of hippocampal progenitor cells. Memantine 59-68 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 0-33 20109533-4 2010 In this study we searched for a factor that mediates memantine-induced cellular proliferation, and found that pigment epithelium-derived factor (PEDF), a broad-acting neurotrophic factor, is up-regulated in the dentate gyrus of adult mice after the injection of memantine. Memantine 53-62 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 110-143 20109533-4 2010 In this study we searched for a factor that mediates memantine-induced cellular proliferation, and found that pigment epithelium-derived factor (PEDF), a broad-acting neurotrophic factor, is up-regulated in the dentate gyrus of adult mice after the injection of memantine. Memantine 53-62 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 145-149 20109533-4 2010 In this study we searched for a factor that mediates memantine-induced cellular proliferation, and found that pigment epithelium-derived factor (PEDF), a broad-acting neurotrophic factor, is up-regulated in the dentate gyrus of adult mice after the injection of memantine. Memantine 262-271 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 110-143 20109533-4 2010 In this study we searched for a factor that mediates memantine-induced cellular proliferation, and found that pigment epithelium-derived factor (PEDF), a broad-acting neurotrophic factor, is up-regulated in the dentate gyrus of adult mice after the injection of memantine. Memantine 262-271 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 145-149 20109533-5 2010 PEDF mRNA expression increased significantly by 3.5-fold at 1 day after the injection of memantine. Memantine 89-98 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 0-4 20109533-6 2010 In addition, the expression level of PEDF protein also increased by 1.8-fold at 2 days after the injection of memantine. Memantine 110-119 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 37-41 20109533-10 2010 These findings suggest that the memantine induced PEDF up-regulation is involved in increased proliferation of hippocampal progenitor cells. Memantine 32-41 serine (or cysteine) peptidase inhibitor, clade F, member 1 Mus musculus 50-54 20176108-4 2010 One mutant we have characterized is a catalytically inactive form of IKK-2, D145A IKK-2, wherein the catalytic aspartic acid, D145 was replaced with alanine. Memantine 76-80 inhibitor of nuclear factor kappa B kinase subunit beta Homo sapiens 69-74 20176108-4 2010 One mutant we have characterized is a catalytically inactive form of IKK-2, D145A IKK-2, wherein the catalytic aspartic acid, D145 was replaced with alanine. Memantine 76-80 inhibitor of nuclear factor kappa B kinase subunit beta Homo sapiens 82-87 19784770-4 2010 Cell growth was found to be significantly (P < 0.0001) impaired down to 10% of normal growth by the irreversible NMDAR1 antagonists MK-801 and memantine with IC 50s ranging from 600 to >800 microM and from 200 to 300 microM for the two lines. Memantine 146-155 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 116-122 20540654-0 2010 Memantine ER, a once-daily formulation for the treatment of Alzheimer"s disease. Memantine 0-9 epiregulin Homo sapiens 10-12 20540654-5 2010 AREAS COVERED IN THIS REVIEW: The goal of this article is to review the once-daily memantine ER 28 mg formulation for the treatment of Alzheimer"s disease, which, by simplifying the dosage regimen, decreases the problems of medication adherence. Memantine 83-92 epiregulin Homo sapiens 9-11 19959636-6 2010 RESULTS: At 30-microM concentrations, the genistein, resveratrol, and memantine inhibitors were able to reverse significantly the loss of cell viability, the activation of caspase-3/7 and caspase-9, and the production of ROS/RNS in ARPE-19 cell cultures. Memantine 70-79 caspase 9 Homo sapiens 188-197 20421694-0 2010 Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. Memantine 0-9 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 56-62 19954760-5 2010 Brain-derived neurotrophic factor (BDNF) hippocampal levels were assessed in imipramine- and memantine-treated rats by ELISA sandwich assay. Memantine 93-102 brain-derived neurotrophic factor Rattus norvegicus 0-33 19954760-6 2010 Interesting enough, acute administration, but not chronic administration of memantine at higher dose (20 mg/kg) increased BDNF protein levels in the rat hippocampus (p < 0.05). Memantine 76-85 brain-derived neurotrophic factor Rattus norvegicus 122-126 20079839-5 2010 We found that exposure to anoxia induces rapid dephosphorylation of Kv2.1 in the brain, which can be blocked by pre-administration of a NMDA-type glutamate receptor antagonist, memantine. Memantine 177-186 potassium voltage-gated channel subfamily B member 1 Homo sapiens 68-73 19948208-0 2010 Memantine treatment decreases levels of secreted Alzheimer"s amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Memantine 0-9 amyloid beta precursor protein Homo sapiens 105-117 19948208-2 2010 Several studies have documented protective roles of memantine against amyloid beta (A beta) peptide-mediated damage to neurons in both in vitro and in vivo models. Memantine 52-61 amyloid beta precursor protein Homo sapiens 78-90 19948208-4 2010 However, the exact mechanism by which memantine provides protection against A beta-mediated neurodegenerative cascade, including APP metabolism, remains to be elucidated. Memantine 38-47 amyloid beta precursor protein Homo sapiens 76-82 19948208-5 2010 Herein, we investigated the effect of memantine on levels of the secreted form of A beta precursor protein (APP), secreted A beta and cell viability markers under short/acute conditions. Memantine 38-47 amyloid beta precursor protein Homo sapiens 82-106 19948208-5 2010 Herein, we investigated the effect of memantine on levels of the secreted form of A beta precursor protein (APP), secreted A beta and cell viability markers under short/acute conditions. Memantine 38-47 amyloid beta precursor protein Homo sapiens 82-88 19948208-7 2010 Memantine significantly decreased the levels of the secreted form of sAPP, sAPP alpha and A beta((1-40)) compared to vehicle treated cells. Memantine 0-9 amyloid beta precursor protein Homo sapiens 90-96 20042680-3 2010 After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. Memantine 21-30 amyloid beta (A4) precursor protein Mus musculus 131-136 20042680-3 2010 After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. Memantine 21-30 amyloid beta (A4) precursor protein Mus musculus 139-144 20042680-3 2010 After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. Memantine 21-30 amyloid beta (A4) precursor protein Mus musculus 139-144 20042680-6 2010 Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice. Memantine 9-18 amyloid beta (A4) precursor protein Mus musculus 44-49 20104942-3 2010 Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change). Memantine 157-166 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 20104942-3 2010 Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change). Memantine 157-166 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 20033305-5 2010 Patients treated with memantine had better measures on the MMSE (p < 0.05), ADAS-cog (p < 0.05), clock drawing test (p < 0.05), and FAB (p < 0.01) as compared with the control group by the end of study week 24. Memantine 22-31 alkylglycerone phosphate synthase Homo sapiens 76-80 20033305-5 2010 Patients treated with memantine had better measures on the MMSE (p < 0.05), ADAS-cog (p < 0.05), clock drawing test (p < 0.05), and FAB (p < 0.01) as compared with the control group by the end of study week 24. Memantine 22-31 FA complementation group B Homo sapiens 132-135 20033305-6 2010 Members of the group of patients with high homocysteine levels mounted significantly better responses with memantine treatment, as compared with patients of the control group with high homocysteine levels but not receiving memantine, at the ends of study weeks 24 and 52, in terms of all rating scales (UPDRS, MMSE, ADAS-cog, D-KEFS Verbal Fluency Test, FAB. Memantine 107-116 alkylglycerone phosphate synthase Homo sapiens 316-320 20033305-6 2010 Members of the group of patients with high homocysteine levels mounted significantly better responses with memantine treatment, as compared with patients of the control group with high homocysteine levels but not receiving memantine, at the ends of study weeks 24 and 52, in terms of all rating scales (UPDRS, MMSE, ADAS-cog, D-KEFS Verbal Fluency Test, FAB. Memantine 107-116 FA complementation group B Homo sapiens 354-357 22291485-4 2010 Cell viability tests showed cell growth was significantly (P < 0.0001) impaired by NMDAR1 antagonists MK-801 and memantine. Memantine 116-125 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 86-92 20164552-3 2010 We propose that folic acid might have a synergistic effect for memantine in protecting neurons from Abeta accumulation. Memantine 63-72 amyloid beta (A4) precursor protein Mus musculus 100-105 20421694-7 2010 After memantine treatment, the levels of hippocampal VGLUT1 were significantly increased, reaching the levels observed in vehicle treated-control animals. Memantine 6-15 solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 Mus musculus 53-59 19642202-0 2010 Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. Memantine 0-9 amyloid beta (A4) precursor protein Mus musculus 73-80 19642202-10 2010 In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Abeta(1-42), oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 microM and significantly reduced the cortical levels of soluble Abeta(1-42). Memantine 102-111 presenilin 1 Mus musculus 3-19 19642202-10 2010 In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Abeta(1-42), oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 microM and significantly reduced the cortical levels of soluble Abeta(1-42). Memantine 102-111 presenilin 1 Mus musculus 21-24 19679463-3 2009 Anti-cancer effects of a selective sigma-1 agonist, 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), in glioblastoma were shown previously, leading to the present work where the effects on glioblastoma cells of 17 agonists or antagonists of sigma-1 receptors were studied, including currently marketed drugs fluvoxamine, dextromethorphan, donepezil, memantine and haloperidol. Memantine 353-362 translocator protein Homo sapiens 98-101 21572937-2 2010 While NMDAR competitive antagonists, such as D-2-Amino-5-Phosphopentanoic acid (AP5) have been shown to impair learning and memory, the non-competitive antagonist, memantine, is paradoxically beneficial in mild to moderate Alzheimer"s disease (AD) patients. Memantine 164-173 adaptor related protein complex 5 subunit beta 1 Homo sapiens 80-83 19733635-4 2009 The present study aims to investigate the protective effects of memantine on Abeta(25-35)-induced changes in peptidergic and glial systems. Memantine 64-73 amyloid beta precursor protein Rattus norvegicus 77-82 19733635-8 2009 Treatment with memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist significantly attenuated Abeta(25-35)-induced changes of neuropeptides, their metabolizing enzymes, glial marker proteins, and activation of iNOS. Memantine 15-24 amyloid beta precursor protein Rattus norvegicus 117-122 19915593-7 2009 By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic NMDAR activity, decreases neuronal inclusions and worsens these outcomes. Memantine 23-32 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 79-84 19653132-8 2009 Immunohistochemical experiments revealed that the expression of CD11b, a marker protein of microglia, was increased in the hypothalamus and periaqueductal gray in the chronic constriction injury rat brain as compared with the controls, and memantine treatment could suppress the activation of microglia, suggesting the involvement of microglia in pain mechanism. Memantine 240-249 integrin subunit alpha M Rattus norvegicus 64-69 19739697-3 2009 Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change). Memantine 157-166 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 19615394-11 2009 Furthermore, attenuation in oxidative damage following antioxidants or memantine pretreatment was accompanied by rescue from dendritic degeneration of pyramidal neurons in the CA1 hippocampal area. Memantine 71-80 carbonic anhydrase 1 Rattus norvegicus 176-179 19739697-3 2009 Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change). Memantine 157-166 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 19694907-8 2009 Interestingly, memantine co-exposure blocked elevations in the obligatory NR1 subunit. Memantine 15-24 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 74-77 19521778-0 2009 An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. Memantine 69-78 brain derived neurotrophic factor Homo sapiens 18-22 19361551-9 2009 ERK activation could indicate a stress-mediated increase in glutamatergic signaling, therefore mice were treated prior to SNI and stress with memantine, an N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine 142-151 mitogen-activated protein kinase 1 Mus musculus 0-3 19361551-9 2009 ERK activation could indicate a stress-mediated increase in glutamatergic signaling, therefore mice were treated prior to SNI and stress with memantine, an N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 156-185 19361551-9 2009 ERK activation could indicate a stress-mediated increase in glutamatergic signaling, therefore mice were treated prior to SNI and stress with memantine, an N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 187-192 19536110-0 2009 Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Memantine 36-45 neurotrophin 3 Homo sapiens 59-78 19536110-7 2009 More specifically, it seems to be that astroglia, not microglia, are the source of the memantine-elicited neurotrophic effects through the increased production of glial cell line-derived neurotrophic factor (GDNF). Memantine 87-96 glial cell derived neurotrophic factor Homo sapiens 163-206 19536110-7 2009 More specifically, it seems to be that astroglia, not microglia, are the source of the memantine-elicited neurotrophic effects through the increased production of glial cell line-derived neurotrophic factor (GDNF). Memantine 87-96 glial cell derived neurotrophic factor Homo sapiens 208-212 19536110-9 2009 In addition, memantine also displays neuroprotective effects against LPS-induced DA neuronal damage through its inhibition of microglia activation showed by both OX-42 immunostaining and reduction of pro-inflammatory factor production, such as extracellular superoxide anion, intracellular reactive oxygen species, nitric oxide, prostaglandin E(2), and tumor necrosis factor-alpha. Memantine 13-22 tumor necrosis factor Homo sapiens 353-380 19536110-10 2009 These results suggest that the neuroprotective effects of memantine shown in our cell culture studies are mediated in part through alternative novel mechanisms by reducing microglia-associated inflammation and by stimulating neurotrophic factor release from astroglia. Memantine 58-67 neurotrophin 3 Homo sapiens 225-244 19521778-0 2009 An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. Memantine 69-78 AKT serine/threonine kinase 1 Homo sapiens 33-36 19521778-3 2009 Memantine (0.1-2 muM) suppressed neuronal apoptosis evoked by staurosporine in 7 DIV cortical neurons, whereas other antagonists of NMDA receptor, MK-801 (1 muM) and AP-5 (100 muM) were ineffective. Memantine 0-9 latexin Homo sapiens 17-20 19521778-5 2009 The immunoblot analysis showed that the staurosporine induced a decrease in p-Akt protein kinase level and that this effect was reversed by memantine treatment. Memantine 140-149 AKT serine/threonine kinase 1 Homo sapiens 78-81 19521778-7 2009 Furthermore, the ELISA studies showed increased cellular and released BDNF protein level after combined treatment with memantine and staurosporine. Memantine 119-128 brain derived neurotrophic factor Homo sapiens 70-74 19526301-5 2009 We have shown that the NMDA ion channel blockers, MK801 and memantine, and the nitric oxide synthase (NOS) inhibitor, L-NAME, significantly attenuate QUIN-mediated PARP activation, NAD(+) depletion, and LDH release in both neurons and astrocytes. Memantine 60-69 poly(ADP-ribose) polymerase 1 Homo sapiens 164-168 19204022-0 2009 Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Memantine 44-53 butyrylcholinesterase Homo sapiens 59-73 19103181-8 2009 In this study, the association of 10 mg/kg memantine with 10 mg/kg galantamine increased the number of living pyramidal neurons, reduced TUNEL, active caspase-3 and SOD-2 immunoreactivity, and preserved spatial memory after ischemia-reperfusion injury; however, the effects of the combination were not statistically different from those observed in animals treated with galantamine alone. Memantine 43-52 caspase 3 Homo sapiens 151-160 19420753-11 2009 Memantine at 1 mM inhibited both MAO-A and MAO-B activities in mouse forebrain homogenates to 37% and 64% of controls, respectively. Memantine 0-9 monoamine oxidase A Mus musculus 33-38 19420753-11 2009 Memantine at 1 mM inhibited both MAO-A and MAO-B activities in mouse forebrain homogenates to 37% and 64% of controls, respectively. Memantine 0-9 monoamine oxidase B Mus musculus 43-48 19274640-1 2009 OBJECTIVES: The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD. Memantine 81-90 alkylglycerone phosphate synthase Homo sapiens 104-108 19274640-5 2009 RESULTS: The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. Memantine 71-80 alkylglycerone phosphate synthase Homo sapiens 103-107 19274640-6 2009 The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). Memantine 65-74 alkylglycerone phosphate synthase Homo sapiens 4-8 18843265-5 2009 Results showed that one N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, but not another, dextromethorphan, potentiated the ataxic but not hypothermic or sedative/hypnotic effects of ethanol. Memantine 74-83 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 24-53 18843265-5 2009 Results showed that one N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, but not another, dextromethorphan, potentiated the ataxic but not hypothermic or sedative/hypnotic effects of ethanol. Memantine 74-83 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 55-60 19236854-0 2009 Memantine treatment reduces the expression of the K(+)/Cl(-) cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA(A) receptor activation in mice. Memantine 0-9 solute carrier family 12, member 5 Mus musculus 75-79 19236854-3 2009 Knowing that KCC2 maintains low intracellular Cl(-) concentrations, which drive Cl(-) influx in response to GABA(A) receptor activation, we monitored the behavioural response to the GABA(A) receptor enhancer, diazepam, in mice pre-treated for 7 days with saline or 25 mg/kg of memantine. Memantine 277-286 solute carrier family 12, member 5 Mus musculus 13-17 19371579-0 2009 Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Memantine 169-178 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 194-199 19371579-4 2009 In the present study we compared the potency of memantine, ketamine and (+)MK-801 in binding to NMDA receptors in post-mortem human cortical tissue and to antagonize intracellular Ca(2+) responses of human GluN1/GluN2A receptors expressed in HEK-293 cells. Memantine 48-57 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 206-211 19371579-4 2009 In the present study we compared the potency of memantine, ketamine and (+)MK-801 in binding to NMDA receptors in post-mortem human cortical tissue and to antagonize intracellular Ca(2+) responses of human GluN1/GluN2A receptors expressed in HEK-293 cells. Memantine 48-57 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 212-218 19371579-6 2009 Memantine was confirmed to be a moderate affinity (IC(50) at -70 mV of 0.79+/-0.02 microM, Hill=0.92+/-0.02), strongly voltage-dependent (delta=0.90+/-0.09) uncompetitive antagonist of human GluN1/GluN2A receptors. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 191-196 19371579-6 2009 Memantine was confirmed to be a moderate affinity (IC(50) at -70 mV of 0.79+/-0.02 microM, Hill=0.92+/-0.02), strongly voltage-dependent (delta=0.90+/-0.09) uncompetitive antagonist of human GluN1/GluN2A receptors. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 197-203 19946392-12 2009 This bias favours cholinesterase inhibitors, potentially preventing funding of and patient access to less toxic treatment options such as memantine. Memantine 138-147 butyrylcholinesterase Homo sapiens 18-32 19103181-8 2009 In this study, the association of 10 mg/kg memantine with 10 mg/kg galantamine increased the number of living pyramidal neurons, reduced TUNEL, active caspase-3 and SOD-2 immunoreactivity, and preserved spatial memory after ischemia-reperfusion injury; however, the effects of the combination were not statistically different from those observed in animals treated with galantamine alone. Memantine 43-52 superoxide dismutase 2 Homo sapiens 165-170 19154422-5 2009 We assessed the effects of truncating [at residue Iso1098; NR2A(trunC)] and deleting [from residue Phe822; NR2A(delC)] the CTD of NR2A NMDAR subunits on agonist potencies, channel block by Mg(2+) and memantine and potentiation of NMDAR-mediated responses by chelating contaminating divalent cations. Memantine 200-209 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 135-140 18836176-8 2009 Memantine, EGTA, or autocamtide-2-related inhibitory peptide (AIP) inhibited NFkappaB activation in the retina. Memantine 0-9 nuclear factor kappa B subunit 1 Homo sapiens 77-85 18936150-0 2009 Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Memantine 0-9 OPA1, mitochondrial dynamin like GTPase Mus musculus 31-35 18936150-7 2009 RESULTS: Memantine treatment significantly increased RGC survival in glaucomatous DBA/2J mice and increased the 75-kDa OPA1 isoform, but did not alter the 80- and 90-kDa isoforms. Memantine 9-18 OPA1, mitochondrial dynamin like GTPase Mus musculus 119-123 18936150-8 2009 The isoforms of OPA1 were significantly increased in the cytosol of the vehicle-treated glaucomatous retinas but were significantly decreased in memantine-treated glaucomatous retinas. Memantine 145-154 OPA1, mitochondrial dynamin like GTPase Mus musculus 16-20 18936150-9 2009 OPA1 immunoreactivity was decreased in the photoreceptors of both vehicle- and memantine-treated glaucomatous retinas, but was increased in the outer plexiform layer of only the memantine-treated glaucomatous retinas. Memantine 79-88 OPA1, mitochondrial dynamin like GTPase Mus musculus 0-4 18936150-9 2009 OPA1 immunoreactivity was decreased in the photoreceptors of both vehicle- and memantine-treated glaucomatous retinas, but was increased in the outer plexiform layer of only the memantine-treated glaucomatous retinas. Memantine 178-187 OPA1, mitochondrial dynamin like GTPase Mus musculus 0-4 18936150-10 2009 Memantine blocked apoptotic cell death in the GCL, increased Bcl-2 gene expression, and decreased Bax gene expression. Memantine 0-9 germ cell-less, spermatogenesis associated 1 Mus musculus 46-49 18936150-10 2009 Memantine blocked apoptotic cell death in the GCL, increased Bcl-2 gene expression, and decreased Bax gene expression. Memantine 0-9 B cell leukemia/lymphoma 2 Mus musculus 61-66 18936150-10 2009 Memantine blocked apoptotic cell death in the GCL, increased Bcl-2 gene expression, and decreased Bax gene expression. Memantine 0-9 BCL2-associated X protein Mus musculus 98-101 20021448-10 2009 An alternative hypothesis is based on the observation that increased tangle formation is associated with agitation, and on recent studies where memantine has been shown to reduce tau phosphorylation via glycogen synthase kinase (GSK)-3 or activation of protein phosphatase (PP)-2A, which might subsequently lead to reduced agitation. Memantine 144-153 protein phosphatase 2 phosphatase activator Homo sapiens 253-280 19022367-7 2009 PCB-mediated cell death was attenuated with 10microM NMDAR antagonists: 1-amino-3,5-dimethyladamantane hydrochloride (memantine) and (+)-5-methyl-10,11-dihydro-5H-debenzocyclhepten-5,10-imine maleate ((+)-MK-801), thus demonstrating the importance of NMDAR in PCB neurotoxicity. Memantine 72-116 pyruvate carboxylase Homo sapiens 0-3 19022367-7 2009 PCB-mediated cell death was attenuated with 10microM NMDAR antagonists: 1-amino-3,5-dimethyladamantane hydrochloride (memantine) and (+)-5-methyl-10,11-dihydro-5H-debenzocyclhepten-5,10-imine maleate ((+)-MK-801), thus demonstrating the importance of NMDAR in PCB neurotoxicity. Memantine 118-127 pyruvate carboxylase Homo sapiens 0-3 19661628-1 2009 Previous studies showed that memantine inhibits tau hyperphosphorylation in vitro. Memantine 29-38 microtubule associated protein tau Homo sapiens 48-51 18579741-7 2008 Using an H/I rat model of white matter injury, we show in vivo that post-H/I treatment with memantine attenuates acute loss of the developing OL cell surface marker O1 and the mature OL marker MBP (myelin basic protein), and also prevents the long-term reduction in cerebral mantle thickness seen at postnatal day 21 in this model. Memantine 92-101 myelin basic protein Rattus norvegicus 193-196 18607526-1 2008 Previous experiments on primary cultures of hippocampal/cortical neurones revealed that the block and unblock of N-Methyl-D-Aspartate (NMDA) receptor channels by memantine showed double exponential kinetics and that the offset kinetics following a voltage-step were much faster than following a concentration jump. Memantine 162-171 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 113-149 18607526-5 2008 Block and unblock of the NMDA receptor by memantine after both voltage jump and concentration jumps showed triple exponential kinetics. Memantine 42-51 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 25-38 18615702-2 2008 Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss. Memantine 0-9 amyloid beta precursor protein Homo sapiens 54-66 18615702-2 2008 Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss. Memantine 0-9 amyloid beta precursor protein Homo sapiens 68-74 18615702-2 2008 Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss. Memantine 0-9 amyloid beta precursor protein Homo sapiens 136-142 18615702-3 2008 In this study, we assessed whether NMDA receptor inhibition by memantine in transgenic mice expressing human amyloid-beta precursor protein (APP) and presenilin 1 (PS1) is associated with cognitive benefit and amyloid burden reduction by using object recognition, micromagnetic resonance imaging (micro MRI), and histology. Memantine 63-72 amyloid beta precursor protein Homo sapiens 109-139 18615702-3 2008 In this study, we assessed whether NMDA receptor inhibition by memantine in transgenic mice expressing human amyloid-beta precursor protein (APP) and presenilin 1 (PS1) is associated with cognitive benefit and amyloid burden reduction by using object recognition, micromagnetic resonance imaging (micro MRI), and histology. Memantine 63-72 presenilin 1 Homo sapiens 150-162 18615702-3 2008 In this study, we assessed whether NMDA receptor inhibition by memantine in transgenic mice expressing human amyloid-beta precursor protein (APP) and presenilin 1 (PS1) is associated with cognitive benefit and amyloid burden reduction by using object recognition, micromagnetic resonance imaging (micro MRI), and histology. Memantine 63-72 presenilin 1 Homo sapiens 164-167 18346200-6 2008 In addition, Abeta(1-42)-induced AA release was inhibited by d(-)-2-amino-5-phosphonopentanoic acid and memantine, two different NMDA receptor antagonists, suggesting action of Abeta through the NMDA receptor. Memantine 104-113 amyloid beta precursor protein Homo sapiens 33-35 18346200-6 2008 In addition, Abeta(1-42)-induced AA release was inhibited by d(-)-2-amino-5-phosphonopentanoic acid and memantine, two different NMDA receptor antagonists, suggesting action of Abeta through the NMDA receptor. Memantine 104-113 amyloid beta precursor protein Homo sapiens 13-18 18828800-5 2008 An exception is the moderate affinity NMDAR channel blocker memantine, used in Alzheimer"s dementia. Memantine 60-69 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 38-43 18989117-8 2008 Memantine also holds promise to treat neuropsychiatric symptoms, but more prospective trials are needed.With better understanding of pathogenic molecular pathways involving microtubule-associated protein tau, progranulin and TDP-43, potential disease-modifying therapies are being studied in animal models and approaching human trials. Memantine 0-9 microtubule associated protein tau Homo sapiens 173-207 18989117-8 2008 Memantine also holds promise to treat neuropsychiatric symptoms, but more prospective trials are needed.With better understanding of pathogenic molecular pathways involving microtubule-associated protein tau, progranulin and TDP-43, potential disease-modifying therapies are being studied in animal models and approaching human trials. Memantine 0-9 granulin precursor Homo sapiens 209-220 18989117-8 2008 Memantine also holds promise to treat neuropsychiatric symptoms, but more prospective trials are needed.With better understanding of pathogenic molecular pathways involving microtubule-associated protein tau, progranulin and TDP-43, potential disease-modifying therapies are being studied in animal models and approaching human trials. Memantine 0-9 TAR DNA binding protein Homo sapiens 225-231 18418360-5 2008 Administration of the two higher doses of memantine (10 and 20 mg/kg) was associated with a significant decrease in beta-amyloid (Abeta) plaque deposition, increases in synaptic density and the appearance of degenerating axons; the latter two effects were independent of genotype. Memantine 42-51 amyloid beta (A4) precursor protein Mus musculus 130-135 18418360-6 2008 Administration of the lowest dose of memantine (5 mg/kg) was associated with a significant decrease in Abeta plaque deposition and a significant increase in synaptic density, but not a significant increase in degenerating axons. Memantine 37-46 amyloid beta (A4) precursor protein Mus musculus 103-108 19046381-4 2008 However, very little is currently known about the potential role of memantine against Abeta-induced toxicity. Memantine 68-77 amyloid beta precursor protein Homo sapiens 86-91 19046381-8 2008 Memantine treatment significantly protected cultured neurons against Abeta-induced toxicity by attenuating tau-phosphorylation and its associated signaling mechanisms. Memantine 0-9 amyloid beta precursor protein Rattus norvegicus 69-74 18579741-7 2008 Using an H/I rat model of white matter injury, we show in vivo that post-H/I treatment with memantine attenuates acute loss of the developing OL cell surface marker O1 and the mature OL marker MBP (myelin basic protein), and also prevents the long-term reduction in cerebral mantle thickness seen at postnatal day 21 in this model. Memantine 92-101 myelin basic protein Rattus norvegicus 198-218 18486118-2 2008 We tested the hypothesis that uncompetitive NMDAR blockade with memantine prevents mitochondrial dysfunction-related neurodegeneration in vivo, using a mouse model of retinal ganglion cell layer (GCL) degeneration induced by rotenone, a mitochondrial complex I inhibitor. Memantine 64-73 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 44-49 18486118-3 2008 Rotenone induced an increase in cell death and oxidative stress in GCL compared to controls, and these changes were prevented by the co-administration of memantine. Memantine 154-163 germ cell-less, spermatogenesis associated 1 Mus musculus 67-70 18456253-3 2008 We therefore investigated whether memantine can also block the NMDA receptor channel from the intracellular compartment. Memantine 34-43 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 63-76 17700645-0 2008 Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Memantine 49-58 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 94-100 17700645-7 2008 of the uncompetitive NMDAR antagonist memantine rescue performance deficits of Ts65Dn mice on a fear conditioning test. Memantine 38-47 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 21-26 17700645-7 2008 of the uncompetitive NMDAR antagonist memantine rescue performance deficits of Ts65Dn mice on a fear conditioning test. Memantine 38-47 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 79-85 17700645-8 2008 Because the actions of memantine on NMDAR kinetics had been shown by others to mimic somewhat the actions of calcineurin, we attributed this positive effect of memantine on Ts65Dn mice to a drug-mediated "normalization" of NMDAR function. Memantine 23-32 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 36-41 17700645-8 2008 Because the actions of memantine on NMDAR kinetics had been shown by others to mimic somewhat the actions of calcineurin, we attributed this positive effect of memantine on Ts65Dn mice to a drug-mediated "normalization" of NMDAR function. Memantine 160-169 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 173-179 18288936-0 2008 Memantine treatment in patients with mild to moderate Alzheimer"s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Memantine 0-9 butyrylcholinesterase Homo sapiens 94-108 18434534-0 2008 Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. Memantine 99-108 caspase 3 Homo sapiens 19-28 18434534-8 2008 Memantine (4 microM) inhibited isoflurane-induced elevations in cytosolic calcium levels and attenuated isoflurane-induced caspase-3 activation, apoptosis, and cell viability. Memantine 0-9 caspase 3 Homo sapiens 123-132 18434534-12 2008 We also show for the first time that the NMDA receptor partial antagonist, memantine, can prevent isoflurane-induced caspase-3 activation and apoptosis in vivo and in vitro. Memantine 75-84 caspase 3 Homo sapiens 117-126 18525283-6 2008 Memantine was prescribed with a cholinesterase inhibitor in 53.3% of cases. Memantine 0-9 butyrylcholinesterase Homo sapiens 32-46 17996985-4 2008 Memantine (0.1-2 microM) attenuated staurosporine-induced apoptosis as evidenced by reversal of the changes in mitochondrial membrane potential (DeltaPsi(m)) and decreased caspase-3 activity, lactate dehydrogenase (LDH) release and DNA fragmentation. Memantine 0-9 caspase 3 Homo sapiens 172-181 17996985-5 2008 Wortmannin (10 nM) and LY 294002 (10 microM) (inhibitors of phosphatidylinositol-3-kinase, PI3-K) reversed the inhibitory effect of memantine on the staurosporine-induced LDH release, suggesting that the PI3-K/Akt prosurvival pathway is a possible target for antiapoptotic action of memantine. Memantine 132-141 AKT serine/threonine kinase 1 Homo sapiens 210-213 17996985-6 2008 Memantine at low micromolar concentrations also attenuated salsolinol- and doxorubicin-induced LDH release and DNA fragmentation, but only in the case of salsolinol was this effect accompanied by a decrease in caspase-3 activity. Memantine 0-9 caspase 3 Homo sapiens 210-219 18288936-1 2008 OBJECTIVE: To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer"s disease (AD) receiving cholinesterase inhibitor (ChEI) treatment. Memantine 50-59 butyrylcholinesterase Homo sapiens 129-143 17962329-0 2008 Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. Memantine 9-18 glutamate receptor, ionotropic, N-methyl D-aspartate 2A L homeolog Xenopus laevis 79-83 18000814-6 2008 Memantine, between 200 and 2000 nM, directly acted on D2(High) to inhibit the release of prolactin from isolated anterior pituitary cells in culture. Memantine 0-9 prolactin Homo sapiens 89-98 17962329-1 2008 N-methyl-d-aspartate receptors (NMDARs) display differences in their sensitivity to the channel blockers Mg(2+) and memantine that are dependent on the identity of the NR2 subunit present in the receptor-channel complex. Memantine 116-125 nodal homolog 2 L homeolog Xenopus laevis 168-171 17962329-8 2008 Memantine block of glutamate-evoked currents is most potent at NR1/NR2D NMDARs, but no differences are observed in its ability to inhibit NR2A-containing or NR2A/2D chimeric NMDARs. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 63-66 17962329-8 2008 Memantine block of glutamate-evoked currents is most potent at NR1/NR2D NMDARs, but no differences are observed in its ability to inhibit NR2A-containing or NR2A/2D chimeric NMDARs. Memantine 0-9 glutamate receptor, ionotropic, N-methyl D-aspartate 2D L homeolog Xenopus laevis 67-71 17980434-3 2008 The aim of the present study was to investigate the utility of memantine (MEM), an alpha-7 nAChR antagonist used for treatment of Alzheimer"s disease patients, to prevent neurotoxicity induced by MDMA in rats and the oxidative effect of this amphetamine derivative in mice striatal synaptosomes. Memantine 63-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 91-96 19008850-6 2008 Patients treated with memantine had better MMSE (p<0,05), ADAS-cog (p<0,05), clock drawing test (p<0,05) and FAB (p<0,01) scores compared to patients in the control group at week 24. Memantine 22-31 alkylglycerone phosphate synthase Homo sapiens 58-62 19513129-2 2007 Memantine is a low-affinity, noncompetitive NMDA receptor antagonist that may protect against motor neuron degeneration. Memantine 0-9 CLN8 transmembrane ER and ERGIC protein Mus musculus 94-119 17469692-4 2007 Several studies provide support for the use of the NMDA receptor antagonist memantine as monotherapy or added to a cholinesterase inhibitor for moderate to severe AD. Memantine 76-85 butyrylcholinesterase Homo sapiens 115-129 17942238-10 2007 Treatment with memantine resulted in a significant reduction in RGC loss and NR1 expression in the eyes of rats COHT. Memantine 15-24 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 77-80 17466645-5 2007 The N-methyl-D-aspartate receptor-antagonist, memantine, may be used as monotherapy or in combination with a cholinesterase inhibitor for patients with moderate Alzheimer"s disease, and as monotherapy for patients with severe Alzheimer"s disease. Memantine 46-55 butyrylcholinesterase Homo sapiens 109-123 17267580-13 2007 These results indicate that NR2B-containing NMDA receptors are key mediators of SD, and as such, memantine- and NR2B-selective antagonists may be useful new therapeutic agents for the treatment of migraine and other SD-related disorders (e.g., stroke and brain injury). Memantine 97-106 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 28-32 17308309-0 2007 Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. Memantine 148-157 amyloid beta precursor protein Homo sapiens 0-5 17188316-6 2007 Pretreatment with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine (18 mg/kg, sc), in combination with atropine sulfate (16 mg/kg, sc), significantly attenuated carbofuran-induced changes in AChE activity and levels of F(2)-IsoPs and F(4)-NeuroPs, declines in HEPs, as well as the alterations in morphology of hippocampal neurons. Memantine 70-79 acetylcholinesterase Rattus norvegicus 204-208 17196560-3 2007 We found that administration of memantine for 7 days significantly reduced cerebral hypoxia-induced neurodegeneration in the CA1 of the hippocampus, the reticular thalamic nucleus (RTN) and the primary fissure of the cerebellum of the posthypoxic animals. Memantine 32-41 carbonic anhydrase 1 Rattus norvegicus 125-128 17700020-0 2007 Reduction of phosphorylated tau during memantine treatment of Alzheimer"s disease. Memantine 39-48 microtubule associated protein tau Homo sapiens 28-31 17251419-9 2007 Synaptic deterioration, which was accompanied by decreased levels of the spine cytoskeletal protein drebrin, was blocked by the Alzheimer"s therapeutic drug Namenda. Memantine 157-164 drebrin 1 Homo sapiens 100-107 17334274-5 2007 Subjects treated with placebo also declined significantly more than individuals in the memantine group on 5 of 11 ADAS-cog individual items: orientation, language, comprehension, word finding, and recall of test instructions. Memantine 87-96 alkylglycerone phosphate synthase Homo sapiens 114-118 17334274-6 2007 Out of 3 ADAS-cog aggregated item subscales (language, memory, and praxis), outcomes in 2 (language and memory) favored memantine. Memantine 120-129 alkylglycerone phosphate synthase Homo sapiens 9-13 17700020-4 2007 It has been shown in vitro that memantine reverse induced abnormal hyperphosphorylation of tau in hippocampal neurons of rats. Memantine 32-41 microtubule associated protein tau Homo sapiens 91-94 16959224-5 2006 Memantine increased Bcl-xl and decreased Bax level. Memantine 0-9 Bcl2-like 1 Rattus norvegicus 20-26 16959224-5 2006 Memantine increased Bcl-xl and decreased Bax level. Memantine 0-9 BCL2 associated X, apoptosis regulator Rattus norvegicus 41-44 16959224-6 2006 Memantine also exerted an inhibitory effect on the micro-calpain level and decreased the huntingtin proteolytic fragments. Memantine 0-9 huntingtin Rattus norvegicus 89-99 16989956-8 2006 The results reported here demonstrate that memantine reduces OX6-immunolabeling for activated microglia, spares resident microglia, returns Arc (activity-regulated cytoskeletal associated protein, protein) -expressing neuronal populations to control levels (as revealed by Arc immunolabeling and fluorescence in situ hybridization), and ameliorates the spatial memory impairments produced by LPS alone. Memantine 43-52 nucleolar protein 3 Rattus norvegicus 140-143 16989956-8 2006 The results reported here demonstrate that memantine reduces OX6-immunolabeling for activated microglia, spares resident microglia, returns Arc (activity-regulated cytoskeletal associated protein, protein) -expressing neuronal populations to control levels (as revealed by Arc immunolabeling and fluorescence in situ hybridization), and ameliorates the spatial memory impairments produced by LPS alone. Memantine 43-52 nucleolar protein 3 Rattus norvegicus 145-195 16989956-8 2006 The results reported here demonstrate that memantine reduces OX6-immunolabeling for activated microglia, spares resident microglia, returns Arc (activity-regulated cytoskeletal associated protein, protein) -expressing neuronal populations to control levels (as revealed by Arc immunolabeling and fluorescence in situ hybridization), and ameliorates the spatial memory impairments produced by LPS alone. Memantine 43-52 nucleolar protein 3 Rattus norvegicus 273-276 17033976-9 2006 CONCLUSION: This study showed significative differences in the global treatment persistence among the considered drug-cholinesterase inhibitors, showing higher persistence resulting in patients treated with donepezil compared to those who received rivastigmine, galantamine or memantine. Memantine 277-286 butyrylcholinesterase Homo sapiens 118-132 16806196-0 2006 Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. Memantine 86-95 SET like protein Rattus norvegicus 15-21 16859831-2 2006 NMDAR antagonists, including MK-801 and memantine, have previously been shown to assuage symptoms stemming from opiate withdrawal. Memantine 40-49 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 0-5 16806196-4 2006 Memantine, an un-competitive inhibitor of N-methyl-D-aspartate receptors, inhibits this abnormal phosphorylation of tau and cell death and prevents the I2PP2A-induced inhibition of PP2A activity in vitro. Memantine 0-9 SET like protein Rattus norvegicus 152-158 16670247-8 2006 CONCLUSIONS: These responder analyses may assist clinicians in evaluating the impact of memantine in a relevant clinical scenario, i.e., in patients with AD previously stabilized on a cholinesterase inhibitor. Memantine 88-97 butyrylcholinesterase Homo sapiens 184-198 16464655-4 2006 Treatment with memantine, an NMDA receptor antagonist, also increased the serine-phosphorylation of both GSK3 isoforms in mouse brain. Memantine 15-24 glycogen synthase kinase 3 beta Mus musculus 105-109 16107786-2 2006 Memantine, which is known to be a moderate-affinity, uncompetitive, NMDA receptor antagonist, was investigated with regard to its ability to block the glutamate overstimulation and tissue plasminogen activator (tPA)/urokinase plasminogen activator (uPA)/matrix metalloproteinase (MMP)-9 modulation in experimental ICH. Memantine 0-9 plasminogen activator, tissue type Rattus norvegicus 181-209 16107786-2 2006 Memantine, which is known to be a moderate-affinity, uncompetitive, NMDA receptor antagonist, was investigated with regard to its ability to block the glutamate overstimulation and tissue plasminogen activator (tPA)/urokinase plasminogen activator (uPA)/matrix metalloproteinase (MMP)-9 modulation in experimental ICH. Memantine 0-9 plasminogen activator, urokinase Rattus norvegicus 216-247 16107786-2 2006 Memantine, which is known to be a moderate-affinity, uncompetitive, NMDA receptor antagonist, was investigated with regard to its ability to block the glutamate overstimulation and tissue plasminogen activator (tPA)/urokinase plasminogen activator (uPA)/matrix metalloproteinase (MMP)-9 modulation in experimental ICH. Memantine 0-9 plasminogen activator, urokinase Rattus norvegicus 249-252 16107786-2 2006 Memantine, which is known to be a moderate-affinity, uncompetitive, NMDA receptor antagonist, was investigated with regard to its ability to block the glutamate overstimulation and tissue plasminogen activator (tPA)/urokinase plasminogen activator (uPA)/matrix metalloproteinase (MMP)-9 modulation in experimental ICH. Memantine 0-9 matrix metallopeptidase 9 Rattus norvegicus 254-286 16625572-16 2006 Pooled data from two six month studies indicated a small beneficial effect of memantine on cognition (1.85 ADAS-Cog points, 95% CI 0.88 to 2.83, P = 0.0002), and behaviour (0.84 95% CI 0.06 to 0.91, P = 0.03) but this was not supported by clinical global measures.4. Memantine 78-87 alkylglycerone phosphate synthase Homo sapiens 107-111 16107786-6 2006 In the memantine group, the numbers of TUNEL+, myeloperoxidase (MPO)+, and OX42+ cells decreased in the periphery of the hematoma. Memantine 7-16 myeloperoxidase Mus musculus 47-62 16107786-6 2006 In the memantine group, the numbers of TUNEL+, myeloperoxidase (MPO)+, and OX42+ cells decreased in the periphery of the hematoma. Memantine 7-16 myeloperoxidase Mus musculus 64-67 16107786-7 2006 Memantine resulted in an upregulation of bcl-2 expression and an inhibition of caspase-3 activation. Memantine 0-9 BCL2, apoptosis regulator Rattus norvegicus 41-46 16107786-7 2006 Memantine resulted in an upregulation of bcl-2 expression and an inhibition of caspase-3 activation. Memantine 0-9 caspase 3 Rattus norvegicus 79-88 16107786-8 2006 Memantine also exerted a profound inhibitory effect on the upregulation of tPA/uPA mRNA, and finally decreased the MMP-9 level in the hemorrhagic brain. Memantine 0-9 plasminogen activator, urokinase Rattus norvegicus 79-82 16107786-8 2006 Memantine also exerted a profound inhibitory effect on the upregulation of tPA/uPA mRNA, and finally decreased the MMP-9 level in the hemorrhagic brain. Memantine 0-9 matrix metallopeptidase 9 Rattus norvegicus 115-120 16107786-10 2006 Here, we show that memantine causes a reduction of hematoma expansion, coupled with an inhibitory effect on the tPA/uPA and MMP-9 level. Memantine 19-28 plasminogen activator, urokinase Rattus norvegicus 116-119 16107786-10 2006 Here, we show that memantine causes a reduction of hematoma expansion, coupled with an inhibitory effect on the tPA/uPA and MMP-9 level. Memantine 19-28 matrix metallopeptidase 9 Rattus norvegicus 124-129 16354790-7 2006 Memantine treatment reduced the total cortical levels of membrane-bound amyloid precursor protein (45-55%) in both transgenic and nontransgenic mice, which eventually may decrease the level of Abeta. Memantine 0-9 amyloid beta (A4) precursor protein Mus musculus 193-198 16354790-8 2006 In conclusion, galantamine, memantine, and nicotine have different interactions with Abeta processes, alpha7 nAChRs, and NMDA receptors in APPswe mice. Memantine 28-37 amyloid beta (A4) precursor protein Mus musculus 85-90 16289784-0 2006 Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice. Memantine 96-105 mitogen-activated protein kinase 1 Mus musculus 25-28 16289784-5 2006 Taken together, these results firstly demonstrate that the acute antidepressant-like effect of memantine seems to be dependent on the cellular signaling modulated by PKA, CaMKII and MAPK/ERK, but not by PKC. Memantine 95-104 calcium/calmodulin-dependent protein kinase II, delta Mus musculus 171-177 16289784-5 2006 Taken together, these results firstly demonstrate that the acute antidepressant-like effect of memantine seems to be dependent on the cellular signaling modulated by PKA, CaMKII and MAPK/ERK, but not by PKC. Memantine 95-104 mitogen-activated protein kinase 1 Mus musculus 187-190 16464655-5 2006 Co-administration of physostigmine and memantine increased serine-phosphorylated GSK3 levels equally to that achieved by either agent alone, indicating that the actions of these two drugs converge on overlapping pools of GSK3. Memantine 39-48 glycogen synthase kinase 3 beta Mus musculus 81-85 16464655-5 2006 Co-administration of physostigmine and memantine increased serine-phosphorylated GSK3 levels equally to that achieved by either agent alone, indicating that the actions of these two drugs converge on overlapping pools of GSK3. Memantine 39-48 glycogen synthase kinase 3 beta Mus musculus 221-225 16518518-6 2006 Pretreatment with N-methyl D-aspartate (NMDA) receptor antagonist memantine, in combination with atropine sulfate, provides significant protection against inhibition of AChE, increases of ROS/RNS, and depletion of high-energy phosphates induced by DFP/carbofuran. Memantine 66-75 acetylcholinesterase (Cartwright blood group) Homo sapiens 169-173 16298481-0 2006 Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Memantine 15-24 glial cell derived neurotrophic factor Rattus norvegicus 54-97 16298481-4 2006 For this purpose, we measured the modulation of GDNF release in C6 glioma cell cultures treated for 24 h with amantadine and memantine. Memantine 125-134 glial cell derived neurotrophic factor Rattus norvegicus 48-52 16298481-7 2006 Together, these results demonstrate that the neuroprotective effect of amantadine and memantine could involve the regulation of GDNF production by glial cells. Memantine 86-95 glial cell derived neurotrophic factor Rattus norvegicus 128-132 16262676-7 2005 In the current study, we have examined the therapeutic efficacy of memantine in an ALS mouse model carrying a high copy number of SOD1(G93A). Memantine 67-76 superoxide dismutase 1, soluble Mus musculus 130-134 16386235-0 2006 Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures. Memantine 0-9 caspase 3 Mus musculus 57-66 16386235-5 2006 Memantine alone (0.05-2.0 microM) did not induce any cytotoxic effect but attenuated the staurosporine-induced caspase-3 activity and LDH release in hippocampal cultured neurons on each investigated day in vitro. Memantine 0-9 caspase 3 Mus musculus 111-120 16262676-8 2005 Memantine treatment significantly delayed the disease progression and increased the life span of SOD1(G93A) mice, from 121.4 +/- 5.5 to 129.7 +/- 4.5 days (P = 0.032). Memantine 0-9 superoxide dismutase 1, soluble Mus musculus 97-101 16262676-10 2005 Therefore, the neuroprotective effect of memantine in SOD1(G93A) mice is most probably due to the inhibition of spinal cord NMDA receptors. Memantine 41-50 superoxide dismutase 1, soluble Mus musculus 54-58 15192085-8 2004 Memantine significantly improved the acquisition of the water maze in APP/PS1 mice without affecting swimming speed. Memantine 0-9 presenilin 1 Mus musculus 74-77 15901795-1 2005 Unlike other N-methyl-D-aspartate receptor (NMDAR) antagonists, clinical trials have shown that memantine is clinically tolerated and effective in the treatment of Alzheimer"s disease. Memantine 96-105 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 13-42 15901795-1 2005 Unlike other N-methyl-D-aspartate receptor (NMDAR) antagonists, clinical trials have shown that memantine is clinically tolerated and effective in the treatment of Alzheimer"s disease. Memantine 96-105 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 44-49 15901795-3 2005 The specific site of memantine block in the NMDAR channel interacts with magnesium and is assumed to be at or near a narrow constriction representing the channel selectivity filter. Memantine 21-30 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 44-49 15901795-5 2005 Here, using mutational analysis and substituted cysteine accessibility methods on recombinant NR1/NR2A NMDARs expressed in Xenopus oocytes, we precisely localize both the specific and second memantine-blocking sites. Memantine 191-200 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 94-97 15901795-5 2005 Here, using mutational analysis and substituted cysteine accessibility methods on recombinant NR1/NR2A NMDARs expressed in Xenopus oocytes, we precisely localize both the specific and second memantine-blocking sites. Memantine 191-200 glutamate receptor, ionotropic, N-methyl D-aspartate 2A L homeolog Xenopus laevis 98-102 16009352-5 2005 Coincubation with memantine (10 microM) completely blocked the ethanol-induced up-regulation of NR1 (102 +/- 4%), NR2A (95 +/- 7%) and NR2B (105 +/- 13%). Memantine 18-27 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 96-99 16009352-5 2005 Coincubation with memantine (10 microM) completely blocked the ethanol-induced up-regulation of NR1 (102 +/- 4%), NR2A (95 +/- 7%) and NR2B (105 +/- 13%). Memantine 18-27 glutamate ionotropic receptor NMDA type subunit 2A Rattus norvegicus 114-118 16009352-5 2005 Coincubation with memantine (10 microM) completely blocked the ethanol-induced up-regulation of NR1 (102 +/- 4%), NR2A (95 +/- 7%) and NR2B (105 +/- 13%). Memantine 18-27 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 135-139 15522999-4 2005 Memantine caused a concentration-dependent reduction of the amplitudes of whole-cell currents evoked by the alpha7(*) nAChR-selective agonist choline (10 mM) or by N-methyl-d-aspartate (NMDA) (50 muM) plus glycine (10 muM). Memantine 0-9 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 118-123 15522999-8 2005 Memantine-induced alpha7(*) nAChR inhibition had an n(H) < 1 and showed a variable voltage dependence; the effect was voltage-independent at 0.1 muM, becoming voltage-dependent at >/=1 muM. Memantine 0-9 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 28-33 15522999-12 2005 It is suggested that blockade of alpha7(*) nAChRs by memantine could decrease its effectiveness for treatment of AD, particularly at early stages when the degrees of nAChR dysfunction and of cognitive decline correlate well. Memantine 53-62 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 43-48 15372325-3 2005 Treatment with memantine, 20 mg/kg/day during 14 days, significantly increased the number of [(125)I]alphabungarotoxin (alpha7 nAChR) binding sites in the frontal- and retrosplenial cortex of hAChE-Tg mice and synaptophysin- and LMW MAP-2 levels in the cortex of both hAChE-Tg and FVB/N controls. Memantine 15-24 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 120-132 15372325-3 2005 Treatment with memantine, 20 mg/kg/day during 14 days, significantly increased the number of [(125)I]alphabungarotoxin (alpha7 nAChR) binding sites in the frontal- and retrosplenial cortex of hAChE-Tg mice and synaptophysin- and LMW MAP-2 levels in the cortex of both hAChE-Tg and FVB/N controls. Memantine 15-24 synaptophysin Mus musculus 210-223 15372325-3 2005 Treatment with memantine, 20 mg/kg/day during 14 days, significantly increased the number of [(125)I]alphabungarotoxin (alpha7 nAChR) binding sites in the frontal- and retrosplenial cortex of hAChE-Tg mice and synaptophysin- and LMW MAP-2 levels in the cortex of both hAChE-Tg and FVB/N controls. Memantine 15-24 microtubule-associated protein 2 Mus musculus 233-238 15372325-5 2005 Whether the effect of memantine on alpha7 nAChRs, synaptophysin- and LMW MAP-2 levels is a direct effect, or an indirect effect via the NMDA receptors, has to be further evaluated. Memantine 22-31 synaptophysin Mus musculus 50-63 15372325-5 2005 Whether the effect of memantine on alpha7 nAChRs, synaptophysin- and LMW MAP-2 levels is a direct effect, or an indirect effect via the NMDA receptors, has to be further evaluated. Memantine 22-31 microtubule-associated protein 2 Mus musculus 73-78 15452358-8 2005 In contrast, intrathecal injection of a non-selective NMDA antagonist, memantine, significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist. Memantine 71-80 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 260-264 15901795-7 2005 Thus, the N-site asparagine (N) in the M2 region of the NR1 subunit represents the dominant site for uncompetitive antagonism by memantine. Memantine 129-138 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 56-59 15901795-8 2005 The N and N + 1 site asparagines in NR2A produce strong electrostatic interactions with memantine. Memantine 88-97 glutamate receptor, ionotropic, N-methyl D-aspartate 2A L homeolog Xenopus laevis 36-40 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 48-54 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 56-62 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 64-70 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 72-78 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 80-87 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 89-95 15378224-2 2004 METHODS: The inhibitory potency of memantine on CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 activities was examined with specific probe drugs in HLM and recombinant P450s. Memantine 35-44 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 109-115 15378224-4 2004 RESULTS: In HLM, memantine inhibited CYP2B6 and CYP2D6 activities, with KI (IC50) values of 76.7 (279.7) and 94.9 (368.7) microM, respectively. Memantine 17-26 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 15378224-4 2004 RESULTS: In HLM, memantine inhibited CYP2B6 and CYP2D6 activities, with KI (IC50) values of 76.7 (279.7) and 94.9 (368.7) microM, respectively. Memantine 17-26 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 48-54 15378224-11 2004 CONCLUSION: Memantine exerts selective inhibition of CYP2B6 activity at clinically relevant concentrations, suggesting the potential for clinically significant drug interactions. Memantine 12-21 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 53-59 15378224-13 2004 Moreover, memantine represents a new, potent, selective inhibitor of recombinant CYP2B6, which may prove useful for screening purposes during early phases of in vitro drug metabolism studies with new chemical entities. Memantine 10-19 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-87 15266045-2 2004 OBJECTIVE: To determine whether an in vivo pharmacokinetic interaction exists between memantine and the acetylcholinesterase (AChE) inhibitor donepezil. Memantine 86-95 acetylcholinesterase (Cartwright blood group) Homo sapiens 104-124 15266045-2 2004 OBJECTIVE: To determine whether an in vivo pharmacokinetic interaction exists between memantine and the acetylcholinesterase (AChE) inhibitor donepezil. Memantine 86-95 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-130 15266045-7 2004 In addition, AChE inhibition was measured in red blood cells by radiolabeled-enzyme assay following administration of donepezil alone and after a single memantine dose. Memantine 153-162 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 15275830-6 2004 The results from the present study provide evidence that rivastigmine as a pseudo-irreversible (or slow-reversible) AChE inhibitor shares this property described for reversible inhibitors, since memantine (1-100 microM), irrespective of whether given prior to or after rivastigmine did not influence rivastigmine"s AChE inhibition in vitro. Memantine 195-204 acetylcholinesterase Rattus norvegicus 116-120 15228642-16 2004 A Cochrane review of memantine shows benefits on cognitive and global function of the same order of magnitude as seen for the cholinesterase inhibitors. Memantine 21-30 butyrylcholinesterase Homo sapiens 126-140 15090047-5 2004 Our binding studies using [3H]-(+)SKF-10,047 indicated that amantadine and memantine behave as ligands of the sigma(1) receptor in rat forebrain homogenates (Ki values of 7.44 +/- 0.82 and 2.60 +/- 0.62 microm, respectively). Memantine 75-84 sigma non-opioid intracellular receptor 1 Rattus norvegicus 110-127 15281522-0 2004 Intraarticular pretreatment with ketamine and memantine could prevent arthritic pain: relevance to the decrease of spinal c-fos expression in rats. Memantine 46-55 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 122-127 15281522-3 2004 The intraarticular injection of ketamine (1 mg) or memantine (0.2 mg) also suppressed c-Fos expression in the laminae I-II and laminae V-VI at the L3-4 spinal level. Memantine 51-60 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 86-91 14970830-7 2004 Western blot analysis showed increases (approximately 30-65%) in GDI-1 protein present in both cytosolic and membrane fractions that were significant in the 84-kDa Rab bound form, suggesting that memantine influences Ras-like GTPase function. Memantine 196-205 GDP dissociation inhibitor 1 Rattus norvegicus 65-70 15090047-6 2004 In NG108-15 neuroblastoma cells, both drugs (amantadine (100 microm) and memantine (10 microm)) potentiated the bradykinin-induced mobilization of intracellular Ca2+, mimicking the effect of the sigma1 receptor agonist PRE-084 (1 microm). Memantine 73-82 sigma non-opioid intracellular receptor 1 Mus musculus 195-210 12875722-0 2003 The regulatory effect of memantine on expression and synthesis of heat shock protein 70 gene in neonatal rat models with cerebral hypoxic ischemia. Memantine 25-34 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 66-87 15222774-5 2004 Memantine, a glutamate NMDA receptor antagonist, is newly licensed in Europe for the treatment of more advanced Alzheimer"s disease and will provide the first non-cholinesterase inhibitor option for the treatment of Alzheimer"s disease. Memantine 0-9 butyrylcholinesterase Homo sapiens 163-177 15099690-7 2004 Furthermore, combined treatment of these mice with memantine demonstrated that the neurotoxic effects of tumor necrosis factor-alpha upon cholinergic cells did not require the activation of the N-methyl-d-aspartate receptors. Memantine 51-60 tumor necrosis factor Mus musculus 105-132 14730114-0 2003 Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Memantine 131-140 sigma non-opioid intracellular receptor 1 Rattus norvegicus 0-15 14730114-1 2003 The obtained results show that DTG, the sigma1/sigma2 receptor agonist, exerts a synergistic effect with memantine, an uncompetitive NMDA receptor antagonist, in the forced swimming test in rats, and that progesterone and BD 1047, the sigma1 receptor antagonists, counteract this effect. Memantine 105-114 sigma non-opioid intracellular receptor 1 Rattus norvegicus 40-62 14730114-1 2003 The obtained results show that DTG, the sigma1/sigma2 receptor agonist, exerts a synergistic effect with memantine, an uncompetitive NMDA receptor antagonist, in the forced swimming test in rats, and that progesterone and BD 1047, the sigma1 receptor antagonists, counteract this effect. Memantine 105-114 sigma non-opioid intracellular receptor 1 Rattus norvegicus 235-250 14730114-2 2003 The results suggest that the sigma1 receptor subtype may contribute to the behavioral response induced by combined administration of DTG and memantine in Porsolt"s test in rats. Memantine 141-150 sigma non-opioid intracellular receptor 1 Rattus norvegicus 29-44 12750440-5 2003 Memantine produced a partial reversal of both thermal and mechanical hyperalgesia (MED = 10 and 15 mg/kg i.p., respectively). Memantine 0-9 mediator complex subunit 10 Rattus norvegicus 83-91 12750440-7 2003 In the mouse formalin test, CHF3381 and memantine preferentially inhibited the late phase (MED = 30 and 20 mg/kg i.p., respectively); gabapentin inhibited only the late phase (MED = 30 mg/kg s.c.). Memantine 40-49 mediator complex subunit 30 Mus musculus 91-99 15307296-3 2004 Further investigation require usefulness of memantine in less advanced stages of Alzheimer"s disease as well as other types of dementia especially vascular; promising results are shown in dual therapy: memantine + cholinesterase inhibitor. Memantine 44-53 butyrylcholinesterase Homo sapiens 214-228 15033007-5 2004 The AChE activities both in blood and brain of memantine treated groups were not significantly different from those in dichlorvos alone group. Memantine 47-56 acetylcholinesterase Rattus norvegicus 4-8 14741410-0 2004 Adenosine A2A receptor mRNA expression is increased in rat striatum and nucleus accumbens after memantine administration. Memantine 96-105 adenosine A2a receptor Rattus norvegicus 0-22 12875722-1 2003 OBJECTIVE: To evaluate the neuroprotective effect of memantine, a non-competitive antagonist at the N-methyl-D-aspartate receptor, against hypoxic ischemia (HI) by exploring its regulation on the expression and synthesis of heat shock protein 70 (HSP70) gene in neonatal rat models with cerebral HI. Memantine 53-62 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 224-245 12875722-1 2003 OBJECTIVE: To evaluate the neuroprotective effect of memantine, a non-competitive antagonist at the N-methyl-D-aspartate receptor, against hypoxic ischemia (HI) by exploring its regulation on the expression and synthesis of heat shock protein 70 (HSP70) gene in neonatal rat models with cerebral HI. Memantine 53-62 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 247-252 12875722-8 2003 CONCLUSION: It was shown that HI is very sensitive to the expression of the HSP70 gene and synthesis of its corresponding product, which could be regulated by memantine. Memantine 159-168 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 76-81 11369029-11 2001 The up-regulations observed after memantine (cortex, NR2B: 172+/-17%; hippocampus, NR1-1/1-2: 156+/-8%) or MK-801 (cortex, NR2B: 174+/-22%; hippocampus, NR1-1/1-2: 140+/-3%) were almost identical. Memantine 34-43 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 53-57 12468047-10 2002 Memantine treated animals had significant reductions in the amount of neuronal degeneration, pyknotic nuclei, and GFAP immunostaining as compared with vehicle treated animals. Memantine 0-9 glial fibrillary acidic protein Rattus norvegicus 114-118 11854433-3 2002 In this study, the effects of mutations in and around the membrane-spanning and pore-forming regions of NMDA receptor subunits were studied with three blockers, MK-801, memantine, and TB-3-4, using recombinant NMDA receptors expressed in Xenopus laevis oocytes. Memantine 169-178 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 104-117 11854433-4 2002 Mutations at the critical asparagine residues in the M2 loop of NR1 and NR2B and at a tryptophan residue in M2 of NR2B reduced block by MK-801, memantine, and TB-3-4. Memantine 144-153 glutamate receptor ionotropic, NMDA 2B Xenopus laevis 114-118 11823786-8 2002 Moreover, NR1/NR3A or -3B receptors form relatively Ca2+-impermeable cation channels that are resistant to Mg2+, MK-801, memantine and competitive antagonists. Memantine 121-130 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 10-13 11823786-8 2002 Moreover, NR1/NR3A or -3B receptors form relatively Ca2+-impermeable cation channels that are resistant to Mg2+, MK-801, memantine and competitive antagonists. Memantine 121-130 nodal homolog 3, gene 1 L homeolog Xenopus laevis 14-18 12409683-7 2002 At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of -1.75 points (95% confidence intervals -3.023 to -0.49) and a median of 2 points between the two groups, while CGI-C ratings showed no significant differences between treatment groups. Memantine 13-22 alkylglycerone phosphate synthase Homo sapiens 96-100 11591126-0 2001 The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Memantine 26-35 brain-derived neurotrophic factor Rattus norvegicus 44-77 11591126-0 2001 The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Memantine 26-35 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 82-86 11591126-2 2001 We have examined the effect of memantine (ip 5-50 mg/kg; 4 h) on the expression of brain-derived neurotrophic factor (BDNF) and trkB receptor mRNAs in rat brain by in situ hybridization. Memantine 31-40 brain-derived neurotrophic factor Rattus norvegicus 83-116 11591126-2 2001 We have examined the effect of memantine (ip 5-50 mg/kg; 4 h) on the expression of brain-derived neurotrophic factor (BDNF) and trkB receptor mRNAs in rat brain by in situ hybridization. Memantine 31-40 brain-derived neurotrophic factor Rattus norvegicus 118-122 11591126-2 2001 We have examined the effect of memantine (ip 5-50 mg/kg; 4 h) on the expression of brain-derived neurotrophic factor (BDNF) and trkB receptor mRNAs in rat brain by in situ hybridization. Memantine 31-40 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 128-132 11591126-3 2001 Memantine at a clinically relevant dose markedly increased BDNF mRNA levels in the limbic cortex, and this effect was more widespread and pronounced at higher doses. Memantine 0-9 brain-derived neurotrophic factor Rattus norvegicus 59-63 11591126-4 2001 Effects of memantine on BDNF mRNA were also reflected in changes in BDNF protein levels. Memantine 11-20 brain-derived neurotrophic factor Rattus norvegicus 24-28 11591126-4 2001 Effects of memantine on BDNF mRNA were also reflected in changes in BDNF protein levels. Memantine 11-20 brain-derived neurotrophic factor Rattus norvegicus 68-72 11591126-5 2001 Moreover, memantine induced isoforms of the BDNF receptor trkB. Memantine 10-19 brain-derived neurotrophic factor Rattus norvegicus 44-48 11591126-5 2001 Moreover, memantine induced isoforms of the BDNF receptor trkB. Memantine 10-19 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 58-62 11591126-6 2001 Taken together, these data suggest that the neuroprotective properties of memantine could be mediated by the increased endogenous production of BDNF in the brain. Memantine 74-83 brain-derived neurotrophic factor Rattus norvegicus 144-148 11326240-2 2001 The goal of the present study was to determine the potential efficacy of memantine, an N -methyl-D -aspartate receptor antagonist, to mitigate cerebral injury after hypothermic circulatory arrest. Memantine 73-82 glutamate ionotropic receptor NMDA type subunit 1 Sus scrofa 87-118 11060751-4 2000 HIV-1 proteins Tat and gp120 have been implicated in the pathogenesis of dementia associated with HIV infection and the neurotoxicity caused by HIV-1 proteins can be blocked completely by memantine. Memantine 188-197 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 23-28 11282259-0 2001 Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. Memantine 42-51 prolactin Homo sapiens 55-64 11169168-5 2001 Synapse-associated protein-97 (SAP97) mRNA levels were increased in the entorhinal cortex layer III after MK-801 or after relatively high doses of other uncompetitive NMDA receptor antagonists: phencyclidine (15 mg/kg; 6 hr) and memantine (50 mg/kg; 6 hr). Memantine 229-238 discs large MAGUK scaffold protein 1 Rattus norvegicus 0-29 11169168-5 2001 Synapse-associated protein-97 (SAP97) mRNA levels were increased in the entorhinal cortex layer III after MK-801 or after relatively high doses of other uncompetitive NMDA receptor antagonists: phencyclidine (15 mg/kg; 6 hr) and memantine (50 mg/kg; 6 hr). Memantine 229-238 discs large MAGUK scaffold protein 1 Rattus norvegicus 31-36 11169168-6 2001 Memantine also increased SAP97 mRNA expression in other cortical regions, but this effect was not observed with MK-801 or phencyclidine. Memantine 0-9 discs large MAGUK scaffold protein 1 Rattus norvegicus 25-30 11069578-7 2000 OGD produced neuronal damage predominantly in the CA1 region, which was prevented by MK-801 and memantine, but not by APV or CPP. Memantine 96-105 carbonic anhydrase 1 Rattus norvegicus 50-53 10665489-0 2000 Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Memantine 96-105 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 75-80 10737358-5 2000 The current study investigated whether memantine would attenuate the inhibition of AChE produced by these three drugs. Memantine 39-48 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-87 10737358-7 2000 Our in vitro data suggest that the clinical combination of memantine with a reversible AChE inhibitor should be a valuable pharmacotherapeutic approach to dementia. Memantine 59-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-91 10665489-7 2000 The neurotoxicity caused by Tat and gp120 applied in combination was blocked completely by memantine, partially by amiloride, and not at all by dipyridamole or vigabatrin. Memantine 91-100 tyrosine aminotransferase Homo sapiens 28-31 10665489-7 2000 The neurotoxicity caused by Tat and gp120 applied in combination was blocked completely by memantine, partially by amiloride, and not at all by dipyridamole or vigabatrin. Memantine 91-100 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 36-41 10217297-9 1999 NMDA-driven Cd2(+) entry was almost completely prevented by 1 mM Mg2+, 50 microM memantine, and 10 microM 5,7-dichlorokynurenic acid, suggesting a major contribution of NMDA-gated channels in glutamate-stimulated Cd2+ influx. Memantine 81-90 CD2 molecule Homo sapiens 12-15 10471078-0 1999 Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Memantine 0-9 mucin 7, secreted Homo sapiens 131-134 8724036-7 1996 The release elicited by NMDA plus gp120 was prevented by the classical NMDA receptor antagonists dizocilpine or 7-chlorokynurenic acid, as well as by memantine. Memantine 150-159 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 34-39 10885864-9 1999 The results in the BGP subscore "care dependence" were 3.1 points improvement under memantine and 1.1 points under placebo (p = 0.016). Memantine 84-93 CEA cell adhesion molecule 1 Homo sapiens 19-22 10051128-18 1999 The high affinity of NMDA to this receptor, its sensitivity to ifenprodil and memantine may suggest that the mesencephalic NMDA receptor comprises the NR1 splice variant lacking E5, NR2B, and NR2C, respectively. Memantine 78-87 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 151-154 9687576-3 1998 In Xenopus laevis oocytes expressing hOCT2, electrogenic transport of norepinephrine, histamine, dopamine, serotonin, and the antiparkinsonian drugs memantine and amantadine was demonstrated by tracer influx, tracer efflux, electrical measurements, or a combination. Memantine 149-158 POU class 2 homeobox 2 Homo sapiens 37-42 9593857-3 1998 Even more striking increases in AADC were noted with 40 mg/kg amantadine (3.8-fold for CS, 9.0-fold for SN), 40 mg/kg memantine (3.4-fold for CS, 3.1-fold for SN; 20 mg/kg no effect) and 40 mg/kg dextromethorphan (3.4-fold for CS, 6.2-fold for SN, in 6/10 "responders"). Memantine 118-127 dopa decarboxylase Rattus norvegicus 32-36 8973791-0 1996 Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Memantine 0-9 selenoprotein K Rattus norvegicus 18-36 8973791-0 1996 Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Memantine 0-9 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 37-42 8973791-4 1996 The present study evaluated the neurotoxic potential of memantine and amantadine using the induction of HSP70 immunoreactivity in rat brain. Memantine 56-65 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 104-109 8973791-5 1996 Memantine (25, 50, 75 mg/kg) induced HSP70 in the posterior cingulate, retrosplenial cortex and dentate gyrus of rat brain. Memantine 0-9 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 37-42 10391443-11 1999 The N-methyl-D-aspartate receptor antagonists (+/-)-2-amino-5-phosphonopentanoic acid (AP5), memantine and dizocilpine significantly (P < 0.01) lowered gp120-induced increases in [Ca2+]i in neurons. Memantine 93-102 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 155-160 10391443-12 1999 AP5 and memantine, but not dizocilpine, significantly (P < 0.01) reduced increases in [Ca2+]i by gp120 in astrocytes. Memantine 8-17 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 100-105 9687576-0 1998 Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Memantine 129-138 POU class 2 homeobox 2 Homo sapiens 58-63 9871440-3 1998 The NMDA receptor-ion channel antagonists MK 801, budipine, amantadine, memantine and dextromethorphan all caused a pronounced in creased in AADC activity, more especially in the SNr than CS. Memantine 72-81 dopa decarboxylase Rattus norvegicus 141-145 9296567-2 1997 The administration of memantine and phencyclidine induced HSP-70 in the retrosplenial cortex of rat brain. Memantine 22-31 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 58-64 8886398-7 1996 Memantine (0.3-30 microM) blocked L-glutamate (100 microM)-mediated currents in a concentration-dependent manner in NR1a/NR2A, NR1a/NR2B and NR1a/NR2D transfected cells with IC50 values (at -70 mV) of 0.93 +/- 0.15 microM, 0.82 +/- 0.12 microM and 0.47 +/- 0.06 microM (mean +/- s.c. mean), respectively. Memantine 0-9 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 121-125 8886398-7 1996 Memantine (0.3-30 microM) blocked L-glutamate (100 microM)-mediated currents in a concentration-dependent manner in NR1a/NR2A, NR1a/NR2B and NR1a/NR2D transfected cells with IC50 values (at -70 mV) of 0.93 +/- 0.15 microM, 0.82 +/- 0.12 microM and 0.47 +/- 0.06 microM (mean +/- s.c. mean), respectively. Memantine 0-9 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 132-136 8886398-7 1996 Memantine (0.3-30 microM) blocked L-glutamate (100 microM)-mediated currents in a concentration-dependent manner in NR1a/NR2A, NR1a/NR2B and NR1a/NR2D transfected cells with IC50 values (at -70 mV) of 0.93 +/- 0.15 microM, 0.82 +/- 0.12 microM and 0.47 +/- 0.06 microM (mean +/- s.c. mean), respectively. Memantine 0-9 glutamate receptor, ionotropic, NMDA2D (epsilon 4) Mus musculus 146-150 8886398-12 1996 The kinetics of the actions of memantine (30 microM) were investigated for the NR1a/2A combination, in 6 cells (13-15 determinations). Memantine 31-40 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 79-82 8822372-2 1996 Brains of mice treated chronically with memantine and of untreated controls were analysed for structural damage by laser scanning confocal microscopy of sections immunolabeled for microtubule-associated protein-2 (MAP-2) and synaptophysin. Memantine 40-49 synaptophysin Mus musculus 225-238 8731170-6 1996 Neuronal damage in the CA1 sector of the hippocampus and in the striatum produced by 4VO was significantly attenuated by 20 mg/kg memantine. Memantine 130-139 carbonic anhydrase 1 Rattus norvegicus 23-26 8646415-5 1996 Memantine (100 microM) antagonized NMDA receptor-mediated excitatory postsynaptic currents recorded in area CA1 in a strongly voltage-dependent manner i.e. depressed to 11 +/- 4% of control at -35 mV and 95 +/- 5% of control at +40 mV (n = 9), with no apparent effect on response kinetics. Memantine 0-9 carbonic anhydrase 1 Rattus norvegicus 108-111 8822372-0 1996 Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Memantine 131-140 Envelope surface glycoprotein gp160, precursor Human immunodeficiency virus 1 20-25 8822372-2 1996 Brains of mice treated chronically with memantine and of untreated controls were analysed for structural damage by laser scanning confocal microscopy of sections immunolabeled for microtubule-associated protein-2 (MAP-2) and synaptophysin. Memantine 40-49 microtubule-associated protein 2 Mus musculus 180-212 8822372-2 1996 Brains of mice treated chronically with memantine and of untreated controls were analysed for structural damage by laser scanning confocal microscopy of sections immunolabeled for microtubule-associated protein-2 (MAP-2) and synaptophysin. Memantine 40-49 microtubule-associated protein 2 Mus musculus 214-219 8822791-7 1996 Two compounds were found to act cytoprotectively against the deleterious effect caused by gp120 on neurons: Memantine [1-amino-3,5-dimethyladamantane] and Flupirtine [2-amino-3-ethoxycarbonylamino-6-(4-fluoro-benzyl-amino)-pyridine maleate]. Memantine 108-117 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 90-95 8822791-7 1996 Two compounds were found to act cytoprotectively against the deleterious effect caused by gp120 on neurons: Memantine [1-amino-3,5-dimethyladamantane] and Flupirtine [2-amino-3-ethoxycarbonylamino-6-(4-fluoro-benzyl-amino)-pyridine maleate]. Memantine 119-149 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 90-95 8822791-9 1996 The NMDA antagonist Memantine, a drug currently used in the therapy of spasticity and Parkinson"s disease, prevented the effects of gp120 at micromolar concentrations. Memantine 20-29 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 132-137 8822372-3 1996 Qualitative and quantitative analysis of confocal images revealed that memantine treatment substantially decreased neuropathology in gp120 transgenic mice; this included statistically significant improvements in both dendritic and presynaptic terminal density. Memantine 71-80 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 133-138 2241428-9 1990 These results suggest that memantine may counteract the acute methyl parathion toxicity by (a) protection of acetylcholinesterase from inhibition, (b) rapid reactivation of inhibited acetylcholinesterase and (c) rapid bioelimination of methyl parathion, in addition to cholinolytic effects of atropine sulfate. Memantine 27-36 acetylcholinesterase Rattus norvegicus 109-129 1426020-0 1992 gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Memantine 78-87 Envelope surface glycoprotein gp160, precursor Human immunodeficiency virus 1 0-5 1426020-4 1992 Memantine (1-amino-3,5-dimethyladamantane), a drug currently used in the therapy of spasticity and Parkinson"s disease as well as the NMDA antagonist MK-801 both prevented the effects of gp120 at micromolar concentrations. Memantine 0-9 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 187-192 1426020-4 1992 Memantine (1-amino-3,5-dimethyladamantane), a drug currently used in the therapy of spasticity and Parkinson"s disease as well as the NMDA antagonist MK-801 both prevented the effects of gp120 at micromolar concentrations. Memantine 11-41 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 187-192 1620355-3 1992 We studied memantine, a drug that blocks NMDA receptor-operated ion channels, for possible protective effects from gp120-induced neuronal injury. Memantine 11-20 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 115-120 1620355-4 1992 In identified rat retinal ganglion cells in culture, we found that 2 microM memantine completely prevented the injury engendered by 20 pM gp120. Memantine 76-85 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 138-143 1620355-5 1992 These data suggest that memantine has therapeutic potential as an NMDA antagonist capable of ameliorating neuronal damage associated with gp120. Memantine 24-33 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 138-143 1733053-8 1992 Memantine reduced inhibition of AChE activity in crude brain homogenates by soman, but not by edrophonium (anionic site inhibitor) or decamethonium (peripheral site inhibitor). Memantine 0-9 acetylcholinesterase Rattus norvegicus 32-36 1707644-9 1991 Memantine (1-amino-3,5-dimethyladamantane), a blocker of the N-methyl-D-aspartate receptor channels, was found to display a significant anti-HIV effect (at a concentration of 1 microgram/ml) on enriched cultures of GFAP+ cells in vitro. Memantine 0-9 glial fibrillary acidic protein Homo sapiens 215-219 1707644-9 1991 Memantine (1-amino-3,5-dimethyladamantane), a blocker of the N-methyl-D-aspartate receptor channels, was found to display a significant anti-HIV effect (at a concentration of 1 microgram/ml) on enriched cultures of GFAP+ cells in vitro. Memantine 11-41 glial fibrillary acidic protein Homo sapiens 215-219 7893259-1 1995 CA1 pyramidal cell response (population spike) in the hippocampal slice preparation was monitored after electrical stimulation of the Schaffer collaterals at CA2 in the presence of different concentrations of memantine (1-amino-3,5-dimethyladamantane, Akatinol Memantine, CAS 41100-52-1) currently being prescribed for the treatment of e.g. dementia. Memantine 209-218 carbonic anhydrase 1 Homo sapiens 0-3 7874313-5 1994 The [3H]noradrenaline release evoked by NMDA (100 microM)+gp120 (100 pM) was prevented by classical NMDA receptor antagonists, as well as by 10 microM memantine. Memantine 151-160 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 58-63 8207837-13 1994 The N-methyl-D-aspartate receptor antagonist MK-801 or memantine partially blocked the neurotoxic effects of PAF. Memantine 55-64 PCNA clamp associated factor Homo sapiens 109-112 1475066-3 1992 Pretreatment with memantine HCl (MEM, 18 mg/kg, sc) together with atropine sulfate (ATS, 16 mg/kg, sc), 60 min and 15 min, respectively, prior to nerve agents attenuated AChE inhibition, prevented myonecrosis, and muscle fasciculations as well as other signs of cholinergic toxicity. Memantine 18-31 acetylcholinesterase Rattus norvegicus 170-174 24194107-3 1991 The results show that the non-competitive NMDA antagonists dizocilpine and memantine as well as the competitive antagonists CGP 39551, CGP 37849 and CPPene antagonized dopamine D2 receptor mediated catalepsy induced by haloperidol. Memantine 75-84 dopamine receptor D2 Homo sapiens 168-188 24194107-6 1991 Dopamine D1 receptor mediated catalepsy induced by SCH 23390 was antagonized by dizocilpine, memantine, CPPene, but not by CGP 37849. Memantine 93-102 dopamine receptor D1 Homo sapiens 0-20 2226632-10 1990 When administered after ischemia, 10 mg/kg memantine significantly protected CA1 neurons against ischemic damage. Memantine 43-52 carbonic anhydrase 1 Rattus norvegicus 77-80 2241428-9 1990 These results suggest that memantine may counteract the acute methyl parathion toxicity by (a) protection of acetylcholinesterase from inhibition, (b) rapid reactivation of inhibited acetylcholinesterase and (c) rapid bioelimination of methyl parathion, in addition to cholinolytic effects of atropine sulfate. Memantine 27-36 acetylcholinesterase Rattus norvegicus 183-203 32860269-5 2020 Furthermore, the NMDAR antagonist memantine can relieve the stress-induced depression-like behaviors of FGR mice. Memantine 34-43 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 17-22 33773999-7 2021 In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Memantine 113-122 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 72-77 33773999-7 2021 In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Memantine 206-215 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 72-77 33773999-7 2021 In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Memantine 206-215 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 164-169 33773999-8 2021 Finally, we found that memantine was the most neuroprotective in hippocampal neurons expressing GluN1-M641I subunits, followed by neurons expressing wild-type GluN1 and then GluN1-A645S subunits in an NMDA-induced excitotoxicity assay. Memantine 23-32 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 96-101 19115386-2 2009 In this study, we examined the effect of memantine, an NMDA-R antagonist that is clinically used for the treatment of Alzheimer"s disease, on primary progenitor cells exhibiting a radial glia-like (RGL) morphology in the DG. Memantine 41-50 ral guanine nucleotide dissociation stimulator,-like 1 Mus musculus 198-201 31447667-4 2019 Memantine and donepezil can attenuate the upregulation of cofilin 2 expression in APP/PS1 mice. Memantine 0-9 cofilin 2, muscle Mus musculus 58-67 31447667-4 2019 Memantine and donepezil can attenuate the upregulation of cofilin 2 expression in APP/PS1 mice. Memantine 0-9 presenilin 1 Mus musculus 86-89 19115386-8 2009 These results clearly demonstrated that memantine promotes the proliferation of RGL progenitor cells. Memantine 40-49 ral guanine nucleotide dissociation stimulator,-like 1 Mus musculus 80-83 19115386-9 2009 We also found that memantine increased the ratio of horizontally aligned RGL progenitor cells, which are probably produced by symmetric division. Memantine 19-28 ral guanine nucleotide dissociation stimulator,-like 1 Mus musculus 73-76 34715352-7 2021 As demonstrated by immunoblotting, the reductions of calcium/calmodulin-dependent protein kinase II (CaMKII) alpha (Thr-286) autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV; Thr-196) phosphorylation in the CA1 region of OBX mice were significantly restored with memantine. Memantine 293-302 calcium/calmodulin-dependent protein kinase II alpha Mus musculus 53-114 34907850-7 2021 Where these drugs, with the exception of memantine, are inhibitors of acetylcholinesterase, thus inhibiting the enzyme that destroys acetylcholine, thus increasing the availability of this neurotransmitter. Memantine 41-50 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 34715352-7 2021 As demonstrated by immunoblotting, the reductions of calcium/calmodulin-dependent protein kinase II (CaMKII) alpha (Thr-286) autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV; Thr-196) phosphorylation in the CA1 region of OBX mice were significantly restored with memantine. Memantine 293-302 calcium/calmodulin-dependent protein kinase IV Mus musculus 149-195 34715352-7 2021 As demonstrated by immunoblotting, the reductions of calcium/calmodulin-dependent protein kinase II (CaMKII) alpha (Thr-286) autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV; Thr-196) phosphorylation in the CA1 region of OBX mice were significantly restored with memantine. Memantine 293-302 calcium/calmodulin-dependent protein kinase IV Mus musculus 197-203 34715352-7 2021 As demonstrated by immunoblotting, the reductions of calcium/calmodulin-dependent protein kinase II (CaMKII) alpha (Thr-286) autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV; Thr-196) phosphorylation in the CA1 region of OBX mice were significantly restored with memantine. Memantine 293-302 carbonic anhydrase 1 Mus musculus 237-240 34715352-9 2021 Finally, improvement of cognitive deficits by memantine treatments was observed in OBX-operated Kir6.1 heterozygous (+/-) mice but not in OBX-operated Kir6.2 heterozygous (+/-) mice. Memantine 46-55 potassium inwardly-rectifying channel, subfamily J, member 8 Mus musculus 96-102 34715352-10 2021 Overall, our study demonstrates that memantine rescues OBX-induced cognitive deficits via Kir6.2 channel inhibition in the CA1 region. Memantine 37-46 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 90-96 34715352-10 2021 Overall, our study demonstrates that memantine rescues OBX-induced cognitive deficits via Kir6.2 channel inhibition in the CA1 region. Memantine 37-46 carbonic anhydrase 1 Mus musculus 123-126 34517281-9 2021 RESULTS: Compared with the control group, the flap survival area of memantine group, especially the high-dose group, was larger, VEGF expression, microvascular density, angiogenesis, blood perfusion, and superoxide dismutase in the flap were higher in the Memantine-H group than in the Memantine-L and control groups (P < 0.01). Memantine 68-77 vascular endothelial growth factor A Rattus norvegicus 129-133 34830191-13 2021 Memantine or bCDsuMema nanoparticles efficiently suppressed the NMDAR1 protein, which is deeply associated with Alzheimer"s disease. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 64-70 34830191-16 2021 When memantine or bCDsuMema nanoparticles were treated in cells, the oxidative stress-mediated expression of NMDAR1 protein in cells was significantly decreased, indicating that bCDsuMema nanoparticles have the capacity to suppress NMDAR1 expression in brain cells, which has relevance in terms of applications in Alzheimer"s disease. Memantine 5-14 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 109-115 34830191-16 2021 When memantine or bCDsuMema nanoparticles were treated in cells, the oxidative stress-mediated expression of NMDAR1 protein in cells was significantly decreased, indicating that bCDsuMema nanoparticles have the capacity to suppress NMDAR1 expression in brain cells, which has relevance in terms of applications in Alzheimer"s disease. Memantine 5-14 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 232-238 34844267-0 2021 Favorable Response to "Memantine" in a Child with GRIN2B Epileptic Encephalopathy. Memantine 23-32 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 50-56 34517281-9 2021 RESULTS: Compared with the control group, the flap survival area of memantine group, especially the high-dose group, was larger, VEGF expression, microvascular density, angiogenesis, blood perfusion, and superoxide dismutase in the flap were higher in the Memantine-H group than in the Memantine-L and control groups (P < 0.01). Memantine 256-265 vascular endothelial growth factor A Rattus norvegicus 129-133 34517281-10 2021 In addition, levels of neutrophil density, IL-1beta, IL-6, TNF-alpha, TLR4, NF-kappaB, MAPK and malondialdehyde decreased significantly in the Memantine-H group (P < 0.01). Memantine 143-152 interleukin 1 alpha Rattus norvegicus 43-51 34517281-10 2021 In addition, levels of neutrophil density, IL-1beta, IL-6, TNF-alpha, TLR4, NF-kappaB, MAPK and malondialdehyde decreased significantly in the Memantine-H group (P < 0.01). Memantine 143-152 interleukin 6 Rattus norvegicus 53-57 34517281-10 2021 In addition, levels of neutrophil density, IL-1beta, IL-6, TNF-alpha, TLR4, NF-kappaB, MAPK and malondialdehyde decreased significantly in the Memantine-H group (P < 0.01). Memantine 143-152 tumor necrosis factor Rattus norvegicus 59-68 34517281-10 2021 In addition, levels of neutrophil density, IL-1beta, IL-6, TNF-alpha, TLR4, NF-kappaB, MAPK and malondialdehyde decreased significantly in the Memantine-H group (P < 0.01). Memantine 143-152 toll-like receptor 4 Rattus norvegicus 70-74 34508722-0 2021 Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer"s drugs. Memantine 85-94 transferrin Homo sapiens 106-117 34387707-2 2021 However, results of preclinical studies are promising when memantine is combined with agonists and allosteric modulators of the alpha7 nicotinic acetylcholine receptor (nAChR). Memantine 59-68 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 169-174 34776984-6 2021 Intriguingly, we found that while treatment with memantine can effectively block GluN2A-P552R-mediated dendrotoxicity, treatment with ketamine does not, despite the fact that both drugs work as open NMDAR channel blockers. Memantine 49-58 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 81-87 34776984-7 2021 Interestingly, we found that neurons expressing GluN2A-P552R were more vulnerable to an excitotoxic insult-an effect that, in this case, could be equally rescued by both memantine and ketamine. Memantine 170-179 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 48-54 34776984-9 2021 The differences between memantine and ketamine in halting GluN2A-P552R dendrotoxicity could not be explained by NMDA antagonist induced changes in MAP or Src kinase activation, previously shown to participate in NMDA-induced excitotoxicity. Memantine 24-33 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 58-64 34768760-7 2021 Importantly, pharmacological inhibition of ionotropic NMDA glutamate receptors by their antagonist memantine improved the physical activity of EAE rats, alleviated neurological deficits such as paralysis of tail and hind limbs, and modulated oxidative stress parameters (MDA, -SH groups, SOD"s). Memantine 99-108 superoxide dismutase 1 Rattus norvegicus 288-291 34576998-6 2021 The synthesized conjugates showed new properties compared to their prototypes (memantine and dimebon), including the ability to bind to the ifenprodil-binding site of the NMDA receptor and to occupy the peripheral anionic site of acetylcholinesterase (AChE), which indicates that these compounds can act as blockers of AChE-induced beta-amyloid aggregation. Memantine 79-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 230-250 34474083-5 2021 The blockage of N-methyl-d-aspartate receptors (NMDAR) by memantine reduced LPS-induced depression-like behaviors, NLRP3 inflammasome and astrocyte activation, and calpain-1 expression. Memantine 58-67 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 16-46 34474083-5 2021 The blockage of N-methyl-d-aspartate receptors (NMDAR) by memantine reduced LPS-induced depression-like behaviors, NLRP3 inflammasome and astrocyte activation, and calpain-1 expression. Memantine 58-67 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 48-53 34474083-5 2021 The blockage of N-methyl-d-aspartate receptors (NMDAR) by memantine reduced LPS-induced depression-like behaviors, NLRP3 inflammasome and astrocyte activation, and calpain-1 expression. Memantine 58-67 NLR family, pyrin domain containing 3 Mus musculus 115-120 34474083-5 2021 The blockage of N-methyl-d-aspartate receptors (NMDAR) by memantine reduced LPS-induced depression-like behaviors, NLRP3 inflammasome and astrocyte activation, and calpain-1 expression. Memantine 58-67 calpain 1 Mus musculus 164-173 34474083-6 2021 Additionally, memantine also inhibited LPS-induced reduction of postsynaptic density protein 95 (PSD-95) and Arc expression. Memantine 14-23 discs large MAGUK scaffold protein 4 Mus musculus 64-95 34474083-6 2021 Additionally, memantine also inhibited LPS-induced reduction of postsynaptic density protein 95 (PSD-95) and Arc expression. Memantine 14-23 discs large MAGUK scaffold protein 4 Mus musculus 97-103 34594187-0 2021 Early Chronic Memantine Treatment-Induced Transcriptomic Changes in Wild-Type and Shank2-Mutant Mice. Memantine 14-23 SH3 and multiple ankyrin repeat domains 2 Mus musculus 82-88 34594187-3 2021 However, at ~P14, these mice show the opposite change - increased NMDAR function; moreover, suppression of NMDAR activity with early, chronic memantine treatment during P7-21 prevents NMDAR hypofunction and autistic-like behaviors at later (~P21 and >P56) stages. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 66-71 34594187-3 2021 However, at ~P14, these mice show the opposite change - increased NMDAR function; moreover, suppression of NMDAR activity with early, chronic memantine treatment during P7-21 prevents NMDAR hypofunction and autistic-like behaviors at later (~P21 and >P56) stages. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 107-112 34594187-3 2021 However, at ~P14, these mice show the opposite change - increased NMDAR function; moreover, suppression of NMDAR activity with early, chronic memantine treatment during P7-21 prevents NMDAR hypofunction and autistic-like behaviors at later (~P21 and >P56) stages. Memantine 142-151 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 184-189 34594187-7 2021 In memantine-treated Shank2-KO mice, chromatin-related genes were upregulated; mitochondria, extracellular matrix (ECM), and actin-related genes were downregulated; and the reverse-ASD pattern was weakened compared with that in vehicle-treated Shank2-KO mice. Memantine 3-12 SH3 and multiple ankyrin repeat domains 2 Mus musculus 21-27 34594187-7 2021 In memantine-treated Shank2-KO mice, chromatin-related genes were upregulated; mitochondria, extracellular matrix (ECM), and actin-related genes were downregulated; and the reverse-ASD pattern was weakened compared with that in vehicle-treated Shank2-KO mice. Memantine 3-12 glucuronidase, beta Mus musculus 181-184 34594187-8 2021 In WT mice, memantine treatment, which does not alter NMDAR function, upregulated synaptic genes and downregulated ECM genes; memantine-treated WT mice also exhibited a reverse-ASD pattern. Memantine 12-21 glucuronidase, beta Mus musculus 177-180 34594187-8 2021 In WT mice, memantine treatment, which does not alter NMDAR function, upregulated synaptic genes and downregulated ECM genes; memantine-treated WT mice also exhibited a reverse-ASD pattern. Memantine 126-135 glucuronidase, beta Mus musculus 177-180 34594187-9 2021 Therefore, early chronic treatment of Shank2-KO mice with memantine alters expression of chromatin, mitochondria, ECM, actin, and ASD-related genes. Memantine 58-67 SH3 and multiple ankyrin repeat domains 2 Mus musculus 38-44 34594187-9 2021 Therefore, early chronic treatment of Shank2-KO mice with memantine alters expression of chromatin, mitochondria, ECM, actin, and ASD-related genes. Memantine 58-67 glucuronidase, beta Mus musculus 130-133 34270920-0 2021 Memantine exerts neuroprotective effects by modulating alpha-synuclein transmission in a parkinsonian model. Memantine 0-9 synuclein alpha Homo sapiens 55-70 34270920-3 2021 Memantine decreased the levels of internalized cytosolic alpha-synuclein and led to attenuation in alpha-synuclein-induced cell death. Memantine 0-9 synuclein alpha Homo sapiens 57-72 34270920-3 2021 Memantine decreased the levels of internalized cytosolic alpha-synuclein and led to attenuation in alpha-synuclein-induced cell death. Memantine 0-9 synuclein alpha Homo sapiens 99-114 34270920-4 2021 Specifically, memantine attenuated alpha-synuclein-induced expression of clathrin and EEA1, and increased expression of NR2A subunits. Memantine 14-23 synuclein alpha Homo sapiens 35-50 34270920-4 2021 Specifically, memantine attenuated alpha-synuclein-induced expression of clathrin and EEA1, and increased expression of NR2A subunits. Memantine 14-23 early endosome antigen 1 Homo sapiens 86-90 34270920-4 2021 Specifically, memantine attenuated alpha-synuclein-induced expression of clathrin and EEA1, and increased expression of NR2A subunits. Memantine 14-23 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 120-124 34270920-5 2021 Moreover, memantine inhibited propagation of extracellular alpha-synuclein and thus, decreased the expression of the phosphorylated form of alpha-synuclein in dopaminergic neurons of the substantia nigra, which was accompanied by increased survival of dopaminergic neurons with functional improvement of motor deficits. Memantine 10-19 synuclein alpha Homo sapiens 59-74 34270920-5 2021 Moreover, memantine inhibited propagation of extracellular alpha-synuclein and thus, decreased the expression of the phosphorylated form of alpha-synuclein in dopaminergic neurons of the substantia nigra, which was accompanied by increased survival of dopaminergic neurons with functional improvement of motor deficits. Memantine 10-19 synuclein alpha Homo sapiens 140-155 34270920-6 2021 The present study demonstrated that memantine modulates extracellular alpha-synuclein propagation by inhibiting interactions between alpha-synuclein and NR2A subunits, which leads to neuroprotective effects on nigral dopaminergic neurons against alpha-synuclein-enriched conditions. Memantine 36-45 synuclein alpha Homo sapiens 70-85 34270920-6 2021 The present study demonstrated that memantine modulates extracellular alpha-synuclein propagation by inhibiting interactions between alpha-synuclein and NR2A subunits, which leads to neuroprotective effects on nigral dopaminergic neurons against alpha-synuclein-enriched conditions. Memantine 36-45 synuclein alpha Homo sapiens 133-148 34270920-6 2021 The present study demonstrated that memantine modulates extracellular alpha-synuclein propagation by inhibiting interactions between alpha-synuclein and NR2A subunits, which leads to neuroprotective effects on nigral dopaminergic neurons against alpha-synuclein-enriched conditions. Memantine 36-45 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 153-157 34270920-7 2021 The repositioning use of memantine in alpha-synuclein propagation needs to be further evaluated in patients with alpha-synucleinopathies as an effective therapeutic approach. Memantine 25-34 synuclein alpha Homo sapiens 38-53 34576998-6 2021 The synthesized conjugates showed new properties compared to their prototypes (memantine and dimebon), including the ability to bind to the ifenprodil-binding site of the NMDA receptor and to occupy the peripheral anionic site of acetylcholinesterase (AChE), which indicates that these compounds can act as blockers of AChE-induced beta-amyloid aggregation. Memantine 79-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 252-256 34576998-6 2021 The synthesized conjugates showed new properties compared to their prototypes (memantine and dimebon), including the ability to bind to the ifenprodil-binding site of the NMDA receptor and to occupy the peripheral anionic site of acetylcholinesterase (AChE), which indicates that these compounds can act as blockers of AChE-induced beta-amyloid aggregation. Memantine 79-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 319-323 34275562-2 2021 This pilot, open-label, randomized clinical trial was conducted to investigate the impact of memantine on serum concentrations of matrix metalloproteinases (MMP)-2 and MMP-9, as neuronal damage biomarkers, and neurologic function evaluated by the National Institute of Health Stroke Scale(NIHSS) and Barthelindex(BI) in patients with ischemic stroke. Memantine 93-102 matrix metallopeptidase 2 Homo sapiens 130-163 34646371-7 2021 The N-methyl-D-aspartate receptor (NMDAR) antagonist memantine was used to treat the KO mice for rescuing the phenotypes. Memantine 53-62 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-33 34646371-7 2021 The N-methyl-D-aspartate receptor (NMDAR) antagonist memantine was used to treat the KO mice for rescuing the phenotypes. Memantine 53-62 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 35-40 34646371-13 2021 The NMDAR antagonist memantine could rescue GABAergic transmission in the hippocampus and ameliorate autistic-like behaviors of the KO mice. Memantine 21-30 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-9 34275562-2 2021 This pilot, open-label, randomized clinical trial was conducted to investigate the impact of memantine on serum concentrations of matrix metalloproteinases (MMP)-2 and MMP-9, as neuronal damage biomarkers, and neurologic function evaluated by the National Institute of Health Stroke Scale(NIHSS) and Barthelindex(BI) in patients with ischemic stroke. Memantine 93-102 matrix metallopeptidase 9 Homo sapiens 168-173 34275562-8 2021 This effect of memantine on the MMP-2 was not significant (P = 0.448). Memantine 15-24 matrix metallopeptidase 2 Homo sapiens 32-37 34360588-10 2021 Memantine also prevented the loss of the key glial glutamate transporter EAAT1 on BG. Memantine 0-9 solute carrier family 1 (glial high affinity glutamate transporter), member 3 Mus musculus 73-78 34227748-8 2021 Results from screening FDA-approved drugs suggested that GluN1-M641I containing NMDARs are more sensitive to the NMDAR channel blockers memantine, ketamine, and dextromethorphan compared to the wild-type receptors. Memantine 136-145 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 57-62 34131204-10 2021 Lastly, treatment with memantine (NMDAR antagonist) at 4 and 24 h after stroke significantly reduced gliosis at PSD14. Memantine 23-32 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-39 34211388-10 2021 Most surprisingly, the decreased expression of Alix was attenuated after the treatment of Memantine in different AD animal models. Memantine 90-99 programmed cell death 6 interacting protein Homo sapiens 47-51 35587310-6 2022 In in vitro studies, propolis significantly increased intracellular Ca2+ concentration and calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation in Kir6.2-overexpressed N2A cells treated with memantine. Memantine 214-223 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 91-137 34120588-0 2021 Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CA1 projection. Memantine 0-9 carbonic anhydrase 1 Mus musculus 81-84 34120588-2 2021 Here we treated APP/PS1 AD mice with a therapeutic dose of memantine (20 mg/kg/day) and examined its underlying mechanisms in ameliorating cognitive defects. Memantine 59-68 presenilin 1 Mus musculus 20-23 34120588-4 2021 RESULTS: Memantine significantly improved the acquisition in Morris water maze (MWM) in APP/PS1 mice without affecting the speed of swimming. Memantine 9-18 presenilin 1 Mus musculus 92-95 34120588-5 2021 Furthermore, memantine enhanced EC to CA1 synaptic neurotransmission and promoted dendritic spine regeneration of EC neurons that projected to CA1. Memantine 13-22 carbonic anhydrase 1 Mus musculus 38-41 34120588-5 2021 Furthermore, memantine enhanced EC to CA1 synaptic neurotransmission and promoted dendritic spine regeneration of EC neurons that projected to CA1. Memantine 13-22 carbonic anhydrase 1 Mus musculus 143-146 34121969-0 2021 Memantine shifts cancer cell metabolism via AMPK1/2 mediated energetic switch in A549 lung cancer cells. Memantine 0-9 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 44-51 34121969-6 2021 Our results suggest that memantine activates AMPK1/2 significantly (p=0.039 and p=0.0105) that led cells through apoptosis and autophagy by decreasing cancer cell metabolism regulators like HIF1A, B-catenin and PKM as the consequence of this energetic shift. Memantine 25-34 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 45-52 34121969-6 2021 Our results suggest that memantine activates AMPK1/2 significantly (p=0.039 and p=0.0105) that led cells through apoptosis and autophagy by decreasing cancer cell metabolism regulators like HIF1A, B-catenin and PKM as the consequence of this energetic shift. Memantine 25-34 hypoxia inducible factor 1 subunit alpha Homo sapiens 190-195 34121969-6 2021 Our results suggest that memantine activates AMPK1/2 significantly (p=0.039 and p=0.0105) that led cells through apoptosis and autophagy by decreasing cancer cell metabolism regulators like HIF1A, B-catenin and PKM as the consequence of this energetic shift. Memantine 25-34 catenin beta 1 Homo sapiens 197-206 34121969-6 2021 Our results suggest that memantine activates AMPK1/2 significantly (p=0.039 and p=0.0105) that led cells through apoptosis and autophagy by decreasing cancer cell metabolism regulators like HIF1A, B-catenin and PKM as the consequence of this energetic shift. Memantine 25-34 pyruvate kinase M1/2 Homo sapiens 211-214 35543162-0 2022 Antitumor effect of memantine is related to the formation of the splicing isoform of GLG1, a decoy FGF-binding protein. Memantine 20-29 golgi glycoprotein 1 Homo sapiens 85-89 35543162-3 2022 However, the association between memantine and Golgi glycoprotein 1 (GLG1), an intracellular fibroblast growth factor receptor, in cancers has not yet been clarified. Memantine 33-42 golgi glycoprotein 1 Homo sapiens 47-67 35543162-3 2022 However, the association between memantine and Golgi glycoprotein 1 (GLG1), an intracellular fibroblast growth factor receptor, in cancers has not yet been clarified. Memantine 33-42 golgi glycoprotein 1 Homo sapiens 69-73 35543162-4 2022 The present study analyzed the expression and location of GLG1 in tumor cells treated with memantine. Memantine 91-100 golgi glycoprotein 1 Homo sapiens 58-62 35543162-8 2022 Moreover, GLG1 spread in the cytosol of memantine-treated cells, whereas it localized in the Golgi apparatus in control cells. Memantine 40-49 golgi glycoprotein 1 Homo sapiens 10-14 35543162-9 2022 Since GLG1 functions as a decoy FGF receptor, the modulation of GLG1 may prove to be one of the mechanisms underlying the cancer-suppressive effects of memantine. Memantine 152-161 golgi glycoprotein 1 Homo sapiens 64-68 35587310-6 2022 In in vitro studies, propolis significantly increased intracellular Ca2+ concentration and calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation in Kir6.2-overexpressed N2A cells treated with memantine. Memantine 214-223 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 139-145 35587310-6 2022 In in vitro studies, propolis significantly increased intracellular Ca2+ concentration and calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation in Kir6.2-overexpressed N2A cells treated with memantine. Memantine 214-223 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 170-176 35587310-10 2022 Consistent with the rescued cognitive deficits in APP-KI mice, repeated administration of propolis markedly ameliorated memantine-dependent rescue of injured long-term potentiation (LTP) in APP-KI mice, concomitant with increased CaMKII autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV) phosphorylation in the hippocampal CA1 region. Memantine 120-129 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 230-236 35587310-10 2022 Consistent with the rescued cognitive deficits in APP-KI mice, repeated administration of propolis markedly ameliorated memantine-dependent rescue of injured long-term potentiation (LTP) in APP-KI mice, concomitant with increased CaMKII autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV) phosphorylation in the hippocampal CA1 region. Memantine 120-129 calcium/calmodulin-dependent protein kinase IV Mus musculus 261-307 35587310-10 2022 Consistent with the rescued cognitive deficits in APP-KI mice, repeated administration of propolis markedly ameliorated memantine-dependent rescue of injured long-term potentiation (LTP) in APP-KI mice, concomitant with increased CaMKII autophosphorylation and calcium/calmodulin-dependent protein kinase IV (CaMKIV) phosphorylation in the hippocampal CA1 region. Memantine 120-129 calcium/calmodulin-dependent protein kinase IV Mus musculus 309-315 35587310-15 2022 Our study demonstrates that propolis increases ATP contents and promotes the amelioration of cognitive deficits rescued by memantine via Kir6.2 channel inhibition in the CA1 region. Memantine 123-132 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 137-143 35543645-5 2022 In this study, we found that NMDAR antagonist memantine or PKR inhibitor C16 improved gp120-induced learning and memory impairment, and inhibited gp120-induced PKR activity. Memantine 46-55 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 86-91 35453065-1 2022 Currently, of the few accessible symptomatic therapies for Alzheimer"s disease (AD), memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the FDA. Memantine 85-94 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 138-143 35453065-4 2022 Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound. Memantine 177-186 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 157-162 35543645-5 2022 In this study, we found that NMDAR antagonist memantine or PKR inhibitor C16 improved gp120-induced learning and memory impairment, and inhibited gp120-induced PKR activity. Memantine 46-55 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 146-151 35543645-5 2022 In this study, we found that NMDAR antagonist memantine or PKR inhibitor C16 improved gp120-induced learning and memory impairment, and inhibited gp120-induced PKR activity. Memantine 46-55 eukaryotic translation initiation factor 2-alpha kinase 2 Rattus norvegicus 160-163 35543645-6 2022 Furthermore, memantine or C16 was found to attenuate gp120-inducd neuroinflammation, oxidative stress, ER stress and its downstream IRE1alpha/JNK pathway. Memantine 13-22 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 53-58 35543645-6 2022 Furthermore, memantine or C16 was found to attenuate gp120-inducd neuroinflammation, oxidative stress, ER stress and its downstream IRE1alpha/JNK pathway. Memantine 13-22 mitogen-activated protein kinase 8 Rattus norvegicus 142-145 35543645-7 2022 Additionally, memantine or C16 evidently inhibited apoptotic pathways by reducing the Bax and caspase-3, 8, 9 expressions and increasing Bcl-2 expression. Memantine 14-23 BCL2 associated X, apoptosis regulator Rattus norvegicus 86-89 35543645-7 2022 Additionally, memantine or C16 evidently inhibited apoptotic pathways by reducing the Bax and caspase-3, 8, 9 expressions and increasing Bcl-2 expression. Memantine 14-23 caspase 3 Rattus norvegicus 94-103 35543645-7 2022 Additionally, memantine or C16 evidently inhibited apoptotic pathways by reducing the Bax and caspase-3, 8, 9 expressions and increasing Bcl-2 expression. Memantine 14-23 BCL2, apoptosis regulator Rattus norvegicus 137-142 35448027-0 2022 Memantine Disrupts Motor Coordination through Anxiety-like Behavior in CD1 Mice. Memantine 0-9 CD1 antigen complex Mus musculus 71-74 35572136-7 2022 In addition, PTAFR was a putative target of anti-AD compounds, including EGCG, donepezil, curcumin, memantine, and Huperzine A. Memantine 100-109 platelet-activating factor receptor Mus musculus 13-18 35559146-11 2022 Furthermore, the expressions of BDNF, Seladin 1, and Sirtuin 6 as neuroprotective target genes were modified after clavulanic acid and memantine administrations; similarly, the results obtained from clavulanic acid were more significant. Memantine 135-144 brain-derived neurotrophic factor Rattus norvegicus 32-36 35559146-11 2022 Furthermore, the expressions of BDNF, Seladin 1, and Sirtuin 6 as neuroprotective target genes were modified after clavulanic acid and memantine administrations; similarly, the results obtained from clavulanic acid were more significant. Memantine 135-144 24-dehydrocholesterol reductase Rattus norvegicus 38-47 35559146-11 2022 Furthermore, the expressions of BDNF, Seladin 1, and Sirtuin 6 as neuroprotective target genes were modified after clavulanic acid and memantine administrations; similarly, the results obtained from clavulanic acid were more significant. Memantine 135-144 sirtuin 6 Rattus norvegicus 53-62 35448027-4 2022 We previously used memantine to prevent functional damage and to retain morphology of cerebellar neurons and Bergmann glia in an optogenetic mouse model of spinocerebellar ataxia type-1 (SCA1). Memantine 19-28 ataxin 1 Mus musculus 156-185 35448027-4 2022 We previously used memantine to prevent functional damage and to retain morphology of cerebellar neurons and Bergmann glia in an optogenetic mouse model of spinocerebellar ataxia type-1 (SCA1). Memantine 19-28 ataxin 1 Mus musculus 187-191 2897441-1 1988 The effect of memantine on CCK receptors in mouse brain has been investigated using particles of dissected cortex and striatum. Memantine 14-23 cholecystokinin Mus musculus 27-30 35246269-13 2022 Restoring NR2B physiological expression patterns with CK2 inhibition and inhibiting the function of excessive extrasynaptic NR2B with Memantine both mitigated tau accumulation in vitro. Memantine 134-143 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 124-128 35246269-13 2022 Restoring NR2B physiological expression patterns with CK2 inhibition and inhibiting the function of excessive extrasynaptic NR2B with Memantine both mitigated tau accumulation in vitro. Memantine 134-143 microtubule associated protein tau Homo sapiens 159-162 35235756-6 2022 We showed that Memantine treatment ameliorated oxaliplatin-elevated intracellular production of reactive oxygen species (ROS), lipid product malondialdehyde (MDA), and NOX-2 expression. Memantine 15-24 cytochrome b-245 beta chain Homo sapiens 168-173 35235756-9 2022 Moreover, the terminal deoxynucleotidyl Transferase-mediated dUTP nick end labeling (TUNEL) apoptosis assay revealed that Memantine protected oxaliplatin-induced apoptosis through mitigating the ratio of Bax/Bcl-2 and Caspase-3 cleavage. Memantine 122-131 BCL2 associated X, apoptosis regulator Homo sapiens 204-207 35235756-9 2022 Moreover, the terminal deoxynucleotidyl Transferase-mediated dUTP nick end labeling (TUNEL) apoptosis assay revealed that Memantine protected oxaliplatin-induced apoptosis through mitigating the ratio of Bax/Bcl-2 and Caspase-3 cleavage. Memantine 122-131 BCL2 apoptosis regulator Homo sapiens 208-213 35235756-9 2022 Moreover, the terminal deoxynucleotidyl Transferase-mediated dUTP nick end labeling (TUNEL) apoptosis assay revealed that Memantine protected oxaliplatin-induced apoptosis through mitigating the ratio of Bax/Bcl-2 and Caspase-3 cleavage. Memantine 122-131 caspase 3 Homo sapiens 218-227 2548883-0 1989 Memantine inhibits serotonin-induced rise of cytosolic Ca2+ activity and of cyclic GMP level in a neuronal cell line. Memantine 0-9 5'-nucleotidase, cytosolic II Homo sapiens 83-86 2548883-2 1989 The rise of both cytosolic Ca2+ activity and of cyclic GMP level was blocked by memantine (1-amino-3,5-dimethyladamantane). Memantine 80-89 5'-nucleotidase, cytosolic II Homo sapiens 55-58 2548883-2 1989 The rise of both cytosolic Ca2+ activity and of cyclic GMP level was blocked by memantine (1-amino-3,5-dimethyladamantane). Memantine 91-121 5'-nucleotidase, cytosolic II Homo sapiens 55-58 2548883-3 1989 Memantine inhibited the rise of the cyclic GMP level non-competitively (Ki about 50 microM). Memantine 0-9 5'-nucleotidase, cytosolic II Homo sapiens 43-46 2778846-5 1989 A single sc dose of memantine HCl (MEM, 18 mg/kg) and atropine sulfate (ATS, 16 mg/kg) 60 and 15 min, respectively, prior to carbofuran administration completely prevented the expected gross toxic signs and significantly (p less than .01) attenuated the carbofuran-induced inhibition of AChE activity. Memantine 20-33 acetylcholinesterase Rattus norvegicus 287-291 2778846-8 1989 The results of this study suggested that, in addition to cholinolytic effects of atropine, memantine may prevent and antagonize the acute toxicity of carbofuran by (a) protection of AChE activity and its rapid reactivation from inhibition and (b) rapid elimination of carbofuran. Memantine 91-100 acetylcholinesterase Rattus norvegicus 182-186 2897441-5 1988 Memantine increased CCK binding in a concentration-dependent manner, though at high concentrations. Memantine 0-9 cholecystokinin Mus musculus 20-23 2897441-8 1988 The effect of memantine on CCK binding is unique for brain since it was not observed in pancreatic acinar membranes. Memantine 14-23 cholecystokinin Mus musculus 27-30 2897441-9 1988 These data, therefore, suggest a modulatory effect of memantine on CCK receptors in mouse brain (cortex and striatum) particles. Memantine 54-63 cholecystokinin Mus musculus 67-70 887505-2 1977 Bradykinin potentiated the action of nialamide with L-dopa, dopamine, 1,3-dimethyl-5-aminoadamantane, apomorphine and noradrenaline. Memantine 70-100 kininogen 1 Homo sapiens 0-10 33831382-0 2021 Effects of memantine and its metabolite Mrz 2/373 on soman-induced inhibition of acetylcholinesterase in vitro. Memantine 11-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 33831382-4 2021 The results have shown that memantine and Mrz 2/373 exerted concentration-dependent inhibition of AChE, with Mrz 2/373 being a more potent inhibitor than the parent compound. Memantine 28-37 acetylcholinesterase (Cartwright blood group) Homo sapiens 98-102 33831382-2 2021 It also known that memantine pretreatment assured protection of skeletal muscles from poisoning with nerve agents and an interaction between memantine and AChE was proposed. Memantine 19-28 acetylcholinesterase (Cartwright blood group) Homo sapiens 155-159 33831382-6 2021 Memantine (0.1, 0.5 and 1 mmol/l) and Mrz 2/373 (0.1, 0.5 and 1 mmol/l) concentration-dependently slowed down the AChE inhibition. Memantine 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 114-118 33831382-2 2021 It also known that memantine pretreatment assured protection of skeletal muscles from poisoning with nerve agents and an interaction between memantine and AChE was proposed. Memantine 141-150 acetylcholinesterase (Cartwright blood group) Homo sapiens 155-159 33831382-7 2021 After 30 min of incubation of AChE with soman, 5 min of aging and 20 min of reactivation by asoxime (HI-6 dichloride), AChE activity was 8.1% in control medium, 30.7% and 41.9% after addition of 1 and 10 mmol/l memantine, and 16.1% after addition of 1 mmol/l Mrz 2/373. Memantine 211-220 acetylcholinesterase (Cartwright blood group) Homo sapiens 119-123 33831382-8 2021 It was concluded that it is possible that memantine and Mrz 2/373 can prevent AChE from inhibition by soman, which could, along with known memantine"s neuroprotective activity, explain its potent antidotal effect in soman poisoning. Memantine 42-51 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-82 33831382-3 2021 In the study presented we examined interactions of memantine and its main metabolite (1-amino-3-hydroxymethyl-5-methyl adamantine, Mrz 2/373) with AChE in vitro as well as their effect on kinetics of the soman-induced AChE inhibition and aging. Memantine 51-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 147-151 33831382-8 2021 It was concluded that it is possible that memantine and Mrz 2/373 can prevent AChE from inhibition by soman, which could, along with known memantine"s neuroprotective activity, explain its potent antidotal effect in soman poisoning. Memantine 139-148 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-82 33831382-3 2021 In the study presented we examined interactions of memantine and its main metabolite (1-amino-3-hydroxymethyl-5-methyl adamantine, Mrz 2/373) with AChE in vitro as well as their effect on kinetics of the soman-induced AChE inhibition and aging. Memantine 51-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 218-222 33744690-0 2021 Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Memantine 25-34 histone deacetylase 9 Homo sapiens 74-78 33979803-0 2021 The Organic Cation Transporter 2 Inhibitor Quinidine Modulates the Neuroprotective Effect of Nerve Growth Factor and Memantine on Cholinergic Neurons of the Basal Nucleus of Meynert in Organotypic Brain Slices. Memantine 117-126 solute carrier family 22 member 2 Homo sapiens 4-32 33979803-2 2021 Nerve growth factor (NGF) is the most potent protective factor for cholinergic neurons, additionally the NMDA antagonist memantine blocks glutamate-mediated excitotoxic activity. Memantine 121-130 nerve growth factor Homo sapiens 0-19 33970453-8 2021 Additionally, the NR2B antagonists memantine and Ro25-6981 reversed this neurotoxicity induced by propofol postconditioning. Memantine 35-44 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 18-22 33965504-8 2021 Continuous intraganglionic administration of memantine (an antagonist of NMDAR) decreased IANX-induced upregulated expression of p-Src and Panx1. Memantine 45-54 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 131-134 33965504-8 2021 Continuous intraganglionic administration of memantine (an antagonist of NMDAR) decreased IANX-induced upregulated expression of p-Src and Panx1. Memantine 45-54 pannexin 1 Homo sapiens 139-144 33744690-3 2021 By virtue of the blood brain barrier permeability (BBB), memantine was envisioned as an appropriate CAP component for the construction of the HDAC inhibitors. Memantine 57-66 histone deacetylase 9 Homo sapiens 142-146 33470757-0 2021 Memantine protects blood-brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3 inflammasome activation. Memantine 0-9 matrix metallopeptidase 9 Rattus norvegicus 222-248 33882517-5 2021 In this study, we demonstrate that memantine, a N-methyl-D-aspartic acid receptor (NMDAR) antagonist, through suppressing Ca2+ influx and subsequent ASC oligomerization inhibits macrophage Nlrp3 inflammasome activation and pyroptosis, therefore, alleviates ALI in septic mice. Memantine 35-44 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 83-88 33882517-5 2021 In this study, we demonstrate that memantine, a N-methyl-D-aspartic acid receptor (NMDAR) antagonist, through suppressing Ca2+ influx and subsequent ASC oligomerization inhibits macrophage Nlrp3 inflammasome activation and pyroptosis, therefore, alleviates ALI in septic mice. Memantine 35-44 NLR family, pyrin domain containing 3 Mus musculus 189-194 33915770-0 2021 Novel Mechanism for Memantine in Attenuating Diabetic Neuropathic Pain in Mice via Downregulating the Spinal HMGB1/TRL4/NF-kB Inflammatory Axis. Memantine 20-29 high mobility group box 1 Mus musculus 109-114 33915770-0 2021 Novel Mechanism for Memantine in Attenuating Diabetic Neuropathic Pain in Mice via Downregulating the Spinal HMGB1/TRL4/NF-kB Inflammatory Axis. Memantine 20-29 tuberculosis resistance 4 Mus musculus 115-119 33915770-2 2021 The aim of the current work was to uncover the anti-allodynic and neuroprotective effects of memantine in a model of mouse diabetic neuropathy and its ameliorative effect on the high-mobility group box-1 (HMGB1)/toll-like receptor 4 (TLR4)/nuclear factor-k B (NF-kB) inflammatory axis. Memantine 93-102 high mobility group box 1 Mus musculus 178-203 33915770-2 2021 The aim of the current work was to uncover the anti-allodynic and neuroprotective effects of memantine in a model of mouse diabetic neuropathy and its ameliorative effect on the high-mobility group box-1 (HMGB1)/toll-like receptor 4 (TLR4)/nuclear factor-k B (NF-kB) inflammatory axis. Memantine 93-102 high mobility group box 1 Mus musculus 205-210 33915770-2 2021 The aim of the current work was to uncover the anti-allodynic and neuroprotective effects of memantine in a model of mouse diabetic neuropathy and its ameliorative effect on the high-mobility group box-1 (HMGB1)/toll-like receptor 4 (TLR4)/nuclear factor-k B (NF-kB) inflammatory axis. Memantine 93-102 toll-like receptor 4 Mus musculus 212-232 33915770-2 2021 The aim of the current work was to uncover the anti-allodynic and neuroprotective effects of memantine in a model of mouse diabetic neuropathy and its ameliorative effect on the high-mobility group box-1 (HMGB1)/toll-like receptor 4 (TLR4)/nuclear factor-k B (NF-kB) inflammatory axis. Memantine 93-102 toll-like receptor 4 Mus musculus 234-238 33915770-10 2021 Memantine alleviated pain indicators in diabetic mice and suppressed excessive NMDAR1 activation, glutamate, and pro-inflammatory cytokine release in the spinal cord. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 79-85 33915770-11 2021 The current study validated the ability of memantine to combat the HMGB1/TLR4/NF-kB axis and modulate overactive glutamate spinal transmission, corroborating memantine as an appealing therapeutic target in DNP. Memantine 43-52 high mobility group box 1 Mus musculus 67-72 33915770-11 2021 The current study validated the ability of memantine to combat the HMGB1/TLR4/NF-kB axis and modulate overactive glutamate spinal transmission, corroborating memantine as an appealing therapeutic target in DNP. Memantine 43-52 toll-like receptor 4 Mus musculus 73-77 33174139-0 2021 Memantine, NMDA Receptor Antagonist, Attenuates ox-LDL-Induced Inflammation and Oxidative Stress via Activation of BDNF/TrkB Signaling Pathway in HUVECs. Memantine 0-9 brain derived neurotrophic factor Homo sapiens 115-119 33174139-0 2021 Memantine, NMDA Receptor Antagonist, Attenuates ox-LDL-Induced Inflammation and Oxidative Stress via Activation of BDNF/TrkB Signaling Pathway in HUVECs. Memantine 0-9 neurotrophic receptor tyrosine kinase 2 Homo sapiens 120-124 33470757-0 2021 Memantine protects blood-brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3 inflammasome activation. Memantine 0-9 NLR family, pyrin domain containing 3 Rattus norvegicus 249-254 33470757-3 2021 This research probed into the neurovascular protective mechanisms of memantine after ICH and its impacts on neuronal nitric oxide synthase (nNOS) ser1412 phosphorylation. Memantine 69-78 nitric oxide synthase 1 Rattus norvegicus 108-138 33470757-3 2021 This research probed into the neurovascular protective mechanisms of memantine after ICH and its impacts on neuronal nitric oxide synthase (nNOS) ser1412 phosphorylation. Memantine 69-78 nitric oxide synthase 1 Rattus norvegicus 140-144 33470757-9 2021 Memantine improved the neurologic deficits and mitigated brain water content, levels of MMP-9, NLRP3, IL-1beta and dying neurons. Memantine 0-9 matrix metallopeptidase 9 Rattus norvegicus 88-93 33470757-9 2021 Memantine improved the neurologic deficits and mitigated brain water content, levels of MMP-9, NLRP3, IL-1beta and dying neurons. Memantine 0-9 NLR family, pyrin domain containing 3 Rattus norvegicus 95-100 33470757-9 2021 Memantine improved the neurologic deficits and mitigated brain water content, levels of MMP-9, NLRP3, IL-1beta and dying neurons. Memantine 0-9 interleukin 1 alpha Rattus norvegicus 102-110 33470757-10 2021 Additionally, treatment with memantine also reduced nNOS ser1412 phosphorylation and peroxynitrite formation compared with the ICH+V group at 24 h after ICH. Memantine 29-38 nitric oxide synthase 1 Rattus norvegicus 52-56 33026572-7 2021 We have also found that both Memantine (5 microM) and Ibuprofen (200 muM) significantly prevented the STZ-induced change in CaMKIIalpha, CREB, Calpain, and Caspase 3 expressions in C6 astrocytoma cells. Memantine 29-38 cAMP responsive element binding protein 1 Rattus norvegicus 137-141 33026572-7 2021 We have also found that both Memantine (5 microM) and Ibuprofen (200 muM) significantly prevented the STZ-induced change in CaMKIIalpha, CREB, Calpain, and Caspase 3 expressions in C6 astrocytoma cells. Memantine 29-38 caspase 3 Rattus norvegicus 156-165 33153323-2 2020 The measurement of gas-phase basicity (GB) and proton affinity (PA) values of four important and commercially available drugs for Alzheimer"s disease namely, rivastigmine, galantamine, memantine, and tacrine, is attempted for the first time. Memantine 185-194 galactosamine (N-acetyl)-6-sulfatase Homo sapiens 19-22 32914393-4 2021 We demonstrate that a chronic oral memantine treatment for 4 months diminishes hippocampal CA1 neuron loss and rescues learning and memory performance in different behavioral paradigms, such as Morris water maze or a novel object recognition task. Memantine 35-44 carbonic anhydrase 1 Mus musculus 91-94 33290797-0 2021 Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression. Memantine 0-9 cAMP responsive element binding protein 1 Rattus norvegicus 151-155 33290797-0 2021 Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression. Memantine 0-9 brain-derived neurotrophic factor Rattus norvegicus 156-160 33290797-8 2021 Memantine treatment also restored CUS induced increase in oxidative stress parameters [increased neuronal nitric oxide synthase (nNOS) expression, nitric oxide (NO) levels, lipid peroxidation (LPO) and superoxide dismutase (SOD) activity], decrease in mitochondrial electron transport chain (ETC) enzymes activity and mitochondrial membrane potential (MMP). Memantine 0-9 nitric oxide synthase 1 Rattus norvegicus 97-127 33290797-8 2021 Memantine treatment also restored CUS induced increase in oxidative stress parameters [increased neuronal nitric oxide synthase (nNOS) expression, nitric oxide (NO) levels, lipid peroxidation (LPO) and superoxide dismutase (SOD) activity], decrease in mitochondrial electron transport chain (ETC) enzymes activity and mitochondrial membrane potential (MMP). Memantine 0-9 nitric oxide synthase 1 Rattus norvegicus 129-133 33290797-9 2021 CUS also reduced the expression of cell survival genes, cyclic-AMP response element-binding protein (CREB), and brain-derived nerve growth factor (BDNF), which was reversed by treatment with Memantine. Memantine 191-200 cAMP responsive element binding protein 1 Rattus norvegicus 56-99 33290797-9 2021 CUS also reduced the expression of cell survival genes, cyclic-AMP response element-binding protein (CREB), and brain-derived nerve growth factor (BDNF), which was reversed by treatment with Memantine. Memantine 191-200 cAMP responsive element binding protein 1 Rattus norvegicus 101-105 33290797-9 2021 CUS also reduced the expression of cell survival genes, cyclic-AMP response element-binding protein (CREB), and brain-derived nerve growth factor (BDNF), which was reversed by treatment with Memantine. Memantine 191-200 brain-derived neurotrophic factor Rattus norvegicus 112-145 33290797-9 2021 CUS also reduced the expression of cell survival genes, cyclic-AMP response element-binding protein (CREB), and brain-derived nerve growth factor (BDNF), which was reversed by treatment with Memantine. Memantine 191-200 brain-derived neurotrophic factor Rattus norvegicus 147-151 33290797-11 2021 Thus, Memantine treatment exerts an antidepressant-like effect by preventing CUS induced excitotoxicity, oxidative stress, and enhancing CUS induced decrease in mitochondrial functioning and expression of cell survival genes via upregulation of stress-responsive CREB/BDNF signaling. Memantine 6-15 cAMP responsive element binding protein 1 Rattus norvegicus 263-267 33290797-11 2021 Thus, Memantine treatment exerts an antidepressant-like effect by preventing CUS induced excitotoxicity, oxidative stress, and enhancing CUS induced decrease in mitochondrial functioning and expression of cell survival genes via upregulation of stress-responsive CREB/BDNF signaling. Memantine 6-15 brain-derived neurotrophic factor Rattus norvegicus 268-272 33500723-8 2021 The NMDAR blockade by Memantine decreased the susceptibility to insulin resistance and hepatic steatosis in obese mice. Memantine 22-31 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 4-9 33069748-9 2020 As western blot analysis revealed that FTY720 failed to completely restore PP2A, another PP2A modulator, Memantine, was used for co-treatment. Memantine 105-114 protein phosphatase 2 phosphatase activator Homo sapiens 89-93 32765929-0 2020 GRIN2A -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. Memantine 61-70 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 0-6 32765929-4 2020 GRIN2A gene encodes for a subunit of N-methyl-D-aspartate (NMDA) receptor and it has been suggested from in vitro studies and few case reports that memantine, a NMDA receptor antagonist, was shown to reduce seizures in patients with GRIN2A mutations. Memantine 148-157 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 0-6 32765929-4 2020 GRIN2A gene encodes for a subunit of N-methyl-D-aspartate (NMDA) receptor and it has been suggested from in vitro studies and few case reports that memantine, a NMDA receptor antagonist, was shown to reduce seizures in patients with GRIN2A mutations. Memantine 148-157 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 233-239 32765929-5 2020 Here, we describe a patient with a novel GRIN2A mutation and severe drug-resistant ES who became seizure free with memantine. Memantine 115-124 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 41-47 33174867-5 2020 Our findings indicate that pretreatment with memantine significantly reduced the expression of interleukin (IL)-6 and IL-8, which are both serum markers if AMI severity. Memantine 45-54 interleukin 6 Homo sapiens 95-113 33174867-5 2020 Our findings indicate that pretreatment with memantine significantly reduced the expression of interleukin (IL)-6 and IL-8, which are both serum markers if AMI severity. Memantine 45-54 C-X-C motif chemokine ligand 8 Homo sapiens 118-122 33174867-6 2020 We also demonstrate that memantine could prevent mitochondrial dysfunction and oxidative stress by rescuing mitochondrial membrane potential and reducing the production of reactive oxygen species (ROS) by NADPH oxidase-4 (NOX-4). Memantine 25-34 NADPH oxidase 4 Homo sapiens 205-220 33174867-6 2020 We also demonstrate that memantine could prevent mitochondrial dysfunction and oxidative stress by rescuing mitochondrial membrane potential and reducing the production of reactive oxygen species (ROS) by NADPH oxidase-4 (NOX-4). Memantine 25-34 NADPH oxidase 4 Homo sapiens 222-227 32914577-10 2020 Memantine was more acceptable than placebo (MD 0.93, 95% Crl 0.69 to 1.22). Memantine 0-9 interleukin 31 receptor A Homo sapiens 57-60 33174867-7 2020 Importantly, memantine also promoted the expression of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant signaling pathway. Memantine 13-22 NFE2 like bZIP transcription factor 2 Homo sapiens 59-102 33174867-7 2020 Importantly, memantine also promoted the expression of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant signaling pathway. Memantine 13-22 NFE2 like bZIP transcription factor 2 Homo sapiens 104-108 33174867-7 2020 Importantly, memantine also promoted the expression of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant signaling pathway. Memantine 13-22 heme oxygenase 1 Homo sapiens 110-126 33174867-7 2020 Importantly, memantine also promoted the expression of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant signaling pathway. Memantine 13-22 heme oxygenase 1 Homo sapiens 128-132 33174867-9 2020 Through a phosphoinositide-3-kinase (PI3K) inhibition experiment, we determined that the PI3K/protein kinase B (Akt) pathway is essential for the effects of memantine on angiogenesis. Memantine 157-166 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 10-35 33174867-9 2020 Through a phosphoinositide-3-kinase (PI3K) inhibition experiment, we determined that the PI3K/protein kinase B (Akt) pathway is essential for the effects of memantine on angiogenesis. Memantine 157-166 protein tyrosine kinase 2 beta Homo sapiens 94-110 33174867-9 2020 Through a phosphoinositide-3-kinase (PI3K) inhibition experiment, we determined that the PI3K/protein kinase B (Akt) pathway is essential for the effects of memantine on angiogenesis. Memantine 157-166 AKT serine/threonine kinase 1 Homo sapiens 112-115 33081685-12 2021 Memantine treatment decreased GSK3B protein expression levels in tumor tissue samples. Memantine 0-9 glycogen synthase kinase 3 beta Mus musculus 30-35 32665905-3 2020 Therefore, we aimed to investigate the contribution of sigma receptors and lysosome inhibition to the neuroprotective effects of memantine against amyloid-beta (Abeta)-induced neurotoxicity in SH-SY5Y cells. Memantine 129-138 amyloid beta precursor protein Homo sapiens 161-166 32768741-4 2020 This compound is relatively selective to HDAC6 with IC50 of 0.18 muM and also maintains comparable activity on NMDAR (Ki = 0.59 muM) as memantine. Memantine 136-145 histone deacetylase 6 Homo sapiens 41-46 32531473-0 2020 Memantine improves depressive-like behaviors via Kir6.1 channel inhibition in olfactory bulbectomized mice. Memantine 0-9 potassium inwardly-rectifying channel, subfamily J, member 8 Mus musculus 49-55 32531473-6 2020 In the immunoblot analysis, memantine significantly increased phosphorylation of CaMKIV (Thr-196) and Akt (Ser-473), but not ERK (Thr-202/Tyr-204), in the DG of OBX mice. Memantine 28-37 calcium/calmodulin-dependent protein kinase IV Mus musculus 81-87 32531473-6 2020 In the immunoblot analysis, memantine significantly increased phosphorylation of CaMKIV (Thr-196) and Akt (Ser-473), but not ERK (Thr-202/Tyr-204), in the DG of OBX mice. Memantine 28-37 thymoma viral proto-oncogene 1 Mus musculus 102-105 32531473-8 2020 In contrast, both the improvement of depressive-like behaviors and increase in BrdU-positive neurons in the DG following treatment with memantine were unapparent in OBX-treated Kir6.1 heterozygous (+/-) mice but not OBX-treated Kir6.2 heterozygous (+/-) mice. Memantine 136-145 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 228-234 32531473-10 2020 Overall, our study shows that memantine improves OBX-induced depressive-like behaviors by increasing adult neurogenesis in the DG via Kir6.1 channel inhibition. Memantine 30-39 potassium inwardly-rectifying channel, subfamily J, member 8 Mus musculus 134-140 32782018-9 2020 RESULTS: Oral administration of memantine ameliorated the motor impairments induced by AQP4-IgG, no matter the treatment was initiated before (preventive) or after (therapeutic) disease flare. Memantine 32-41 aquaporin 4 Mus musculus 87-91 32782018-12 2020 In addition, memantine elevated growth factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in the spinal cord. Memantine 13-22 brain derived neurotrophic factor Mus musculus 57-90 32782018-12 2020 In addition, memantine elevated growth factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in the spinal cord. Memantine 13-22 brain derived neurotrophic factor Mus musculus 92-96 32544502-5 2020 Moreover, in in vivo studies in rats, the protective effects of memantine on isoproterenol-induced myocardial infarction model (administration of 100 mg/kg isoproterenol subcutaneously for 2 consecutive days) was evaluated by measuring ECG pattern, mean arterial pressure, malondialdehyde (MDA) levels, myeloperoxidase (MPO) activity, cardiac tumor necrosis factor-alpha (TNF-alpha) level and cardiac remodeling. Memantine 64-73 myeloperoxidase Rattus norvegicus 303-318 32544502-5 2020 Moreover, in in vivo studies in rats, the protective effects of memantine on isoproterenol-induced myocardial infarction model (administration of 100 mg/kg isoproterenol subcutaneously for 2 consecutive days) was evaluated by measuring ECG pattern, mean arterial pressure, malondialdehyde (MDA) levels, myeloperoxidase (MPO) activity, cardiac tumor necrosis factor-alpha (TNF-alpha) level and cardiac remodeling. Memantine 64-73 myeloperoxidase Rattus norvegicus 320-323 32544502-5 2020 Moreover, in in vivo studies in rats, the protective effects of memantine on isoproterenol-induced myocardial infarction model (administration of 100 mg/kg isoproterenol subcutaneously for 2 consecutive days) was evaluated by measuring ECG pattern, mean arterial pressure, malondialdehyde (MDA) levels, myeloperoxidase (MPO) activity, cardiac tumor necrosis factor-alpha (TNF-alpha) level and cardiac remodeling. Memantine 64-73 tumor necrosis factor Rattus norvegicus 343-370 32544502-5 2020 Moreover, in in vivo studies in rats, the protective effects of memantine on isoproterenol-induced myocardial infarction model (administration of 100 mg/kg isoproterenol subcutaneously for 2 consecutive days) was evaluated by measuring ECG pattern, mean arterial pressure, malondialdehyde (MDA) levels, myeloperoxidase (MPO) activity, cardiac tumor necrosis factor-alpha (TNF-alpha) level and cardiac remodeling. Memantine 64-73 tumor necrosis factor Rattus norvegicus 372-381 32544502-7 2020 The isoproterenol-induced MI (Iso) as used in the in vivo model demonstrated that MDA levels and MPO activity were decreased in memantine groups. Memantine 128-137 myeloperoxidase Rattus norvegicus 97-100 32544502-8 2020 Memantine treatment reduced the expression of cardiac TNF-alpha in comparison to Iso group. Memantine 0-9 tumor necrosis factor Rattus norvegicus 54-63 32782018-12 2020 In addition, memantine elevated growth factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in the spinal cord. Memantine 13-22 glial cell line derived neurotrophic factor Mus musculus 99-142 32782018-12 2020 In addition, memantine elevated growth factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in the spinal cord. Memantine 13-22 glial cell line derived neurotrophic factor Mus musculus 144-148 32782018-12 2020 In addition, memantine elevated growth factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in the spinal cord. Memantine 13-22 vascular endothelial growth factor A Mus musculus 155-189 32782018-12 2020 In addition, memantine elevated growth factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in the spinal cord. Memantine 13-22 vascular endothelial growth factor A Mus musculus 191-195 32648077-0 2020 Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats. Memantine 10-19 beta-secretase 1 Rattus norvegicus 37-42 32648077-0 2020 Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats. Memantine 10-19 beta-secretase 1 Rattus norvegicus 50-55 32648077-2 2020 In the present study, the effects of memantine on the level of Bace1-as and Bace1 genes" expression in streptozotocin (STZ)-induced Alzheimer"s and memantine treated rats were investigated. Memantine 37-46 beta-secretase 1 Rattus norvegicus 63-68 32648077-2 2020 In the present study, the effects of memantine on the level of Bace1-as and Bace1 genes" expression in streptozotocin (STZ)-induced Alzheimer"s and memantine treated rats were investigated. Memantine 37-46 beta-secretase 1 Rattus norvegicus 76-81 32665905-8 2020 Results: Memantine (2.5 microM), dizocilpine (5 microM), chloroquine (10 and 20 microM) and BD-1063 (1, 10 and 30 microM) decreased the neurotoxic effects of Abeta on the SH-SY5Y cells. Memantine 9-18 amyloid beta precursor protein Homo sapiens 158-163 32665905-10 2020 Cell viability in the cells treated with memantine + Abeta + chloroquine (10, 20, and 40 muM) was significantly lower than the memantine + Abeta-treated group. Memantine 127-136 amyloid beta precursor protein Homo sapiens 139-144 32665905-11 2020 Moreover, cell viability in the memantine + Abeta group was higher than the memantine + Abeta + BD-1063 (10 and 30 muM) groups. Memantine 32-41 amyloid beta precursor protein Homo sapiens 44-49 31907339-0 2020 Concomitant memantine and Lactobacillus plantarum treatment attenuates cognitive impairments in APP/PS1 mice. Memantine 12-21 presenilin 1 Mus musculus 100-103 32435183-17 2020 Memantine reduced the levels of MDA, GSH, and GR while increased the level of CAT in the cerebrum. Memantine 0-9 glutathione-disulfide reductase Rattus norvegicus 46-48 32435183-17 2020 Memantine reduced the levels of MDA, GSH, and GR while increased the level of CAT in the cerebrum. Memantine 0-9 catalase Rattus norvegicus 78-81 32096857-13 2020 Medications approved to treat Alzheimer disease (donepezil, galantamine, rivastigmine, and memantine) improved scores on the ADAS-Cog 11 by 1 to 2.5 points over 3 months to 3 years. Memantine 91-100 alkylglycerone phosphate synthase Homo sapiens 125-129 32020309-7 2020 RESULTS: ALZc3 and memantine improved memory impairment and antioxidant activity and reduced TNF-alpha expression, caspase-3 activity and Bax/Bcl-2 ratio in the rat"s hippocampus. Memantine 19-28 tumor necrosis factor Rattus norvegicus 93-102 32020309-7 2020 RESULTS: ALZc3 and memantine improved memory impairment and antioxidant activity and reduced TNF-alpha expression, caspase-3 activity and Bax/Bcl-2 ratio in the rat"s hippocampus. Memantine 19-28 caspase 3 Rattus norvegicus 115-124 32020309-7 2020 RESULTS: ALZc3 and memantine improved memory impairment and antioxidant activity and reduced TNF-alpha expression, caspase-3 activity and Bax/Bcl-2 ratio in the rat"s hippocampus. Memantine 19-28 BCL2 associated X, apoptosis regulator Rattus norvegicus 138-141 32020309-7 2020 RESULTS: ALZc3 and memantine improved memory impairment and antioxidant activity and reduced TNF-alpha expression, caspase-3 activity and Bax/Bcl-2 ratio in the rat"s hippocampus. Memantine 19-28 BCL2, apoptosis regulator Rattus norvegicus 142-147 32340037-11 2020 In adults with moderate to severe CATD receiving cholinesterase inhibitors, low- to insufficient-strength evidence suggested that, compared with placebo, add-on memantine inconsistently improved cognition and improved global clinical impression but not function. Memantine 161-170 butyrylcholinesterase Homo sapiens 49-63 32477103-7 2020 Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma. Memantine 14-23 CD4 antigen Mus musculus 59-62 32477103-7 2020 Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma. Memantine 14-23 CD28 antigen Mus musculus 63-67 32477103-7 2020 Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma. Memantine 14-23 tumor necrosis factor Mus musculus 140-149 32477103-7 2020 Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma. Memantine 14-23 interleukin 1 alpha Mus musculus 151-159 32477103-7 2020 Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma. Memantine 14-23 colony stimulating factor 3 (granulocyte) Mus musculus 165-170 31834143-9 2020 Memantine treatment can prevent okadaic acid induced impairment of hippocampal-dependent spatial memory and accompanied by modulation of the expression level of alpha7 subunit of nACh and NR2B subunit of NMDA receptors in the hippocampus. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 188-192 32067580-6 2020 Administration of the N-methyl-D-aspartate receptor antagonist memantine protected Cbs+/- but not Cbs-/- mice from cerebral infarction and blood brain barrier disruption. Memantine 63-72 cystathionine beta-synthase Mus musculus 83-86 32067580-7 2020 Our data suggest that the differential effect of memantine in Cbs+/- versus Cbs-/- mice may be related to changes in expression of N-methyl-D-aspartate receptor subunits. Memantine 49-58 cystathionine beta-synthase Mus musculus 62-65 32067580-7 2020 Our data suggest that the differential effect of memantine in Cbs+/- versus Cbs-/- mice may be related to changes in expression of N-methyl-D-aspartate receptor subunits. Memantine 49-58 cystathionine beta-synthase Mus musculus 76-79 31907339-6 2020 These experiments demonstrate that L. plantarum augments the beneficial therapeutic effects of memantine treatment in APP/PS1 mice by remodeling the intestinal microbiota, inhibiting the synthesis of TMAO, and reducing clusterin levels. Memantine 95-104 presenilin 1 Mus musculus 122-125 32990004-0 2020 Alzheimer"s drug Memantine inhibits metastasis and p-Erk protein expression on 4T1 breast cancer cells. Memantine 17-26 mitogen-activated protein kinase 1 Mus musculus 53-56 32990004-6 2020 RESULTS: Memantine altered the Bcl-2, Bax, Casp3, Casp-9 apoptotic protein expression levels. Memantine 9-18 B cell leukemia/lymphoma 2 Mus musculus 31-36 32990004-6 2020 RESULTS: Memantine altered the Bcl-2, Bax, Casp3, Casp-9 apoptotic protein expression levels. Memantine 9-18 BCL2-associated X protein Mus musculus 38-41 32990004-6 2020 RESULTS: Memantine altered the Bcl-2, Bax, Casp3, Casp-9 apoptotic protein expression levels. Memantine 9-18 caspase 3 Mus musculus 43-48 32990004-6 2020 RESULTS: Memantine altered the Bcl-2, Bax, Casp3, Casp-9 apoptotic protein expression levels. Memantine 9-18 caspase 9 Mus musculus 50-56 32990004-7 2020 We found that memantine inhibited p-Erk expression and that result suggested a plausible mechanism of action for memantine"s antineoplastic effect. Memantine 14-23 mitogen-activated protein kinase 1 Mus musculus 36-39 32990004-7 2020 We found that memantine inhibited p-Erk expression and that result suggested a plausible mechanism of action for memantine"s antineoplastic effect. Memantine 113-122 mitogen-activated protein kinase 1 Mus musculus 36-39 31929157-7 2020 RESULTS: Memantine was favored over AChEIs as first-line treatment to AD in persons with asthma/COPD compared to those without asthma/COPD (odds ratio 1.23, 95% confidence interval (CI) 1.15-1.31). Memantine 9-18 COPD Homo sapiens 96-100 30872082-0 2020 Memantine Induces Reflex Syncope in Elderly Patients With Dementia: Results From the Syncope and Dementia Study (SYD-Study). Memantine 0-9 mitogen-activated protein kinase 8 interacting protein 3 Homo sapiens 113-116 31929157-8 2020 Memantine was also more commonly used among those who used multiple asthma/COPD medications (7.9% of memantine initiators used >=3 asthma/COPD medications compared with 5.5% of those who initiated with AChEI). Memantine 0-9 COPD Homo sapiens 75-79 31929157-8 2020 Memantine was also more commonly used among those who used multiple asthma/COPD medications (7.9% of memantine initiators used >=3 asthma/COPD medications compared with 5.5% of those who initiated with AChEI). Memantine 0-9 COPD Homo sapiens 138-142 31929157-10 2020 CONCLUSION: More frequent use of memantine instead of AChEI may result from an attempt to prevent possible worsening of asthma/COPD by AChEIs. Memantine 33-42 COPD Homo sapiens 127-131 31773661-3 2020 Among four available therapeutics (donepezil, rivastigmine, galantamine, and memantine), three of them are cholinesterase inhibitors. Memantine 77-86 butyrylcholinesterase Homo sapiens 107-121 31890854-4 2019 The proposed hypothesis may be validated in persons with aMCI after raising their brain levels of TGF-beta1 and 2 by using a combination of three drugs, lithium, memantine, plus either glatiramer or venlafaxine, and then assessing their progression to AD. Memantine 162-171 transforming growth factor beta 1 Homo sapiens 98-113 31531878-5 2019 METHODS: In this study, we evaluated whether a combination of memantine with melatonin, administered for 32 days in drinking water, was more effective than either drug alone with respect to Abeta aggregates, neuroinflammation and cognition in the double transgenic APP/PS1 (5xFAD) mouse model of AD. Memantine 62-71 presenilin 1 Mus musculus 269-272 31280448-0 2019 Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression. Memantine 0-9 insulin degrading enzyme Mus musculus 123-147 31280448-9 2019 Compared with controls, memantine-treated APP23 mice had reduced Abeta40 levels and increased levels of hippocampal and vascular IDE. Memantine 24-33 insulin degrading enzyme Mus musculus 129-132 31280448-10 2019 Our results suggest that memantine reduces cerebrovascular Abeta deposits by enhancing Abeta-cleaving IDE expression. Memantine 25-34 amyloid beta (A4) precursor protein Mus musculus 59-64 31280448-10 2019 Our results suggest that memantine reduces cerebrovascular Abeta deposits by enhancing Abeta-cleaving IDE expression. Memantine 25-34 insulin degrading enzyme Mus musculus 102-105 31541561-9 2019 Furthermore, channel blockade of GluN1/2B/2D by extracellular Mg2+ is intermediate compared to GluN1/2B and GluN1/2D, although GluN1/2B/2D is more sensitive to blockade by ketamine and memantine compared to GluN1/2B in the presence of physiological Mg2+ . Memantine 185-194 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 33-43 31541561-9 2019 Furthermore, channel blockade of GluN1/2B/2D by extracellular Mg2+ is intermediate compared to GluN1/2B and GluN1/2D, although GluN1/2B/2D is more sensitive to blockade by ketamine and memantine compared to GluN1/2B in the presence of physiological Mg2+ . Memantine 185-194 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 33-41 31541561-9 2019 Furthermore, channel blockade of GluN1/2B/2D by extracellular Mg2+ is intermediate compared to GluN1/2B and GluN1/2D, although GluN1/2B/2D is more sensitive to blockade by ketamine and memantine compared to GluN1/2B in the presence of physiological Mg2+ . Memantine 185-194 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 33-44 31541561-9 2019 Furthermore, channel blockade of GluN1/2B/2D by extracellular Mg2+ is intermediate compared to GluN1/2B and GluN1/2D, although GluN1/2B/2D is more sensitive to blockade by ketamine and memantine compared to GluN1/2B in the presence of physiological Mg2+ . Memantine 185-194 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 33-40 31682950-3 2019 We have previously shown that the NMDAR antagonist memantine lessens axonal injury and restores long term potentiation after rmTBI. Memantine 51-60 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-39 31682950-8 2019 Compared to vehicle-treated mice, memantine-treated mice were protected against oligodendrocyte loss and decreased MBP expression at subacute time points after injury. Memantine 34-43 myelin basic protein Mus musculus 115-118 31682950-9 2019 Memantine treatment also protected against axon damage assessed by NF-l expression. Memantine 0-9 neurofilament, light polypeptide Mus musculus 67-71 31167109-10 2019 Running+memantine treatment increased adult neurogenesis by only 17%, but completely blocked experience-dependent Fos expression. Memantine 8-17 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 114-117 31301562-2 2019 Acting as an open-channel blocker, the anti-AD drug memantine preferentially targets NMDAR overactivation, which has been proposed to trigger neurotoxic events mediated by amyloid beta peptide (Abeta) and oxidative stress. Memantine 52-61 amyloid beta precursor protein Homo sapiens 194-199 31553175-0 2019 Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer"s Disease in Mice. Memantine 85-94 lactotransferrin Mus musculus 0-11 31517030-10 2019 The Cox model showed a significant reduction in mortality in patients treated with acetylcholinesterase inhibitors (hazard ratio [HR] = 0.78, 95% CI 0.72-0.85) or memantine (HR = 0.75, 95% CI 0.66-0.86) or both (HR = 0.76, 95% CI 0.68-0.94). Memantine 163-172 cytochrome c oxidase subunit 8A Homo sapiens 4-7 31351393-2 2019 Here we describe the synthesis and multitarget biological profiling of a new class of compounds designed by molecular hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different linker lengths and linkage positions, to preserve or not the memantine-like polycyclic unsubstituted primary amine. Memantine 345-354 acetylcholinesterase (Cartwright blood group) Homo sapiens 209-229 31351393-2 2019 Here we describe the synthesis and multitarget biological profiling of a new class of compounds designed by molecular hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different linker lengths and linkage positions, to preserve or not the memantine-like polycyclic unsubstituted primary amine. Memantine 345-354 acetylcholinesterase (Cartwright blood group) Homo sapiens 231-235 31431260-10 2019 In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Memantine 13-22 PTEN induced kinase 1 Homo sapiens 137-142 31431260-10 2019 In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Memantine 13-22 PTEN induced kinase 1 Homo sapiens 177-182 31431260-10 2019 In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Memantine 224-233 parkin RBR E3 ubiquitin protein ligase Homo sapiens 128-133 31431260-10 2019 In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Memantine 224-233 PTEN induced kinase 1 Homo sapiens 137-142 31431260-10 2019 In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Memantine 224-233 PTEN induced kinase 1 Homo sapiens 177-182 31431260-6 2019 Memantine increased the levels of LC3-II in a dose-dependent and time-dependent manner, and upregulated autophagic flux. Memantine 0-9 microtubule associated protein 1 light chain 3 alpha Homo sapiens 34-37 31431260-8 2019 Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Memantine 46-55 phosphatidylinositol 3-kinase catalytic subunit type 3 Homo sapiens 15-20 31431260-8 2019 Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Memantine 46-55 microtubule associated protein 1 light chain 3 alpha Homo sapiens 64-67 31431260-8 2019 Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Memantine 46-55 phosphatidylinositol 3-kinase catalytic subunit type 3 Homo sapiens 122-127 31431260-8 2019 Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Memantine 101-110 phosphatidylinositol 3-kinase catalytic subunit type 3 Homo sapiens 15-20 31431260-8 2019 Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Memantine 101-110 microtubule associated protein 1 light chain 3 alpha Homo sapiens 64-67 31431260-8 2019 Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Memantine 101-110 phosphatidylinositol 3-kinase catalytic subunit type 3 Homo sapiens 122-127 31431260-9 2019 Notably, intracellular Huntington"s disease-specific aggregates of elongated huntingtin, a well-established autophagy substrate, were significantly decreased by memantine. Memantine 161-170 huntingtin Homo sapiens 77-87 31431260-10 2019 In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Memantine 13-22 parkin RBR E3 ubiquitin protein ligase Homo sapiens 128-133 31495078-0 2019 Memantine Attenuates Salicylate-induced Tinnitus Possibly by Reducing NR2B Expression in Auditory Cortex of Rat. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 70-74 31495078-5 2019 NR2B was significantly upregulated in salicylate-treated cells, but downregulated after memantine treatment. Memantine 88-97 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 0-4 31308798-1 2019 Memantine is a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist clinically approved for moderate-to-severe Alzheimer"s disease (AD) to improve cognitive functions. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 31-60 31495078-6 2019 Similarly, expression of the inflammatory cytokine genes TNFalpha and immediate-early gene ARC was significantly increased in the salicylate-treated cells, and decreased when the cells were treated with memantine. Memantine 203-212 tumor necrosis factor Rattus norvegicus 57-65 31495078-10 2019 Additionally, NR2B protein expression in the auditory cortex was markedly increased in the salicylate-treated group, whereas it was reduced in the memantine-treated group. Memantine 147-156 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 14-18 31555132-9 2019 The IC50 value of memantine as an NMDA antagonist is in micromolar range; the lowest limit is 112 ng/ml (GluN2C), and this value was achieved only in three cases. Memantine 18-27 glutamate ionotropic receptor NMDA type subunit 2C Homo sapiens 105-111 31281445-11 2019 PPI networks of DEGs in the striatum samples treated with ketamine, phencyclidine and memantine compared with normal samples were constructed, and Klf2 was involved in more pairs and was therefore a gene hub in the three networks. Memantine 86-95 Kruppel like factor 2 Homo sapiens 147-151 31308798-1 2019 Memantine is a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist clinically approved for moderate-to-severe Alzheimer"s disease (AD) to improve cognitive functions. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 62-67 31308798-4 2019 Mice (8-month) were treated with memantine (5 mg/kg/bid) for 4 months followed by behavioral and molecular evaluation. Memantine 33-42 BH3 interacting domain death agonist Mus musculus 52-55 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 pericentrin (kendrin) Mus musculus 103-107 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 ataxin 2 Mus musculus 109-116 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 TRAF2 and NCK interacting kinase Mus musculus 118-122 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 nucleolar protein 3 (apoptosis repressor with CARD domain) Mus musculus 128-132 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 filamin, alpha Mus musculus 156-160 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 MAP/microtubule affinity regulating kinase 2 Mus musculus 162-168 31308798-7 2019 In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. Memantine 20-29 Braf transforming gene Mus musculus 173-177 31308798-8 2019 In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Memantine 24-33 pericentrin (kendrin) Mus musculus 107-111 31308798-8 2019 In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Memantine 24-33 peptidase (mitochondrial processing) beta Mus musculus 113-118 31308798-8 2019 In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Memantine 24-33 v-crk avian sarcoma virus CT10 oncogene homolog Mus musculus 120-123 31308798-8 2019 In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Memantine 24-33 myelin basic protein Mus musculus 129-132 31308798-8 2019 In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Memantine 24-33 dynamin 2 Mus musculus 156-160 31308798-8 2019 In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Memantine 24-33 transgelin 2 Mus musculus 168-175 31308798-9 2019 Further analysis with bioinformatics showed that memantine modulated biological pathways associated with cytoskeleton and ErbB signaling in the hippocampus, and modulated biological pathways associated with axon guidance, ribosome, cytoskeleton, calcium and MAPK signaling in the cerebral cortex. Memantine 49-58 epidermal growth factor receptor Mus musculus 122-126 31156366-6 2019 These observations suggest that memantine is beneficial for stabilizing or slowing the decline in ADAS-cog and ADCS-ADL19 changes in AD patients. Memantine 32-41 alkylglycerone phosphate synthase Homo sapiens 98-102 30759264-0 2019 Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer"s disease and type 2 diabetes. Memantine 26-35 amyloid beta precursor protein Rattus norvegicus 74-99 30053484-5 2019 We have previously shown systemic administration of piribedil, memantine, and/or ACEMg significantly reduced loss of IHC ribbons induced by a 3 h 4 kHz octave band 117 dB (SPL) noise. Memantine 63-72 sphingosine-1-phosphate lyase 1 Rattus norvegicus 172-175 30442754-0 2019 Awake 18F-FDG PET Imaging of Memantine-Induced Brain Activation and Test-Retest in Freely Running Mice. Memantine 29-38 thyroid stimulating hormone receptor Mus musculus 14-17 30759264-8 2019 Vildagliptin alone and in combination with memantine caused a decrease in blood glucose, HOMA-IR, lipid profile, Hcy, malanodialdhyde, and acetylcholinesterase, and an increase in apolipoprotein E. Memantine 43-52 acetylcholinesterase Rattus norvegicus 139-159 30759264-8 2019 Vildagliptin alone and in combination with memantine caused a decrease in blood glucose, HOMA-IR, lipid profile, Hcy, malanodialdhyde, and acetylcholinesterase, and an increase in apolipoprotein E. Memantine 43-52 apolipoprotein E Rattus norvegicus 180-196 30870728-6 2019 There are also cases where functional disturbances caused by the gene defect may not be corrected by existing AEDs, but can be countered by medications already available in the market for other indications (e.g., memantine has been used to treat the epileptic encephalopathy caused by a specific gain-of-function GRIN2A mutation), thus making "drug repurposing" a valuable tool for personalized epilepsy therapies. Memantine 213-222 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 313-319 30971215-1 2019 BACKGROUND: Previous observational studies and clinical trials have shown that cholinesterase inhibitors (with or without memantine) provide benefit for patients with mild-to-moderate Alzheimer"s disease. Memantine 122-131 butyrylcholinesterase Homo sapiens 79-93 30801976-0 2019 The role of LINC00094/miR-224-5p (miR-497-5p)/Endophilin-1 axis in Memantine mediated protective effects on blood-brain barrier in AD microenvironment. Memantine 67-76 BRD3 opposite strand Homo sapiens 12-21 30801976-0 2019 The role of LINC00094/miR-224-5p (miR-497-5p)/Endophilin-1 axis in Memantine mediated protective effects on blood-brain barrier in AD microenvironment. Memantine 67-76 microRNA 224 Homo sapiens 22-29 30801976-0 2019 The role of LINC00094/miR-224-5p (miR-497-5p)/Endophilin-1 axis in Memantine mediated protective effects on blood-brain barrier in AD microenvironment. Memantine 67-76 SH3 domain containing GRB2 like 2, endophilin A1 Homo sapiens 46-58 30448465-0 2019 Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride. Memantine 59-68 microtubule associated protein tau Homo sapiens 31-34 31111954-15 2019 Surprisingly, the memantine treatment resulted in overexpression of TRPM2-L, to a certain extent. Memantine 18-27 transient receptor potential cation channel, subfamily M, member 2 Rattus norvegicus 68-73 30845688-4 2019 Memantine is an N-methyl-D-aspartate receptor (NMDAR) antagonist commonly used to treat Alzheimer"s disease. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 16-45 30891742-4 2019 To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). Memantine 18-27 butyrylcholinesterase Homo sapiens 67-81 30682440-13 2019 The highest PR of 10.11 obtained in Atr/HI-6-treated rats was achieved after pretreatment with memantine 36 mg/kg. Memantine 95-104 ATR serine/threonine kinase Rattus norvegicus 36-39 30682440-15 2019 Pretreatment with memantine assured higher AChE activity in brain and diaphragm than in unpretreated rats (46% vs 28% and 68% vs. 38%, respectively). Memantine 18-27 acetylcholinesterase Rattus norvegicus 43-47 30682440-20 2019 Mechanism of the antidotal effect of memantine against soman poisoning appears to be a combination of AChE-protecting and NMDA receptor-blocking action. Memantine 37-46 acetylcholinesterase Rattus norvegicus 102-106 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 33-38 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 60-65 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 60-65 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 glutathione S-transferase omega 1 Mus musculus 194-197 30466882-8 2019 Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7-P21) prevents NMDAR hypofunction and autistic-like social behaviors from manifesting at later stages (~P28 and P56). Memantine 77-86 interferon-induced protein with tetratricopeptide repeats 1 Mus musculus 202-205 30845688-4 2019 Memantine is an N-methyl-D-aspartate receptor (NMDAR) antagonist commonly used to treat Alzheimer"s disease. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 47-52 30784206-9 2019 [3 H]GMOM (3 nmol L-1 and 10 nmol L-1 ) was inhibited with dual affinity by (+)-MK-801, (R,S)-ketamine and memantine, in both presence and absence of agonists. Memantine 107-116 L1 cell adhesion molecule Homo sapiens 18-37 30247872-7 2019 Furthermore, cells treated with acetate (6 mM) for 4 h had increased expression levels of TNFalpha relative to control, which was abolished by coapplication of memantine (10 muM). Memantine 160-169 tumor necrosis factor Rattus norvegicus 90-98 30819076-10 2019 RESULTS: A novel molecule formed by combination of 6-chlorotacrine and memantine proved to be a promising multipotent hybrid capable of blocking the action of AChE as well as NMDARs. Memantine 71-80 acetylcholinesterase (Cartwright blood group) Homo sapiens 159-163 30651113-0 2019 Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. Memantine 0-9 potassium voltage-gated channel subfamily A member 3 Homo sapiens 101-106 30651113-0 2019 Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. Memantine 0-9 AKT serine/threonine kinase 1 Homo sapiens 127-130 30651113-0 2019 Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. Memantine 0-9 mitogen-activated protein kinase 3 Homo sapiens 135-141 30551456-12 2019 In conclusion, memantine can effectively ameliorate pulmonary inflammation in CS + LPS-induced COPD in mice via reducing NR-1 and xCT expression, glutamate release, Ca2+ influx, and the phosphorylation of Erk1/2. Memantine 15-24 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 Mus musculus 130-133 30551456-12 2019 In conclusion, memantine can effectively ameliorate pulmonary inflammation in CS + LPS-induced COPD in mice via reducing NR-1 and xCT expression, glutamate release, Ca2+ influx, and the phosphorylation of Erk1/2. Memantine 15-24 mitogen-activated protein kinase 3 Mus musculus 205-211 30651113-4 2019 We reported that Kv1.3 channels of lymphocytes are blocked by memantine, which is known as an antagonist of neuronal N-methyl-D-aspartate type glutamate receptors and clinically applied in therapy of advanced Alzheimer disease. Memantine 62-71 potassium voltage-gated channel subfamily A member 3 Homo sapiens 17-22 30651113-5 2019 Here we evaluated whether pharmacological targeting of Kv1.3 channels by memantine promotes cell death of acute leukemia cells induced by chemotherapeutic cytarabine. Memantine 73-82 potassium voltage-gated channel subfamily A member 3 Homo sapiens 55-60 30651113-9 2019 Molecular effects of memantine co-treatment on activation of Caspases, AKT, ERK1/2, and JNK signaling were analysed by Western blot. Memantine 21-30 caspase 9 Homo sapiens 61-69 30651113-9 2019 Molecular effects of memantine co-treatment on activation of Caspases, AKT, ERK1/2, and JNK signaling were analysed by Western blot. Memantine 21-30 AKT serine/threonine kinase 1 Homo sapiens 71-74 30651113-9 2019 Molecular effects of memantine co-treatment on activation of Caspases, AKT, ERK1/2, and JNK signaling were analysed by Western blot. Memantine 21-30 mitogen-activated protein kinase 3 Homo sapiens 76-82 30651113-11 2019 RESULTS: Our study demonstrates that memantine inhibits Kv1.3 channels of acute leukemia cells and in combination with cytarabine potentiates cell death of acute lymphoid and myeloid leukemia cell lines as well as primary leukemic blasts from acute leukemia patients. Memantine 37-46 potassium voltage-gated channel subfamily A member 3 Homo sapiens 56-61 30651113-12 2019 At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. Memantine 20-29 AKT serine/threonine kinase 1 Homo sapiens 78-81 30651113-12 2019 At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. Memantine 20-29 mitogen-activated protein kinase 3 Homo sapiens 90-96 30651113-12 2019 At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. Memantine 20-29 MYC proto-oncogene, bHLH transcription factor Homo sapiens 139-142 30651113-12 2019 At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. Memantine 20-29 AKT serine/threonine kinase 1 Homo sapiens 163-166 30651113-12 2019 At molecular level, memantine co-application fosters concurrent inhibition of AKT, S6 and ERK1/2 and reinforces nuclear down-regulation of MYC, a common target of AKT and ERK1/2 signaling. Memantine 20-29 mitogen-activated protein kinase 3 Homo sapiens 171-177 30651113-14 2019 CONCLUSIONS: Our study underlines inhibition of Kv1.3 channels as a therapeutic strategy in acute leukemia and proposes co-treatment with memantine, a licensed and safe drug, as a potential approach to promote cytarabine-based cell death of various subtypes of acute leukemia. Memantine 138-147 potassium voltage-gated channel subfamily A member 3 Homo sapiens 48-53 30528722-5 2019 KEY FINDINGS: Memantine reduced ulcer index, reduced MDA, increased SOD, increased total nitrites and reduced expression of both TNF-alpha and NF-kappaB. Memantine 14-23 tumor necrosis factor Rattus norvegicus 129-138 30819076-12 2019 According to results it has been revealed that our novel hybrid blocks NMDARs in the same manner as memantine, potently inhibits AChE and is predicted to cross the blood-brain barrier via passive diffusion. Memantine 100-109 acetylcholinesterase (Cartwright blood group) Homo sapiens 129-133 30646339-10 2018 Meta-analysis showed those receiving ChEIs or memantine were associated with significantly greater annual rate of decline on the ADAS-cog than those receiving neither medication (1.4 points/y; 95% CI, 0.1-2.7). Memantine 46-55 alkylglycerone phosphate synthase Homo sapiens 129-133 31177251-6 2019 RESULTS: When administered at 10 mg/kg, but not 2.5 or 5 mg/kg, memantine preserved cortical tissue and reduced neuronal degeneration 1 day after injury, and attenuated loss of synaptophysin immunoreactivity in the hippocampus 7 days after injury. Memantine 64-73 synaptophysin Rattus norvegicus 177-190 30372825-7 2018 Pre-treatment with memantine 20 mg/kg significantly reduced myocardial edematous, MPO activity and malondialdehyde (MDA) levels in comparison to HF group (p < 0.05, p < 0.05 and p < 0.001 respectively). Memantine 19-28 myeloperoxidase Rattus norvegicus 82-85 30845882-0 2019 Memantine selectively prevented the induction of dynamic allodynia by blocking Kir2.1 channel and inhibiting the activation of microglia in spinal dorsal horn of mice in spared nerve injury model. Memantine 0-9 potassium inwardly-rectifying channel, subfamily J, member 2 Mus musculus 79-85 30845882-10 2019 CONCLUSION: The selective inhibitory effect on the induction of dynamic allodynia in spared nerve injury model by low dose of the memantine (memantine-10) was tightly correlated with the blockade of microglia Kir2.1 channel to suppress the microglia activation. Memantine 130-139 potassium inwardly-rectifying channel, subfamily J, member 2 Mus musculus 209-215 30646339-13 2018 Concomitant use of ChEIs or memantine may be confounded with outcomes on the ADAS-cog and should be considered in design of clinical trials of potential therapeutic agents for AD. Memantine 28-37 alkylglycerone phosphate synthase Homo sapiens 77-81 30213620-0 2018 Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 95-98 30213620-7 2018 Moreover, memantine uniformly suppressed the phosphorylation of NR1-CaMKII-ERK pathway induced by alcohol withdrawal. Memantine 10-19 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 64-67 29100251-8 2018 DISCUSSION: Memantine is an effective and well-tolerated augmentation in severe OCD patients refractory to SRI monotherapy. Memantine 12-21 sorcin Homo sapiens 107-110 29226720-10 2018 We identified for the first time that memantine exerts antineoplastic activity (0.25 mM) by triggering Bax-dependent pathway of apoptosis. Memantine 38-47 BCL2 associated X, apoptosis regulator Homo sapiens 103-106 30233298-0 2018 Prenatal Deltamethrin Exposure-Induced Cognitive Impairment in Offspring Is Ameliorated by Memantine Through NMDAR/BDNF Signaling in Hippocampus. Memantine 91-100 brain-derived neurotrophic factor Rattus norvegicus 115-119 30233298-9 2018 However, the declined cognitive ability were ameliorated by memantine treatment with increased GluN1, GluN2A, GluN2B, BDNF, pCREB/CREB, and pTrkB/TrkB expression in the hippocampus. Memantine 60-69 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 95-100 30233298-9 2018 However, the declined cognitive ability were ameliorated by memantine treatment with increased GluN1, GluN2A, GluN2B, BDNF, pCREB/CREB, and pTrkB/TrkB expression in the hippocampus. Memantine 60-69 glutamate ionotropic receptor NMDA type subunit 2A Rattus norvegicus 102-108 30233298-9 2018 However, the declined cognitive ability were ameliorated by memantine treatment with increased GluN1, GluN2A, GluN2B, BDNF, pCREB/CREB, and pTrkB/TrkB expression in the hippocampus. Memantine 60-69 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 110-116 30233298-9 2018 However, the declined cognitive ability were ameliorated by memantine treatment with increased GluN1, GluN2A, GluN2B, BDNF, pCREB/CREB, and pTrkB/TrkB expression in the hippocampus. Memantine 60-69 brain-derived neurotrophic factor Rattus norvegicus 118-122 30233298-9 2018 However, the declined cognitive ability were ameliorated by memantine treatment with increased GluN1, GluN2A, GluN2B, BDNF, pCREB/CREB, and pTrkB/TrkB expression in the hippocampus. Memantine 60-69 cAMP responsive element binding protein 1 Rattus norvegicus 125-129 30233298-9 2018 However, the declined cognitive ability were ameliorated by memantine treatment with increased GluN1, GluN2A, GluN2B, BDNF, pCREB/CREB, and pTrkB/TrkB expression in the hippocampus. Memantine 60-69 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 141-145 29913137-6 2018 Memantine, a selective NMDAR antagonist, improved prenatal CTM-induced abnormal protein levels and social interaction deficits. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 23-28 30344474-0 2018 Corrigendum: Prenatal Deltamethrin Exposure-Induced Cognitive Impairment in Offspring Is Ameliorated by Memantine Through NMDAR/BDNF Signaling in Hippocampus. Memantine 104-113 brain derived neurotrophic factor Homo sapiens 128-132 30293574-6 2018 NMDAR antagonists also blocked the activation of calcium-calmodulin-dependent protein kinase II and treatment of Tg2576 AD model mice with the NMDAR antagonist, memantine, prevented CCR. Memantine 161-170 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 0-5 30293574-6 2018 NMDAR antagonists also blocked the activation of calcium-calmodulin-dependent protein kinase II and treatment of Tg2576 AD model mice with the NMDAR antagonist, memantine, prevented CCR. Memantine 161-170 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 143-148 30244611-0 2018 An evaluation of memantine ER + donepezil for the treatment of Alzheimer"s disease. Memantine 17-26 epiregulin Homo sapiens 27-29 30244611-6 2018 Namzaric , a fixed dose combination of donepezil and memantine extended-release (ER) (FDC memantine ER/donepezil), was recently approved by the U.S. Food and Drug Administration (FDA) for patients with moderate to severe AD and warrants further consideration as a clinically useful and advantageous pharmacotherapy in AD. Memantine 53-62 epiregulin Homo sapiens 81-83 30244611-6 2018 Namzaric , a fixed dose combination of donepezil and memantine extended-release (ER) (FDC memantine ER/donepezil), was recently approved by the U.S. Food and Drug Administration (FDA) for patients with moderate to severe AD and warrants further consideration as a clinically useful and advantageous pharmacotherapy in AD. Memantine 90-99 epiregulin Homo sapiens 81-83 30244611-7 2018 Areas covered: This review discusses the pharmacological properties, efficacy, and safety/tolerability data of this FDC memantine ER/donepezil as well as its benefits and disadvantages for patients and families. Memantine 120-129 epiregulin Homo sapiens 130-132 30244611-9 2018 Expert opinion: Aside from its cost, FDC memantine ER/donepezil improves adherence to medication and reduces caregiver burden. Memantine 41-50 epiregulin Homo sapiens 51-53 29800586-13 2018 Memantine decreased ethanol-induced spatial memory impairment, caspase-3 activation and apoptosis in the mouse hippocampus. Memantine 0-9 caspase 3 Mus musculus 63-72 29545205-9 2018 In CA1 hippocampal subfield, memantine significantly reduced neurodegeneration at the following times: 3 h prior SE-onset, concomitant with pilocarpine, and 15 min after pilocarpine injection. Memantine 29-38 carbonic anhydrase 1 Rattus norvegicus 3-6 30175228-5 2018 A significant interaction was observed between treatment and the APOE genotype on AD progression: epsilon4 carriers declined faster than noncarriers in the vitamin E plus memantine treatment arm. Memantine 171-180 apolipoprotein E Homo sapiens 65-69 29771687-1 2018 Memantine extended release (ER) significantly outperformed placebo on co-primary endpoints of Clinician"s Interview-based Impression of Change Plus Caregiver Input (CIBIC-Plus) and baseline to endpoint changes on the Severe Impairment Battery (SIB) in a 24-week, randomized trial (NCT00322153) in patients with moderate to severe Alzheimer"s disease taking a cholinesterase inhibitor (ChEI). Memantine 0-9 butyrylcholinesterase Homo sapiens 359-373 29625114-13 2018 Glial fibrillary acidic protein (GFAP) content was higher in the low dose memantine group compared to vehicle-treated group, but there were no differences in GFAP-immunoreactive astrocytes or Iba-1- immunoreactive microglia between groups. Memantine 74-83 glial fibrillary acidic protein Rattus norvegicus 0-31 29625114-13 2018 Glial fibrillary acidic protein (GFAP) content was higher in the low dose memantine group compared to vehicle-treated group, but there were no differences in GFAP-immunoreactive astrocytes or Iba-1- immunoreactive microglia between groups. Memantine 74-83 glial fibrillary acidic protein Rattus norvegicus 33-37 29656414-3 2018 We investigated whether add-on memantine to regular valproic acid treatment ameliorated clinical symptoms, reduced alcohol use, and cytokine levels, and increased plasma brain-derived neurotrophic factor (BDNF) in BD-II patients with comorbid alcohol dependence. Memantine 31-40 brain derived neurotrophic factor Homo sapiens 170-203 29656414-3 2018 We investigated whether add-on memantine to regular valproic acid treatment ameliorated clinical symptoms, reduced alcohol use, and cytokine levels, and increased plasma brain-derived neurotrophic factor (BDNF) in BD-II patients with comorbid alcohol dependence. Memantine 31-40 brain derived neurotrophic factor Homo sapiens 205-209 29656414-9 2018 CONCLUSIONS: BD-II comorbid with alcohol dependence might benefit from add-on memantine treatment, which significantly reduced clinical severity, alcohol use, and plasma cytokine levels, and increased BDNF levels. Memantine 78-87 brain derived neurotrophic factor Homo sapiens 201-205 29680698-0 2018 Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress. Memantine 17-26 brain-derived neurotrophic factor Rattus norvegicus 97-101 29680698-9 2018 Administration of memantine reversed depression-like behavior and memory impairment and significantly increased BDNF and TrkB mRNA levels in both prefrontal cortex and hippocampus of stress exposed rats. Memantine 18-27 brain-derived neurotrophic factor Rattus norvegicus 112-116 29680698-9 2018 Administration of memantine reversed depression-like behavior and memory impairment and significantly increased BDNF and TrkB mRNA levels in both prefrontal cortex and hippocampus of stress exposed rats. Memantine 18-27 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 121-125 29680698-11 2018 Our results also suggest that upregulated mRNA levels of BDNF and TrkB in the brain might be essential for antidepressant-like activity of memantine in stress exposed rats. Memantine 139-148 brain-derived neurotrophic factor Rattus norvegicus 57-61 29680698-11 2018 Our results also suggest that upregulated mRNA levels of BDNF and TrkB in the brain might be essential for antidepressant-like activity of memantine in stress exposed rats. Memantine 139-148 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 66-70 29292072-8 2018 Lastly, comparing these results with those from Ts65Dn treated, using a different protocol, with the NMDA receptor antagonist, memantine, that also rescues LM impairments, identifies common and divergent responses to the two drugs. Memantine 127-136 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 48-54 29382619-1 2018 BACKGROUND: The main aim of this study is to elucidate whether the neuroprotective effect of memantine, a noncompetitive N-methyl-d-aspartate receptor 2B (NR2B) antagonist, affects neuronal nitrosative stress, apoptosis, and NR2B expression and improves functional outcomes. Memantine 93-102 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 121-153 29382619-1 2018 BACKGROUND: The main aim of this study is to elucidate whether the neuroprotective effect of memantine, a noncompetitive N-methyl-d-aspartate receptor 2B (NR2B) antagonist, affects neuronal nitrosative stress, apoptosis, and NR2B expression and improves functional outcomes. Memantine 93-102 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 155-159 29382619-1 2018 BACKGROUND: The main aim of this study is to elucidate whether the neuroprotective effect of memantine, a noncompetitive N-methyl-d-aspartate receptor 2B (NR2B) antagonist, affects neuronal nitrosative stress, apoptosis, and NR2B expression and improves functional outcomes. Memantine 93-102 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 225-229 29382619-9 2018 Simultaneously, without affecting the NR2A expression in neuronal cells, the NR2B expression significantly decreased after memantine therapy, as evaluated by an immunofluorescence stain. Memantine 123-132 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 77-81 29382619-10 2018 CONCLUSIONS: Intraperitoneal injection of memantine in the acute stage may ameliorate TBI in rats by affecting NR2B expression and decreasing neuronal apoptosis and nitrosative stress in the injured cortex. Memantine 42-51 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 111-115 28412305-9 2018 Treatment with memantine also corresponded to normal NMDAR expression after rmTBI. Memantine 15-24 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 53-58 29311134-7 2018 Finally, we found that the Food and Drug Administration-approved anti-dementia drug memantine can increase the expression of Klk7 and Abeta degradation activity specifically in the astrocytes. Memantine 84-93 kallikrein related-peptidase 7 (chymotryptic, stratum corneum) Mus musculus 125-129 29311134-7 2018 Finally, we found that the Food and Drug Administration-approved anti-dementia drug memantine can increase the expression of Klk7 and Abeta degradation activity specifically in the astrocytes. Memantine 84-93 amyloid beta (A4) precursor protein Mus musculus 134-139 29695962-6 2018 We herein demonstrate that a NMDAR antagonist, memantine, prevented excessive calpain activation and TrkB-FL truncation induced by Abeta25-35. Memantine 47-56 neurotrophic receptor tyrosine kinase 2 Homo sapiens 101-105 29695962-8 2018 Moreover, NMDAR inhibition by memantine also prevented Abeta-driven deleterious impact of BDNF loss of function on structural (spine density) and functional outcomes (synaptic potentiation). Memantine 30-39 brain derived neurotrophic factor Homo sapiens 90-94 29849573-3 2018 Additionally, therapeutically relevant doses of the drug memantine were shown to rescue learning and memory deficits in Ts65Dn mice. Memantine 57-66 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 120-126 29849573-4 2018 Here, we observed that 1 muM memantine had no detectable effect on HFS-induced LTP in either Ts65Dn- or control-derived slices, but it rescued TBS-induced LTP in Ts65Dn-derived slices to control euploid levels. Memantine 29-38 reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65 Mus musculus 162-168 29542225-5 2018 First, we found that memantine treatment prevented I/R-induced expression of tumor necrosis factor-alpha and interleukin-1beta at both the mRNA and the protein levels. Memantine 21-30 interleukin 1 beta Homo sapiens 109-126 29542225-6 2018 Additionally, our results indicate that memantine treatment significantly reduced endothelial monolayer permeability after I/R by increasing the expression of tight junction protein occludin and the adherens junction protein VE-cadherin. Memantine 40-49 occludin Homo sapiens 159-190 29542225-6 2018 Additionally, our results indicate that memantine treatment significantly reduced endothelial monolayer permeability after I/R by increasing the expression of tight junction protein occludin and the adherens junction protein VE-cadherin. Memantine 40-49 cadherin 5 Homo sapiens 225-236 29542225-7 2018 In addition, we found that memantine reduced the expression and activity of matrix metalloproteinase (MMP)-2 but not MMP-9 after I/R. Memantine 27-36 matrix metallopeptidase 2 Homo sapiens 76-108 29542225-9 2018 Mechanistically, we found that memantine increased the expression of the transcriptional factor Krueppel-like factor 2 (KFL2) through activating extracellular signal regulated kinase (ERK5). Memantine 31-40 Kruppel like factor 2 Homo sapiens 96-118 29542225-9 2018 Mechanistically, we found that memantine increased the expression of the transcriptional factor Krueppel-like factor 2 (KFL2) through activating extracellular signal regulated kinase (ERK5). Memantine 31-40 mitogen-activated protein kinase 7 Homo sapiens 184-188 29549516-12 2018 RESULTS: According to intention-to-treat, latent growth curve analyses, a significant change in total score of ZAN-BPD symptom severity was observed in the memantine group at 20 mg/daily across time, compared with placebo (p = 0.02). Memantine 156-165 zonadhesin Homo sapiens 111-114 29366650-4 2018 Among the triptolide derivatives tested, a memantine conjugate, compound 8, showed a remarkable neuroprotective effect against Abeta1-42 toxicity in primary cortical neuron cultures as well as an inhibitory effect against LPS-induced TNF-alpha production in BV2 cells at a subnanomolar concentration. Memantine 43-52 tumor necrosis factor Mus musculus 234-243 27777420-0 2018 Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer"s disease therapy. Memantine 39-48 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 29-35 27777420-3 2018 Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of KATP channels. Memantine 0-9 calcium/calmodulin-dependent protein kinase II, delta Mus musculus 20-26 27777420-3 2018 Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of KATP channels. Memantine 72-81 calcium/calmodulin-dependent protein kinase II, delta Mus musculus 150-156 27777420-4 2018 Memantine also inhibited Kir6.1 and Kir6.2 KATP channels and elevated intracellular Ca2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Memantine 0-9 potassium inwardly-rectifying channel, subfamily J, member 8 Mus musculus 25-31 27777420-4 2018 Memantine also inhibited Kir6.1 and Kir6.2 KATP channels and elevated intracellular Ca2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Memantine 0-9 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 36-42 27777420-4 2018 Memantine also inhibited Kir6.1 and Kir6.2 KATP channels and elevated intracellular Ca2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Memantine 0-9 potassium inwardly-rectifying channel, subfamily J, member 8 Mus musculus 136-142 27777420-4 2018 Memantine also inhibited Kir6.1 and Kir6.2 KATP channels and elevated intracellular Ca2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Memantine 0-9 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 146-152 27777420-6 2018 Finally, we confirmed that Kir6.2 mutant mice exhibit severe memory deficits and impaired hippocampal LTP, impairments that cannot be rescued by memantine administration. Memantine 145-154 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 27-33 27777420-7 2018 Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2 channel is a novel target for therapeutics to improve memory impairment in Alzheimer disease patients. Memantine 34-43 potassium inwardly rectifying channel subfamily J member 11 Homo sapiens 54-60 30984874-12 2018 Galantamine and memantine via the alpha7nACh and NMDA receptors can counteract the effects of kynurenic acid and enhance MMN and BDNF. Memantine 16-25 brain derived neurotrophic factor Homo sapiens 129-133 29796036-4 2018 In this study, we assessed the effect of memantine on the pro-inflammatory cytokines such as IL6, TNFalpha and CRP. Memantine 41-50 interleukin 6 Homo sapiens 93-96 29796036-4 2018 In this study, we assessed the effect of memantine on the pro-inflammatory cytokines such as IL6, TNFalpha and CRP. Memantine 41-50 tumor necrosis factor Homo sapiens 98-106 29796036-4 2018 In this study, we assessed the effect of memantine on the pro-inflammatory cytokines such as IL6, TNFalpha and CRP. Memantine 41-50 C-reactive protein Homo sapiens 111-114 28724200-0 2018 Effect of Memantine on Serum Levels of Neuron-Specific Enolase and on the Glasgow Coma Scale in Patients With Moderate Traumatic Brain Injury. Memantine 10-19 enolase 2 Homo sapiens 39-62 28724200-3 2018 We examined the effect of memantine on serum levels of neuron-specific enolase (NSE), a marker of neuronal damage, and the Glasgow Coma Scale (GCS) in patients with moderate TBI. Memantine 26-35 enolase 2 Homo sapiens 55-78 28724200-3 2018 We examined the effect of memantine on serum levels of neuron-specific enolase (NSE), a marker of neuronal damage, and the Glasgow Coma Scale (GCS) in patients with moderate TBI. Memantine 26-35 enolase 2 Homo sapiens 80-83 28724200-8 2018 The mean serum NSE levels for the memantine and the control groups on day 3 were 7.95 +- 2.86 and 12.33 +- 7.09 ng/mL, respectively (P = .05), and on day 7 were 5.03 +- 3.25 and 10.04 +- 5.72 ng/mL, respectively (P = .003). Memantine 34-43 enolase 2 Homo sapiens 15-18 28724200-11 2018 Patients with moderate TBI who received memantine had significantly reduced serum NSE levels by day 7 and marked improvement in their GCS scores on day 3 of the study. Memantine 40-49 enolase 2 Homo sapiens 82-85 29042205-0 2018 Postnatal administration of memantine rescues TNF-alpha-induced decreased hippocampal precursor proliferation. Memantine 28-37 tumor necrosis factor Mus musculus 46-55 28860082-4 2017 Here, we report the synthesis of novel memantine-derived drugs (MP1-10) and their potential antitumor activities in human U87MG glioblastoma cell line. Memantine 39-48 late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 Homo sapiens 64-70 29154484-6 2018 MEM-NPs <200 nm in diameter and incorporating 4 mg mL-1 of memantine were prepared with 0.35 mg mL-1 localized to the aqueous interior. Memantine 62-71 L1 cell adhesion molecule Mus musculus 99-103 28860082-5 2017 MP1-10 were synthetized joining memantine, which is a NMDA antagonist, to different histone deacetylase inhibitors to obtain one molecule with improved therapeutic efficacy. Memantine 32-41 late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 Homo sapiens 0-6 28917837-4 2017 Memantine inhibited the formation of Abeta(1-42) aggregates in a concentration-dependent manner, whereas amantadine, a structurally similar compound, did not affect Abeta aggregation at the same concentrations. Memantine 0-9 amyloid beta precursor protein Homo sapiens 37-42 28917837-5 2017 Furthermore, memantine inhibited the formation of different types of Abeta aggregates, including Abetas carrying familial AD mutations, and disaggregated preformed Abeta(1-42) fibrils. Memantine 13-22 amyloid beta precursor protein Homo sapiens 69-74 28917837-2 2017 We previously reported that chronic treatment of AD with memantine reduces the amount of insoluble beta-amyloid (Abeta) and soluble Abeta oligomers in animal models of AD. Memantine 57-66 amyloid beta precursor protein Homo sapiens 113-118 28917837-2 2017 We previously reported that chronic treatment of AD with memantine reduces the amount of insoluble beta-amyloid (Abeta) and soluble Abeta oligomers in animal models of AD. Memantine 57-66 amyloid beta precursor protein Homo sapiens 132-137 28917837-5 2017 Furthermore, memantine inhibited the formation of different types of Abeta aggregates, including Abetas carrying familial AD mutations, and disaggregated preformed Abeta(1-42) fibrils. Memantine 13-22 amyloid beta precursor protein Homo sapiens 97-102 28917837-3 2017 The mechanisms by which memantine reduces Abeta levels in the brain were evaluated by determining the effect of memantine on Abeta aggregation using thioflavin T and transmission electron microscopy. Memantine 24-33 amyloid beta precursor protein Homo sapiens 42-47 28917837-6 2017 These results suggest that the inhibition of Abeta aggregation and induction of Abeta disaggregation may be involved in the mechanisms by which memantine reduces Abeta deposition in the brain. Memantine 144-153 amyloid beta precursor protein Homo sapiens 45-50 28917837-6 2017 These results suggest that the inhibition of Abeta aggregation and induction of Abeta disaggregation may be involved in the mechanisms by which memantine reduces Abeta deposition in the brain. Memantine 144-153 amyloid beta precursor protein Homo sapiens 80-85 28646711-0 2017 Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. Memantine 10-19 C-reactive protein Homo sapiens 23-41 29112047-2 2017 Memantine, a noncompetitive N-methyl-D-aspartate glutamatergic receptor (NMDA-R) antagonist, has been proposed to be an active cardioprotective drug. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 28-71 29112047-2 2017 Memantine, a noncompetitive N-methyl-D-aspartate glutamatergic receptor (NMDA-R) antagonist, has been proposed to be an active cardioprotective drug. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 73-79 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Memantine 62-71 C-reactive protein Homo sapiens 12-15 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Memantine 62-71 C-reactive protein Homo sapiens 115-118 28646711-12 2017 CONCLUSIONS: BD patients with high initial CRP levels receiving memantine adjunct treatment have a reduced risk of inflammation and metabolic imbalance. Memantine 64-73 C-reactive protein Homo sapiens 43-46 28708400-0 2017 Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine. Memantine 73-82 solute carrier family 47 member 1 Homo sapiens 16-21 28877967-7 2017 As a result, inhibition by memantine of GluN1/2A receptors in tsA201 cells and of native synaptic NMDARs in cortical pyramidal neurons from mice of either sex increased in conditions that enhanced intracellular Ca2+ accumulation. Memantine 27-36 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 40-45 28877967-14 2017 In contrast, memantine binding increases occupancy of GluN1/2A and native NMDAR desensitized states entered after accumulation of intracellular Ca2+, a novel inhibitory mechanism. Memantine 13-22 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 54-59 28708400-2 2017 Potential candidates involved in memantine renal secretion are organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K). Memantine 33-42 solute carrier family 22 member 2 Canis lupus familiaris 63-91 28708400-2 2017 Potential candidates involved in memantine renal secretion are organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K). Memantine 33-42 solute carrier family 22 member 2 Canis lupus familiaris 93-97 28708400-2 2017 Potential candidates involved in memantine renal secretion are organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K). Memantine 33-42 solute carrier family 47 member 1 Homo sapiens 143-148 28708400-2 2017 Potential candidates involved in memantine renal secretion are organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K). Memantine 33-42 solute carrier family 47 member 2 Homo sapiens 150-157 28708400-3 2017 The aim of this in vitro study was the examination of the interaction of memantine with OCT2 and MATEs. Memantine 73-82 solute carrier family 22 member 2 Canis lupus familiaris 88-92 28708400-6 2017 Memantine inhibited OCT2-, MATE1-, and MATE2-K-mediated metformin transport with IC50 values of 3.2, 40.9, and 315.3 muM, respectively. Memantine 0-9 solute carrier family 22 member 2 Canis lupus familiaris 20-24 28708400-6 2017 Memantine inhibited OCT2-, MATE1-, and MATE2-K-mediated metformin transport with IC50 values of 3.2, 40.9, and 315.3 muM, respectively. Memantine 0-9 solute carrier family 47 member 1 Homo sapiens 27-32 28708400-6 2017 Memantine inhibited OCT2-, MATE1-, and MATE2-K-mediated metformin transport with IC50 values of 3.2, 40.9, and 315.3 muM, respectively. Memantine 0-9 solute carrier family 47 member 2 Homo sapiens 39-46 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 72-81 solute carrier family 47 member 1 Homo sapiens 62-67 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 62-67 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 62-67 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 62-67 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-8 2017 Vectorial transport experiments, however, indicated a role of MATE1 for memantine export: After memantine administration to the basal side of the monolayers, memantine cellular accumulation was considerably lower (MDCK-MATE1 vs MDCK control cells, P < 0.01) and memantine transcellular, basal to apical transport was higher in MATE1 expressing cells (MDCK-MATE1 vs MDCK control cells, P < 0.001 at 60 and 180 min). Memantine 96-105 solute carrier family 47 member 1 Homo sapiens 219-224 28708400-10 2017 These experiments suggest a relevant role of MATE1 for renal secretion of memantine. Memantine 74-83 solute carrier family 47 member 1 Homo sapiens 45-50 28730337-0 2017 Memantine Can Reduce Ethanol-Induced Caspase-3 Activity and Apoptosis in H4 Cells by Decreasing Intracellular Calcium. Memantine 0-9 caspase 3 Homo sapiens 37-46 28730337-14 2017 Memantine treatment reduced the ethanol-induced increase of intracellular calcium, caspase-3 activation, apoptosis, and the ethanol-induced decrease in cell viability. Memantine 0-9 caspase 3 Homo sapiens 83-92 28730337-15 2017 Our results indicate that ethanol-induced caspase-3 activation and apoptosis are likely to be dependent on cytosolic calcium levels and that they can be reduced by memantine treatment. Memantine 164-173 caspase 3 Homo sapiens 42-51 28545202-6 2017 Mechanistically, memantine was found to attenuate the upregulation of the transcriptional factor interferon response factor-1 (IRF-1) induced by AGEs, as well as activation of the JAK2/STAT1 pathway. Memantine 17-26 interferon regulatory factor 1 Homo sapiens 127-132 32454608-5 2017 Strong activations were found for these compounds: The CA values of memantine and donepezil against hCAI were 0.013 microM and 1.8 microM, respectively. Memantine 68-77 carbonic anhydrase 1 Homo sapiens 100-104 28545202-6 2017 Mechanistically, memantine was found to attenuate the upregulation of the transcriptional factor interferon response factor-1 (IRF-1) induced by AGEs, as well as activation of the JAK2/STAT1 pathway. Memantine 17-26 Janus kinase 2 Homo sapiens 180-184 28545202-6 2017 Mechanistically, memantine was found to attenuate the upregulation of the transcriptional factor interferon response factor-1 (IRF-1) induced by AGEs, as well as activation of the JAK2/STAT1 pathway. Memantine 17-26 signal transducer and activator of transcription 1 Homo sapiens 185-190 28322842-0 2017 Simultaneous blockade of NMDA receptors and PARP-1 activity synergistically alleviate immunoexcitotoxicity and bioenergetics in 3-nitropropionic acid intoxicated mice: Evidences from memantine and 3-aminobenzamide interventions. Memantine 183-192 poly (ADP-ribose) polymerase family, member 1 Mus musculus 44-50 28398653-9 2017 The effects of xenon were mimicked and improved by the N-methyl-d-aspartate glutamate receptor antagonist memantine and xenon itself appeared to work by antagonizing N-methyl-d-aspartate receptors. Memantine 106-115 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 55-94 28322842-3 2017 Present study was designed to determine whether the combination of memantine (MN) and 3-aminobenzamide (3-AB), PARP inhibitor, can ameliorate immunoexcitotoxicity and improve bioenergetics in a better manner than individual administration against 3-NP intoxication in mice. Memantine 67-76 poly (ADP-ribose) polymerase family, member 1 Mus musculus 111-115 28429235-5 2017 In this study, we investigated the effects of memantine on human brain microvascular endothelial dysfunction induced by the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Memantine 46-55 tumor necrosis factor Homo sapiens 150-177 28545202-5 2017 Our results indicate that memantine ameliorated AGE-induced degradation of collagen II and aggrecan at the post-translational level in SW1353 cells, which were mediated by matrix metalloproteinase-13 (MMP-13) and A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4), respectively. Memantine 26-35 matrix metallopeptidase 13 Homo sapiens 172-199 28545202-5 2017 Our results indicate that memantine ameliorated AGE-induced degradation of collagen II and aggrecan at the post-translational level in SW1353 cells, which were mediated by matrix metalloproteinase-13 (MMP-13) and A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4), respectively. Memantine 26-35 matrix metallopeptidase 13 Homo sapiens 201-207 28545202-5 2017 Our results indicate that memantine ameliorated AGE-induced degradation of collagen II and aggrecan at the post-translational level in SW1353 cells, which were mediated by matrix metalloproteinase-13 (MMP-13) and A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4), respectively. Memantine 26-35 ADAM metallopeptidase with thrombospondin type 1 motif 4 Homo sapiens 213-277 28545202-5 2017 Our results indicate that memantine ameliorated AGE-induced degradation of collagen II and aggrecan at the post-translational level in SW1353 cells, which were mediated by matrix metalloproteinase-13 (MMP-13) and A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4), respectively. Memantine 26-35 ADAM metallopeptidase with thrombospondin type 1 motif 4 Homo sapiens 279-287 28545202-6 2017 Mechanistically, memantine was found to attenuate the upregulation of the transcriptional factor interferon response factor-1 (IRF-1) induced by AGEs, as well as activation of the JAK2/STAT1 pathway. Memantine 17-26 interferon regulatory factor 1 Homo sapiens 97-125 28429235-5 2017 In this study, we investigated the effects of memantine on human brain microvascular endothelial dysfunction induced by the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Memantine 46-55 tumor necrosis factor Homo sapiens 179-188 28429235-7 2017 An in vitro BBB model experiment displayed that memantine could rescue TNF-alpha-induced disruption of the in vitro BBB model. Memantine 48-57 tumor necrosis factor Homo sapiens 71-80 28429235-9 2017 Our results indicate that TNF-alpha significantly increased the expression of cell adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, which was prevented by pretreatment with memantine. Memantine 184-193 tumor necrosis factor Homo sapiens 26-35 28429235-9 2017 Our results indicate that TNF-alpha significantly increased the expression of cell adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, which was prevented by pretreatment with memantine. Memantine 184-193 intercellular adhesion molecule 1 Homo sapiens 111-117 28429235-9 2017 Our results indicate that TNF-alpha significantly increased the expression of cell adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, which was prevented by pretreatment with memantine. Memantine 184-193 vascular cell adhesion molecule 1 Homo sapiens 119-125 28429235-9 2017 Our results indicate that TNF-alpha significantly increased the expression of cell adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, which was prevented by pretreatment with memantine. Memantine 184-193 selectin E Homo sapiens 131-141 28429235-10 2017 Mechanistically, memantine reversed activation of the transcription factor NF-kappaB by preventing the phosphorylation and degradation of its inhibitor IkappaBalpha. Memantine 17-26 nuclear factor kappa B subunit 1 Homo sapiens 75-84 28429235-10 2017 Mechanistically, memantine reversed activation of the transcription factor NF-kappaB by preventing the phosphorylation and degradation of its inhibitor IkappaBalpha. Memantine 17-26 NFKB inhibitor alpha Homo sapiens 152-164 28595035-5 2017 Inhibiting NMDARs using memantine and ifenprodil alleviated NFH reduction and APP accumulation, decreased Cdk5 expression, and inhibited the activity of GSK-3beta in the white matter of PTZ-kindled rats. Memantine 24-33 neurofilament heavy chain Rattus norvegicus 60-63 28359852-10 2017 Moreover, in our study, lithium and/or memantine were able to reverse the decreases observed in the levels of interleukin (IL)-4 that were induced by Abeta1-42 in the frontal cortex. Memantine 39-48 interleukin 4 Rattus norvegicus 110-128 28359852-12 2017 Alone doses of lithium and memantine or the association of lithium and memantine caused reductions in the levels of IL-1beta in the frontal cortex and hippocampus, and decreased the levels of TNF-alpha in the hippocampus. Memantine 27-36 interleukin 1 beta Rattus norvegicus 116-124 28359852-12 2017 Alone doses of lithium and memantine or the association of lithium and memantine caused reductions in the levels of IL-1beta in the frontal cortex and hippocampus, and decreased the levels of TNF-alpha in the hippocampus. Memantine 27-36 tumor necrosis factor Rattus norvegicus 192-201 28359852-12 2017 Alone doses of lithium and memantine or the association of lithium and memantine caused reductions in the levels of IL-1beta in the frontal cortex and hippocampus, and decreased the levels of TNF-alpha in the hippocampus. Memantine 71-80 interleukin 1 beta Rattus norvegicus 116-124 28359852-12 2017 Alone doses of lithium and memantine or the association of lithium and memantine caused reductions in the levels of IL-1beta in the frontal cortex and hippocampus, and decreased the levels of TNF-alpha in the hippocampus. Memantine 71-80 tumor necrosis factor Rattus norvegicus 192-201 28595035-5 2017 Inhibiting NMDARs using memantine and ifenprodil alleviated NFH reduction and APP accumulation, decreased Cdk5 expression, and inhibited the activity of GSK-3beta in the white matter of PTZ-kindled rats. Memantine 24-33 cyclin-dependent kinase 5 Rattus norvegicus 106-110 28595035-5 2017 Inhibiting NMDARs using memantine and ifenprodil alleviated NFH reduction and APP accumulation, decreased Cdk5 expression, and inhibited the activity of GSK-3beta in the white matter of PTZ-kindled rats. Memantine 24-33 glycogen synthase kinase 3 beta Rattus norvegicus 153-162 28167259-0 2017 Memantine reduces the production of amyloid-beta peptides through modulation of amyloid precursor protein trafficking. Memantine 0-9 amyloid beta (A4) precursor protein Mus musculus 80-105 28303894-9 2017 Furthermore, another NMDAR antagonist, Memantine, improved beta-cells function in diabetic mice. Memantine 39-48 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 21-26 28167259-9 2017 Notably, in a cell-surface biotinylation assay, memantine increased the amount of amyloid precursor protein (APP) at the cell surface without changing the total amount of APP. Memantine 48-57 amyloid beta (A4) precursor protein Mus musculus 82-107 27170698-9 2017 Concentrations of BDNF, GDNF, and VEGF were bilaterally elevated by memantine in striatum and cortex. Memantine 68-77 brain derived neurotrophic factor Mus musculus 18-22 27170698-9 2017 Concentrations of BDNF, GDNF, and VEGF were bilaterally elevated by memantine in striatum and cortex. Memantine 68-77 glial cell line derived neurotrophic factor Mus musculus 24-28 27170698-9 2017 Concentrations of BDNF, GDNF, and VEGF were bilaterally elevated by memantine in striatum and cortex. Memantine 68-77 vascular endothelial growth factor A Mus musculus 34-38 27170698-11 2017 In the contralesional motor cortex, the NMDA receptor subunit GluN2B, which is predominantly expressed in extrasynaptic NMDA receptors, was transiently reduced by memantine after 14 days, whereas GluN2A and PSD-95, which preferentially co-localize with synaptic NMDA receptors, were increased after 28 days. Memantine 163-172 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 62-68 28069373-0 2017 Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke. Memantine 0-9 caspase 3 Rattus norvegicus 63-72 28264232-0 2017 Memantine Induces NMDAR1-Mediated Autophagic Cell Death in Malignant Glioma Cells. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 18-24 28264232-5 2017 RESULTS: The antiproliferative effect of memantine was shown on T-98 G cells, which expressed N-methyl-D-aspartate 1 receptor (NMDAR1). Memantine 41-50 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 94-125 28264232-5 2017 RESULTS: The antiproliferative effect of memantine was shown on T-98 G cells, which expressed N-methyl-D-aspartate 1 receptor (NMDAR1). Memantine 41-50 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 127-133 28264232-6 2017 Memantine increased the autophagic-related proteins as the conversion ratio of light chain protein 3-II (LC3-II)-/LC3-I and the expression of beclin-1. Memantine 0-9 beclin 1 Homo sapiens 142-150 28264232-8 2017 Transfection of small interfering RNA (siRNA) to knock down NMDAR1 in the glioma cells induced resistance to memantine and decreased the LC3-II/LC3-I ratio in T-98 G cells. Memantine 109-118 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 60-66 28264232-9 2017 CONCLUSION: Our study demonstrates that in glioma cells, memantine inhibits proliferation and induces autophagy mediated by NMDAR1. Memantine 57-66 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 124-130 28069373-9 2017 Moreover, memantine markedly suppressed the activation of the calpain-caspase-3 pathway and cell apoptosis, and consequently, attenuated brain damage and neuronal loss in MCAO rats. Memantine 10-19 caspase 3 Rattus norvegicus 70-79 27825855-0 2017 Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain. Memantine 31-40 brain-derived neurotrophic factor Rattus norvegicus 96-129 28103749-4 2017 Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer"s disease (A), memantine for moderate to severe Alzheimer"s disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Memantine 142-151 butyrylcholinesterase Homo sapiens 0-14 28103749-4 2017 Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer"s disease (A), memantine for moderate to severe Alzheimer"s disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Memantine 254-263 butyrylcholinesterase Homo sapiens 0-14 28095420-8 2017 Transfection of cultured neurons with GluN2A-P552R prolonged EPSPs, and triggered pronounced dendritic swelling in addition to excitotoxicity, which were both attenuated by memantine. Memantine 173-182 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 38-44 27599619-0 2017 Differential regulation of GluA1 expression by ketamine and memantine. Memantine 60-69 glutamate ionotropic receptor AMPA type subunit 1 Homo sapiens 27-32 27599619-9 2017 Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses. Memantine 175-184 mechanistic target of rapamycin kinase Homo sapiens 62-66 27825855-7 2017 Combined treatment with memantine and sertraline produced stronger increases in the BDNF protein levels in the hippocampus and prefrontal cortex. Memantine 24-33 brain-derived neurotrophic factor Rattus norvegicus 84-88 27825855-9 2017 Antidepressant properties using the combination of memantine and sertraline could be attributed to increased levels of BDNF. Memantine 51-60 brain-derived neurotrophic factor Rattus norvegicus 119-123 28133523-10 2017 Memantine significantly decreased tau and stathmin mRNA expression (by RT-PCR), so that 100 micromol/l of memantine decreased tau and stathmin expression by 46% (P=0.0341) and 33% (P=0.043), respectively. Memantine 0-9 stathmin 1 Homo sapiens 42-50 28133523-10 2017 Memantine significantly decreased tau and stathmin mRNA expression (by RT-PCR), so that 100 micromol/l of memantine decreased tau and stathmin expression by 46% (P=0.0341) and 33% (P=0.043), respectively. Memantine 0-9 stathmin 1 Homo sapiens 134-142 28133523-10 2017 Memantine significantly decreased tau and stathmin mRNA expression (by RT-PCR), so that 100 micromol/l of memantine decreased tau and stathmin expression by 46% (P=0.0341) and 33% (P=0.043), respectively. Memantine 106-115 stathmin 1 Homo sapiens 42-50 28133523-10 2017 Memantine significantly decreased tau and stathmin mRNA expression (by RT-PCR), so that 100 micromol/l of memantine decreased tau and stathmin expression by 46% (P=0.0341) and 33% (P=0.043), respectively. Memantine 106-115 stathmin 1 Homo sapiens 134-142 28133523-12 2017 CONCLUSION: The presented data shows that memantine reduced mRNA levels of tau and stathmin proteins and also reduced cellular migration. Memantine 42-51 stathmin 1 Homo sapiens 83-91 28049192-8 2017 Furthermore, decreased autophosphorylation of calcium/calmodulin dependent protein kinase II (CaMKII) was rescued in hippocampal CA1 and dentate gyrus of OBX mice by combined memantine/donepezil administration. Memantine 175-184 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 94-100 28106556-5 2017 The intensity of DiBAC4(3) fluorescence was increased when primary neurons were stimulated by Abeta; furthermore, pre-treatment with memantine abolished this change. Memantine 133-142 amyloid beta precursor protein Homo sapiens 94-99 28049192-8 2017 Furthermore, decreased autophosphorylation of calcium/calmodulin dependent protein kinase II (CaMKII) was rescued in hippocampal CA1 and dentate gyrus of OBX mice by combined memantine/donepezil administration. Memantine 175-184 carbonic anhydrase 1 Mus musculus 129-132 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 interleukin 1 beta Mus musculus 92-109 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 interleukin 1 beta Mus musculus 111-119 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 interleukin 6 Mus musculus 122-135 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 interleukin 6 Mus musculus 137-141 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 tumor necrosis factor Mus musculus 163-190 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 tumor necrosis factor Mus musculus 192-201 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 myeloperoxidase Mus musculus 207-222 27983945-9 2016 Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis. Memantine 0-9 myeloperoxidase Mus musculus 224-227 26660109-0 2016 Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes. Memantine 21-30 insulin receptor Homo sapiens 57-73 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 brain derived neurotrophic factor Homo sapiens 86-90 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 glial cell derived neurotrophic factor Homo sapiens 92-96 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 insulin receptor Homo sapiens 109-111 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 insulin receptor Homo sapiens 166-168 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 insulin receptor substrate 1 Homo sapiens 208-213 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 AKT serine/threonine kinase 1 Homo sapiens 215-218 26660109-6 2016 Treatment with memantine (1-10 muM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 alpha/beta in astrocytes. Memantine 15-24 glycogen synthase kinase 3 alpha Homo sapiens 224-235 26696493-6 2016 Interestingly, the NMDA receptor antagonist memantine restored behavioral abnormalities in TERT-tg mice. Memantine 44-53 telomerase reverse transcriptase Mus musculus 91-95 27546057-8 2016 These circuitry effects of memantine were occluded by the competitive NMDAR inhibitor AP-5, and thus are associated with NMDAR inhibition. Memantine 27-36 adaptor related protein complex 5 subunit beta 1 Homo sapiens 86-90 27546057-9 2016 We also found that memantine decreased feed-forward disynaptic inhibitory input to pyramidal neurons, which is thought to be mediated by parvalbumin (PV)-positive interneurons. Memantine 19-28 parvalbumin Homo sapiens 137-148 26497037-0 2016 Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment. Memantine 91-100 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 31-36 26660109-7 2016 Further, memantine attenuated STZ-induced amyloid precursor protein (APP), beta-site APP-cleaving enzyme-1 and amyloid-beta1-42 expression and restored IDE expression in astrocytes. Memantine 9-18 beta-secretase 1 Homo sapiens 75-106 26660109-7 2016 Further, memantine attenuated STZ-induced amyloid precursor protein (APP), beta-site APP-cleaving enzyme-1 and amyloid-beta1-42 expression and restored IDE expression in astrocytes. Memantine 9-18 insulin degrading enzyme Homo sapiens 152-155 26660109-8 2016 In addition, memantine also displays protective effects against STZ-induced astrocyte activation showed by reduction of inflammatory markers, nuclear factor kappa-B translocation, glial fibrillary acidic protein, cyclooxygenase-2, tumor necrosis factor-alpha level, and oxidative-nitrostative stress. Memantine 13-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 213-258 26660109-9 2016 The results suggest that besides the NMDA receptor antagonisic activity, effect on astroglial IR and neurotrophic factor may also be an important factor in the beneficial effect of memantine in AD pathology. Memantine 181-190 neurotrophin 3 Homo sapiens 101-120 26497037-0 2016 Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment. Memantine 91-100 nuclear receptor subfamily 4, group A, member 2 Rattus norvegicus 41-46 26497037-2 2016 Since memantine has shown clinically relevant efficacy in Parkinson"s disease (PD) and displayed a potent protective effect on dopaminergic neurons in experimental PD models, we asked if it exerts its neuroprotection by regulating Nur77 and Nurr1 signaling. Memantine 6-15 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 231-236 26497037-2 2016 Since memantine has shown clinically relevant efficacy in Parkinson"s disease (PD) and displayed a potent protective effect on dopaminergic neurons in experimental PD models, we asked if it exerts its neuroprotection by regulating Nur77 and Nurr1 signaling. Memantine 6-15 nuclear receptor subfamily 4, group A, member 2 Rattus norvegicus 241-246 29957983-10 2016 Interestingly, we found that plasma levels of EMB in memantine treated rats were significantlyreduced when compared to the positive control group. Memantine 53-62 embigin Rattus norvegicus 46-49 26497037-4 2016 Different concentrations of memantine were incubated with 6-OHDA-lesioned PC12 cells, and Nur77/Nurr1 and their related signaling molecules were examined by Western blot and immunocytochemistry. Memantine 28-37 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 90-95 26497037-4 2016 Different concentrations of memantine were incubated with 6-OHDA-lesioned PC12 cells, and Nur77/Nurr1 and their related signaling molecules were examined by Western blot and immunocytochemistry. Memantine 28-37 nuclear receptor subfamily 4, group A, member 2 Rattus norvegicus 96-101 26497037-6 2016 We found that memantine reversed Nur77 upregulation and restored Nurr1 downregulation in 6-OHDA-lesioned PC12 cells. Memantine 14-23 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 33-38 26497037-6 2016 We found that memantine reversed Nur77 upregulation and restored Nurr1 downregulation in 6-OHDA-lesioned PC12 cells. Memantine 14-23 nuclear receptor subfamily 4, group A, member 2 Rattus norvegicus 65-70 26497037-8 2016 Memantine strongly reduced the sub-cellular translocations of Nur77/Cyt c/HSP60 under 6-OHDA-induced oxidative condition. Memantine 0-9 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 62-67 26497037-8 2016 Memantine strongly reduced the sub-cellular translocations of Nur77/Cyt c/HSP60 under 6-OHDA-induced oxidative condition. Memantine 0-9 heat shock protein family D (Hsp60) member 1 Rattus norvegicus 74-79 26497037-9 2016 Knockdown of Nur77 enhanced the viability of PC12 cells exposed to 6-OHDA, while memantine-induced neuroprotection was much less in the cells with Nur77 knockdown than in those without it. Memantine 81-90 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 147-152 26497037-11 2016 Memantine effectively suppresses such Nur77-mediated neurodegeneration and promotes survival signaling through post-translational modification of Nurr1. Memantine 0-9 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 38-43 26497037-11 2016 Memantine effectively suppresses such Nur77-mediated neurodegeneration and promotes survival signaling through post-translational modification of Nurr1. Memantine 0-9 nuclear receptor subfamily 4, group A, member 2 Rattus norvegicus 146-151 26497037-12 2016 Nur77 and Nurr1 present a contra-directionally coupling interaction in memantine-mediated neuroprotection. Memantine 71-80 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 0-5 26497037-12 2016 Nur77 and Nurr1 present a contra-directionally coupling interaction in memantine-mediated neuroprotection. Memantine 71-80 nuclear receptor subfamily 4, group A, member 2 Rattus norvegicus 10-15 27423317-8 2016 We used different stimuli such as NMDA and glutamate, LPS and TNFalpha in combination with NMDA-R antagonism using memantine and MK801 in astrocytic cell culture. Memantine 115-124 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 91-97 27462773-0 2016 Immunomodulation by memantine in therapy of Alzheimer"s disease is mediated through inhibition of Kv1.3 channels and T cell responsiveness. Memantine 20-29 potassium voltage-gated channel subfamily A member 3 Homo sapiens 98-103 27462773-4 2016 Here, we provide evidence that memantine blocks Kv1.3 potassium channels, inhibits CD3-antibody- and alloantigen-induced proliferation and suppresses chemokine-induced migration of peripheral blood T cells of healthy donors. Memantine 31-40 potassium voltage-gated channel subfamily A member 3 Homo sapiens 48-53 27462773-5 2016 Concurrent with the in vitro data, CD4+ T cells from AD patients receiving therapeutic doses of memantine show a transient decline of Kv1.3 channel activity and a long-lasting reduced proliferative response to alloantigens in mixed lymphocyte reactions. Memantine 96-105 CD4 molecule Homo sapiens 35-38 27462773-5 2016 Concurrent with the in vitro data, CD4+ T cells from AD patients receiving therapeutic doses of memantine show a transient decline of Kv1.3 channel activity and a long-lasting reduced proliferative response to alloantigens in mixed lymphocyte reactions. Memantine 96-105 potassium voltage-gated channel subfamily A member 3 Homo sapiens 134-139 27462773-6 2016 Furthermore, memantine treatment provokes a profound depletion of peripheral blood memory CD45RO+ CD4+ T cells. Memantine 13-22 protein tyrosine phosphatase receptor type C Homo sapiens 90-96 27462773-6 2016 Furthermore, memantine treatment provokes a profound depletion of peripheral blood memory CD45RO+ CD4+ T cells. Memantine 13-22 CD4 molecule Homo sapiens 90-93 27462773-7 2016 Thus, standard doses of memantine profoundly reduce T cell responses in treated patients through blockade of Kv1.3 channels. Memantine 24-33 potassium voltage-gated channel subfamily A member 3 Homo sapiens 109-114 27495014-5 2016 In the present study, we evaluated the effect of an anti-Alzheimer"s drug, memantine on the working memory deficit observed in DGKbeta KO mice. Memantine 75-84 diacylglycerol kinase, beta Mus musculus 127-134 27495014-6 2016 In the Y-maze test, the administration of memantine significantly improved working memory of DGKbeta KO mice. Memantine 42-51 diacylglycerol kinase, beta Mus musculus 93-100 27382359-10 2016 Memantine, an eNMDAR blocker, mimicked the AP5-induced IAMPA attenuation in SON MNCs. Memantine 0-9 adaptor related protein complex 5 subunit beta 1 Homo sapiens 43-46 27165274-8 2016 CONCLUSION: According to the data from recent treatment trials, there is hope that neuronal loss in ON can be reduced with the help of immunomodulatory substances, such as simvastatin or neuroprotective agents, such as memantine and erythropoietin. Memantine 219-228 erythropoietin Homo sapiens 233-247 26948858-5 2016 Specifically, we administered memantine once daily for 30 days to 5XFAD mice, which showed moderate (6-7 months of age) and robust (12-15 months) beta-amyloid (Abeta) accumulation. Memantine 30-39 amyloid beta (A4) precursor protein Mus musculus 146-166 26471421-7 2016 In addition, memantine-induced LTD was also prevented by the CB1 endocannabinoid receptor antagonist AM 251 (1 muM). Memantine 13-22 cannabinoid receptor 1 Rattus norvegicus 61-64 26639427-6 2016 Notably, melatonin/memantine combination decreased brain injury and DNA fragmentation significantly, which was associated with reduced p38 and ERK-1/2 phosphorylation. Memantine 19-28 mitogen-activated protein kinase 1 Homo sapiens 135-138 26639427-6 2016 Notably, melatonin/memantine combination decreased brain injury and DNA fragmentation significantly, which was associated with reduced p38 and ERK-1/2 phosphorylation. Memantine 19-28 mitogen-activated protein kinase 3 Homo sapiens 143-150 26639427-7 2016 As compared with melatonin and memantine groups, SAPK/JNK-1/2 phosphorylation was also reduced in melatonin/memantine combined animals. Memantine 31-40 mitogen-activated protein kinase 8 Homo sapiens 54-59 26639427-7 2016 As compared with melatonin and memantine groups, SAPK/JNK-1/2 phosphorylation was also reduced in melatonin/memantine combined animals. Memantine 108-117 mitogen-activated protein kinase 8 Homo sapiens 54-59 26639427-9 2016 Here, we provide evidence that melatonin/memantine combination protects brain from traumatic injury, which was associated with decreased DNA fragmentation, p38 phosphorylation and iNOS activity. Memantine 41-50 mitogen-activated protein kinase 1 Homo sapiens 156-159 25421211-10 2016 Furthermore, we found that developmental sevoflurane-induced phospho-ERK1/2 inhibition was restored by synaptic NMDA receptor activation (in vitro), low dose of NMDA (in vitro) or memantine (in vivo). Memantine 180-189 mitogen-activated protein kinase 3 Homo sapiens 69-75 26920629-1 2016 AIMS: Memantine is a low-moderate affinity and uncompetitive N-methyl-d-aspartate receptor (NMDAR) antagonist, which is also a potential neuroprotectant in acute ischemic stroke for its particular action profiles. Memantine 6-15 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 61-90 26920629-1 2016 AIMS: Memantine is a low-moderate affinity and uncompetitive N-methyl-d-aspartate receptor (NMDAR) antagonist, which is also a potential neuroprotectant in acute ischemic stroke for its particular action profiles. Memantine 6-15 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 92-97 26920629-11 2016 Memantine decreased MMP-9 secretion, prevented the degradation of collagen IV in mouse brain. Memantine 0-9 matrix metallopeptidase 9 Mus musculus 20-25 26920629-12 2016 PSD-95 cleavage was also inhibited by memantine. Memantine 38-47 discs large MAGUK scaffold protein 4 Mus musculus 0-6 26374431-3 2016 Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Memantine 130-139 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 62-67 26374431-3 2016 Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Memantine 130-139 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 113-118 26374431-3 2016 Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Memantine 130-139 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 113-118 26697860-5 2015 Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer"s disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer"s disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats. Memantine 15-24 acidic nuclear phosphoprotein 32 family member A Homo sapiens 336-342 26408226-7 2015 However, treatment with memantine decreased glutamate-induced senescent PC12 cells and reversed the changes in SIRT1 and p53 expression. Memantine 24-33 sirtuin 1 Rattus norvegicus 111-116 26408226-7 2015 However, treatment with memantine decreased glutamate-induced senescent PC12 cells and reversed the changes in SIRT1 and p53 expression. Memantine 24-33 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 121-124 26301823-8 2015 When the NMDAR antagonist memantine was administered by intraperitoneal injection prior to daily exposure to CIH, at a sub-therapeutic dose of 5mg/kg/day not shown to impact the neurobehavioral performance in control animals, the neurocognitive impairments as well as the neurobiochemical changes were abolished or normalized in the CIH mice. Memantine 26-35 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 9-14 26609150-6 2015 We further validated these results pharmacologically by demonstrating similar reductions in the alcohol deprivation effect after infusion of the NMDAR antagonist memantine into the nucleus accumbens and ventral tegmental area of control mice, and a rescue of the mutant phenotype via pharmacological potentiation of AMPAR activity using aniracetam. Memantine 162-171 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 145-150 26609150-6 2015 We further validated these results pharmacologically by demonstrating similar reductions in the alcohol deprivation effect after infusion of the NMDAR antagonist memantine into the nucleus accumbens and ventral tegmental area of control mice, and a rescue of the mutant phenotype via pharmacological potentiation of AMPAR activity using aniracetam. Memantine 162-171 glutamate receptor, ionotropic, AMPA1 (alpha 1) Mus musculus 316-321 26519339-0 2015 Memantine ER/Donepezil: A Review in Alzheimer"s Disease. Memantine 0-9 epiregulin Homo sapiens 10-12 26519339-1 2015 A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric ) is available in the USA for patients with moderate to severe Alzheimer"s disease (AD) on stable memantine and donepezil therapy. Memantine 40-49 epiregulin Homo sapiens 68-70 26519339-3 2015 In a 24-week, phase III trial in patients with moderate to severe AD, addition of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clinical status, dementia behaviour and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ. Memantine 82-91 epiregulin Homo sapiens 92-94 26519339-3 2015 In a 24-week, phase III trial in patients with moderate to severe AD, addition of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clinical status, dementia behaviour and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ. Memantine 82-91 butyrylcholinesterase Homo sapiens 122-136 26519339-4 2015 In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behaviour and semantic processing, although there were no significant between-group differences on measures of global clinical status and daily function. Memantine 59-68 epiregulin Homo sapiens 69-71 26519339-5 2015 Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhoea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients. Memantine 0-9 epiregulin Homo sapiens 10-12 26519339-6 2015 Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD. Memantine 6-15 epiregulin Homo sapiens 16-18 25680935-9 2015 Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression. Memantine 26-35 synaptophysin Rattus norvegicus 270-283 26459718-1 2015 Memantine non-competitively blocks the N-methyl-D-aspartate receptor in order to inhibit beta-amyloid (Abeta) secretion, and has been used to treat moderate-to-severe Alzheimer"s disease (AD). Memantine 0-9 amyloid beta precursor protein Homo sapiens 103-108 26459718-8 2015 Further experiments revealed that memantine was able to upregulate the expression of signaling molecules phosphorylated (p)-phosphoinositide 3-kinase, p-Akt and p-mammalian target of rapamycin (mTOR), and also inhibited the phosphorylation of the B-cell lymphoma 2/Beclin-1 complex via mitogen-activated protein kinase 8. Memantine 34-43 AKT serine/threonine kinase 1 Homo sapiens 153-156 26459718-8 2015 Further experiments revealed that memantine was able to upregulate the expression of signaling molecules phosphorylated (p)-phosphoinositide 3-kinase, p-Akt and p-mammalian target of rapamycin (mTOR), and also inhibited the phosphorylation of the B-cell lymphoma 2/Beclin-1 complex via mitogen-activated protein kinase 8. Memantine 34-43 mechanistic target of rapamycin kinase Homo sapiens 161-192 26459718-8 2015 Further experiments revealed that memantine was able to upregulate the expression of signaling molecules phosphorylated (p)-phosphoinositide 3-kinase, p-Akt and p-mammalian target of rapamycin (mTOR), and also inhibited the phosphorylation of the B-cell lymphoma 2/Beclin-1 complex via mitogen-activated protein kinase 8. Memantine 34-43 mechanistic target of rapamycin kinase Homo sapiens 194-198 26459718-8 2015 Further experiments revealed that memantine was able to upregulate the expression of signaling molecules phosphorylated (p)-phosphoinositide 3-kinase, p-Akt and p-mammalian target of rapamycin (mTOR), and also inhibited the phosphorylation of the B-cell lymphoma 2/Beclin-1 complex via mitogen-activated protein kinase 8. Memantine 34-43 beclin 1 Homo sapiens 265-273 26459718-8 2015 Further experiments revealed that memantine was able to upregulate the expression of signaling molecules phosphorylated (p)-phosphoinositide 3-kinase, p-Akt and p-mammalian target of rapamycin (mTOR), and also inhibited the phosphorylation of the B-cell lymphoma 2/Beclin-1 complex via mitogen-activated protein kinase 8. Memantine 34-43 mitogen-activated protein kinase 8 Homo sapiens 286-320 24704249-8 2015 During this period, cholinesterase inhibitors accounted for 76.70% of the drugs consumed and memantine, 23.30%. Memantine 93-102 butyrylcholinesterase Homo sapiens 20-34 25451797-7 2015 Down-regulation of Kir4.1 transcription in rats with ALF was attenuated by intraperitoneal administration of a competitive NMDA receptor antagonist memantine, but not by histidine, which reverses ONS associated with ALF. Memantine 148-157 potassium inwardly-rectifying channel, subfamily J, member 10 Rattus norvegicus 19-25 25974188-4 2015 Adolescent male mice were conditioned with 1 or 10 mg/kg MDMA and pretreated with 5 or 10 mg/kg of the NMDAR antagonist memantine during acquisition of conditioning (experiment 1), or before a reinstatement test (experiment 2). Memantine 120-129 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 103-108 25899790-3 2015 OBJECTIVES: The current experiments explore aggression and medial prefrontal cortex (mPFC) glutamate as consequences of withdrawal from intermittent access to EtOH and changes in aggression and mPFC glutamate caused by NMDAR antagonists memantine and ketamine. Memantine 237-246 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 219-224 26110388-0 2015 Memantine Attenuates Delayed Vasospasm after Experimental Subarachnoid Hemorrhage via Modulating Endothelial Nitric Oxide Synthase. Memantine 0-9 nitric oxide synthase 3 Rattus norvegicus 97-130 26110388-5 2015 This study investigated the effect of memantine on attenuation of vasospasm and restoring eNOS functionality. Memantine 38-47 nitric oxide synthase 3 Rattus norvegicus 90-94 26110388-7 2015 The effects of memantine on SAH were evaluated by assessing the severity of vasospasm and the expression of eNOS. Memantine 15-24 nitric oxide synthase 3 Rattus norvegicus 108-112 26110388-8 2015 Memantine effectively ameliorated cerebral vasospasm by restoring eNOS functionality. Memantine 0-9 nitric oxide synthase 3 Rattus norvegicus 66-70 26089779-5 2015 Memantine, an NMDAR antagonist, was administered daily for 24 days to healthy adult CF-1 mice by oral gavage at doses of 5, 10, or 20 mg/kg. Memantine 0-9 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 14-19 26089779-11 2015 In conclusion, long-term NMDAR antagonism with memantine induces anxiety-like behavior that is associated with reduced glutamate uptake activity but that is not dependent on GLT-1 or GLAST protein expression. Memantine 47-56 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 25-30 25982509-10 2015 The use-dependent NMDAR inhibitor, memantine (100muM), reduced numbers and proliferation of Meg-01 cells to less than 20% of controls (IC50 20muM and 36muM, respectively). Memantine 35-44 latexin Homo sapiens 49-52 26119223-4 2015 Basal dendritic excitation on hippocampal CA1 pyramidal cells showed a robust LTP after theta-frequency primed bursts, and the LTP was higher after 5-10 mg/kg intraperitoneal (ip) memantine pretreatment, as compared with saline pretreatment. Memantine 180-189 carbonic anhydrase 1 Rattus norvegicus 42-45 25195698-0 2015 Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer"s Disease. Memantine 95-104 presenilin 1 Mus musculus 64-67 25680935-9 2015 Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression. Memantine 26-35 brain-derived neurotrophic factor Rattus norvegicus 288-321 25680935-9 2015 Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression. Memantine 26-35 synaptophysin Rattus norvegicus 474-487 25680935-9 2015 Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression. Memantine 230-239 synaptophysin Rattus norvegicus 270-283 25680935-9 2015 Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression. Memantine 230-239 brain-derived neurotrophic factor Rattus norvegicus 288-321 25680935-9 2015 Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression. Memantine 230-239 synaptophysin Rattus norvegicus 474-487 25993608-6 2015 We have demonstrated for the first time that memantine (MEM), a FDA-approved drug for treatment of Alzheimer"s disease, could very efficiently block E. coli-caused bacteremia and meningitis in a mouse model of NSM in a manner dependent on alpha7 nAChR. Memantine 45-54 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 239-251 26074764-4 2015 We report here that memantine, an NMDAR antagonist, administered to VPA mice rescues both social deficits and repetitive behaviors such as self-grooming and jumping. Memantine 20-29 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 34-39 25560396-0 2015 MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway. Memantine 84-93 brain derived neurotrophic factor Mus musculus 106-110 25942563-4 2015 The aim of this study is to examine the effects of memantine, a NMDAR channel blocker, on bleomycin-induced lung injury mice. Memantine 51-60 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 64-69 25560396-0 2015 MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway. Memantine 84-93 neurotrophic tyrosine kinase, receptor, type 2 Mus musculus 111-115 25899711-1 2015 Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that is a well-established treatment option for moderate to severe dementia of the Alzheimer"s type, either alone or in combination with cholinesterase inhibitors. Memantine 0-9 butyrylcholinesterase Homo sapiens 215-229 25899711-3 2015 The memantine extended-release (ER) (Namenda XR( )) 28 mg once-daily capsule formulation was approved in the USA in 2010 and became available more recently. Memantine 4-13 epiregulin Homo sapiens 32-34 25899711-3 2015 The memantine extended-release (ER) (Namenda XR( )) 28 mg once-daily capsule formulation was approved in the USA in 2010 and became available more recently. Memantine 37-47 epiregulin Homo sapiens 32-34 25899711-4 2015 The potential advantages of memantine ER over the IR formulation include a more convenient dosage regimen and lower pill burden that may improve adherence to therapy; also, memantine ER capsules may be opened and the contents sprinkled on applesauce for patients who have difficulty swallowing. Memantine 173-182 epiregulin Homo sapiens 38-40 25899711-4 2015 The potential advantages of memantine ER over the IR formulation include a more convenient dosage regimen and lower pill burden that may improve adherence to therapy; also, memantine ER capsules may be opened and the contents sprinkled on applesauce for patients who have difficulty swallowing. Memantine 173-182 epiregulin Homo sapiens 183-185 25899711-5 2015 Memantine ER provides a higher total daily dosage than the recommended memantine IR regimen and pharmacokinetic data indicate greater exposure with the ER formulation, but the clinical implications of this are unclear, as the two formulations have not been assessed in a comparative clinical trial. Memantine 0-9 epiregulin Homo sapiens 10-12 25899711-6 2015 The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study. Memantine 16-25 epiregulin Homo sapiens 26-28 25899711-6 2015 The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study. Memantine 16-25 epiregulin Homo sapiens 151-153 25899711-6 2015 The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study. Memantine 16-25 butyrylcholinesterase Homo sapiens 170-184 25899711-6 2015 The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study. Memantine 141-150 epiregulin Homo sapiens 26-28